diff --git a/.ebextensions/02_app_config.config b/.ebextensions/02_app_config.config
index 2f328792..6adad56f 100644
--- a/.ebextensions/02_app_config.config
+++ b/.ebextensions/02_app_config.config
@@ -5,7 +5,9 @@ commands:
         command: "yum install -y awscli"
     03_install_unzip:
         command: "yum install -y unzip"
-    04_export_eb_env_var:
+    04_eb_packages:
+       command: "/var/app/venv/staging-LQM1lest/bin/pip install uvloop websockets httptools typing-extensions"
+    05_export_eb_env_var:
         command: "export $(cat /opt/elasticbeanstalk/deployment/env | xargs)"
 
 container_commands:
diff --git a/.github/workflows/release.yaml b/.github/workflows/release.yaml
index 3c569ead..dfbfecfd 100644
--- a/.github/workflows/release.yaml
+++ b/.github/workflows/release.yaml
@@ -9,8 +9,8 @@ jobs:
     runs-on: ubuntu-latest
 
     steps:
-    - uses: actions/checkout@v2
-    - uses: actions/setup-python@v2
+    - uses: actions/checkout@v3
+    - uses: actions/setup-python@v4
     - name: Install dependencies
       run: |
         python3 -m pip install --upgrade pip
diff --git a/.pre-commit-config.yaml b/.pre-commit-config.yaml
index e2d1f19c..7a376c8a 100644
--- a/.pre-commit-config.yaml
+++ b/.pre-commit-config.yaml
@@ -9,5 +9,4 @@ repos:
     - id: check-added-large-files
       args: ['--maxkb=1024']
       exclude: ^tests/data
-    - id: detect-aws-credentials
     - id: detect-private-key
diff --git a/Pipfile b/Pipfile
index 5028a8de..c842ee64 100644
--- a/Pipfile
+++ b/Pipfile
@@ -4,26 +4,22 @@ verify_ssl = true
 name = "pypi"
 
 [packages]
-"ga4gh.vrs" = {version = ">=0.7.5.dev1", extras = ["extras"]}
-civicpy = "*"
+"ga4gh.vrs" = "==0.8.0dev0"
+civicpy = ">=2.0.0"
 requests = "*"
 jsondiff = "*"
 pydantic = "*"
 requests-cache = "*"
-gene-normalizer = ">=0.1.25"
-disease-normalizer = ">=0.2.12"
-thera-py = ">=0.3.4"
+gene-normalizer = {version = "==0.1.30", extras = ["dev"]}
+disease-normalizer = {version = "==0.2.15", extras = ["dev"]}
+thera-py = {version = "==0.3.7", extras = ["dev"]}
 neo4j = "*"
 uvicorn = "*"
 fastapi = "*"
-uvloop = "*"
-websockets = "*"
-httptools = "*"
-typing-extensions = "*"
 boto3 = "*"
 botocore = "*"
-variation-normalizer = ">= 0.4.0a7"
-"ga4gh.vrsatile.pydantic" = ">=0.0.11"
+variation-normalizer = "==0.5.1"
+"ga4gh.vrsatile.pydantic" = "==0.0.11"
 asyncclick = "*"
 
 [dev-packages]
diff --git a/README.md b/README.md
index 70a3097c..5d4809b2 100644
--- a/README.md
+++ b/README.md
@@ -30,15 +30,13 @@ Once Pipenv is installed, clone the repo and install the package requirements in
 ```sh
 git clone https://github.com/cancervariants/metakb
 cd metakb
-pipenv lock
-pipenv sync
+pipenv lock && pipenv sync
 ```
 
 If you intend to provide development support, install the development dependencies:
 
 ```sh
-pipenv lock --dev
-pipenv sync
+pipenv lock --dev && pipenv sync
 ```
 
 ### Setting up Neo4j
@@ -49,14 +47,14 @@ First, follow the [desktop setup instructions](https://neo4j.com/developer/neo4j
 
 Once you have opened Neo4j desktop, use the "New" button in the upper-left region of the window to create a new project. Within that project, click the "Add" button in the upper-right region of the window and select "Local DBMS". The name of the DBMS doesn't matter, but the password will be used later to connect the database to MetaKB (we have been using "admin" by default). Click "Create". Then, click the row within the project screen corresponding to your newly-created DBMS, and click the green "Start" button to start the database service.
 
-The graph will initially be empty, but once you have successfully loaded data, Neo4j Desktop provides an interface for exploring and visualizing relationships within the graph. To access it, click the blue "Open" button. The prompt at the top of this window processes [Cypher queries](https://neo4j.com/docs/cypher-refcard/current/); to start, try `MATCH (n:Statement {id:"civic.eid:5818"}) RETURN n`. Buttons on the left-hand edge of the results pane let you select graph, tabular, or textual output.
+The graph will initially be empty, but once you have successfully loaded data, Neo4j Desktop provides an interface for exploring and visualizing relationships within the graph. To access it, click the blue "Open" button. The prompt at the top of this window processes [Cypher queries](https://neo4j.com/docs/cypher-refcard/current/); to start, try `MATCH (n:Statement {id:"civic.eid:1409"}) RETURN n`. Buttons on the left-hand edge of the results pane let you select graph, tabular, or textual output.
 
 
 ### Setting up normalizers
 
 The MetaKB calls a number of normalizer libraries to transform resource data and resolve incoming search queries. These will be installed as part of the package requirements, but require additional setup.
 
-First, [download and install Amazon's DynamoDB](https://docs.aws.amazon.com/amazondynamodb/latest/developerguide/DynamoDBLocal.DownloadingAndRunning.html). Once installed, in a separate terminal instance, navigate to its source directory and run the following to start the database instance:
+First, [follow these instructions for deploying DynamoDB locally on your computer](https://docs.aws.amazon.com/amazondynamodb/latest/developerguide/DynamoDBLocal.DownloadingAndRunning.html). Once setup, in a separate terminal instance, navigate to its source directory and run the following to start the database instance:
 
 ```sh
 java -Djava.library.path=./DynamoDBLocal_lib -jar DynamoDBLocal.jar -sharedDb
@@ -65,10 +63,10 @@ java -Djava.library.path=./DynamoDBLocal_lib -jar DynamoDBLocal.jar -sharedDb
 Next, navigate to the `site-packages` directory of your virtual environment. Assuming Pipenv is installed to your user directory, this should be something like:
 
 ```sh
-cd ~/.local/share/virtualenvs/metakb-<various characters>/python3.7/site-packages/  # replace <various characters>
+cd ~/.local/share/virtualenvs/metakb-<various characters>/lib/python<python-version>/site-packages/  # replace <various characters> and <python-version>
 ```
 
-Next, initialize the [Variation Normalizer](https://github.com/cancervariants/variation-normalization) by following the instructions in the [README](https://github.com/cancervariants/variation-normalization#installation).
+Next, initialize the [Variation Normalizer](https://github.com/cancervariants/variation-normalization) by following the instructions in the [README](https://github.com/cancervariants/variation-normalization#installation). When setting up the UTA database, [these](https://github.com/ga4gh/vrs-python/tree/main/docs/setup_help) docs may be helpful.
 
 
 The MetaKB can acquire all other needed normalizer data, except for that of [OMIM](https://www.omim.org/downloads), which must be manually placed:
@@ -79,9 +77,46 @@ mkdir -p data/omim
 cp ~/YOUR/PATH/TO/mimTitles.txt data/omim/omim_<date>.tsv  # replace <date> with date of data acquisition formatted as YYYYMMDD
 ```
 
+### Environment Variables
+
+MetaKB relies on environment variables to set in order to work.
+
+* Always Required:
+  * `UTA_DB_URL`
+    * Used in Variation Normalizer which relies on UTA Tools
+    * Format: `driver://user:pass@host/database/schema`
+    * More info can be found [here](https://github.com/GenomicMedLab/uta-tools#connecting-to-the-database)
+
+    Example:
+
+    ```shell script
+    export UTA_DB_URL=postgresql://uta_admin:password@localhost:5432/uta/uta_20210129
+    ```
+
+* Required when using the `--load_normalizers_db` or `--force_load_normalizers_db` arguments in CLI commands
+  * `RXNORM_API_KEY`
+    * Used in Therapy Normalizer to retrieve RxNorm data
+    * RxNorm requires a UMLS license, which you can register for one [here](https://www.nlm.nih.gov/research/umls/index.html). You must set the `RxNORM_API_KEY` environment variable to your API key. This can be found in the [UTS 'My Profile' area](https://uts.nlm.nih.gov/uts/profile) after singing in.
+
+    Example:
+
+    ```shell script
+    export RXNORM_API_KEY={rxnorm_api_key}
+    ```
+
+  * `DATAVERSE_API_KEY`
+    * Used in Therapy Normalizer to retrieve HemOnc data
+    * HemOnc.org data requires a Harvard Dataverse API key. After creating a user account on the Harvard Dataverse website, you can follow [these instructions](https://guides.dataverse.org/en/latest/user/account.html) to generate a key. You will create or login to your account at [this](https://dataverse.harvard.edu/) site. You must set the `DATAVERSE_API_KEY` environment variable to your API key.
+
+    Example:
+
+    ```shell script
+    export DATAVERSE_API_KEY={dataverse_api_key}
+    ```
+
 ### Loading data
 
-Once Neo4j and DynamoDB instances are both active, and necessary normalizer data has been placed, run the MetaKB CLI with the `--initialize_normalizers` flag to acquire all other necessary normalizer source data, and execute harvest, transform, and load operations into the graph datastore.
+Once Neo4j and DynamoDB instances are both running, and necessary normalizer data has been placed, run the MetaKB CLI with the `--initialize_normalizers` flag to acquire all other necessary normalizer source data, and execute harvest, transform, and load operations into the graph datastore.
 
 In the MetaKB project root, run the following:
 
@@ -90,6 +125,8 @@ pipenv shell
 python3 -m metakb.cli --db_url=bolt://localhost:7687 --db_username=neo4j --db_password=<neo4j-password-here> --load_normalizers_db
 ```
 
+For more information on the different CLI arguments, see the [CLI README](docs/cli/README.md).
+
 ### Starting the server
 
 Once data has been loaded successfully, use the following to start service on localhost port 8000:
@@ -98,6 +135,8 @@ Once data has been loaded successfully, use the following to start service on lo
 uvicorn metakb.main:app --reload
 ```
 
+Ensure that both the MetaKB Neo4j and Normalizers databases are running.
+
 Navigate to [http://localhost:8000/api/v2](http://localhost:8000/api/v2) in your browser to enter queries.
 
 ## Running tests
diff --git a/docs/cli/README.md b/docs/cli/README.md
new file mode 100644
index 00000000..1930d8f7
--- /dev/null
+++ b/docs/cli/README.md
@@ -0,0 +1,30 @@
+# MetaKB CLI
+
+More information on MetaKB CLI arguments
+
+* `--db_url`
+  * URL endpoint for the application Neo4j database. Can also be provided via environment variable `METAKB_DB_URL`.
+
+* `--db_username`
+  * Username to provide to application Neo4j database. Can also be provided via environment variable `METAKB_DB_USERNAME`.
+
+* `--db_password`
+  * Password to provide to application Neo4j database. Can also be provided via environment variable `METAKB_DB_PASSWORD`.
+
+* `--load_normalizers_db`
+  * Check normalizers' (therapy, disease, and gene) DynamoDB database and load data if source data is not present.
+
+* `--force_load_normalizers_db`
+  * Load all normalizers' (therapy, disease, and gene) data into DynamoDB database. Overrides `--load_normalizers_db` if both are selected.
+
+* `--normalizers_db_url`
+  * URL endpoint of normalizers' (therapy, disease, and gene) DynamoDB database. Set to `http://localhost:8000` by default.
+
+* `--load_latest_cdms`
+  * Deletes all nodes from the MetaKB Neo4j database and loads it with the latest source transformed CDM files stored locally in the `metakb/data` directory. This bypasses having to run the source harvest and transform steps. Exclusive with `--load_target_cdm` and `--load_latest_s3_cdms`.
+
+* `--load_target_cdm`
+  * Load a source's transformed CDM file at specified path. This bypasses having to run the source harvest and transform steps. Exclusive with `--load_latest_cdms` and `--load_latest_s3_cdms`.
+
+* `--load_latest_s3_cdms`
+  * Deletes all nodes from the MetaKB Neo4j database, retrieves latest source transformed CDM files from public s3 bucket, and loads the Neo4j database with the retrieved data. This bypasses having to run the source harvest and transform steps Exclusive with `--load_latest_cdms` and `--load_target_cdms`.
\ No newline at end of file
diff --git a/metakb/__init__.py b/metakb/__init__.py
index cbb43f50..46186a18 100644
--- a/metakb/__init__.py
+++ b/metakb/__init__.py
@@ -7,10 +7,6 @@
 PROJECT_ROOT = Path(__file__).resolve().parents[1]
 
 if 'METAKB_NORM_EB_PROD' in environ:
-    environ['VARIATION_NORM_EB_PROD'] = "true"
-    environ['GENE_NORM_EB_PROD'] = "true"
-    environ['THERAPY_NORM_EB_PROD'] = "true"
-    environ['DISEASE_NORM_EB_PROD'] = "true"
     LOG_FN = "/tmp/metakb.log"
 else:
     LOG_FN = "metakb.log"
diff --git a/metakb/cli.py b/metakb/cli.py
index 68ff7fa0..8bb3234f 100644
--- a/metakb/cli.py
+++ b/metakb/cli.py
@@ -114,11 +114,21 @@ class CLI:
               "from VICC S3 bucket, and load the database with retrieved "
               "data. Exclusive with --load_latest_cdms and load_target_cdm.")
     )
+    @click.option(
+        "--update_cached",
+        "-u",
+        is_flag=True,
+        default=False,
+        required=False,
+        help=("`True` if civicpy cache should be updated. Note this will take serveral"
+              "minutes. `False` if local cache should be used")
+    )
     async def update_metakb_db(
         db_url: str, db_username: str, db_password: str,
         load_normalizers_db: bool, force_load_normalizers_db: bool,
         normalizers_db_url: str, load_latest_cdms: bool,
-        load_target_cdm: Optional[Path], load_latest_s3_cdms: bool
+        load_target_cdm: Optional[Path], load_latest_s3_cdms: bool,
+        update_cached: bool
     ):
         """Execute data harvest and transformation from resources and upload
         to graph datastore.
@@ -141,7 +151,7 @@ async def update_metakb_db(
             if load_normalizers_db or force_load_normalizers_db:
                 CLI()._load_normalizers_db(force_load_normalizers_db)
 
-            CLI()._harvest_sources()
+            CLI()._harvest_sources(update_cached)
             await CLI()._transform_sources()
 
         # Load neo4j database
@@ -225,7 +235,7 @@ def _retrieve_s3_cdms(self) -> str:
         return newest_version
 
     @staticmethod
-    def _harvest_sources() -> None:
+    def _harvest_sources(update_cached) -> None:
         """Run harvesting procedure for all sources."""
         echo_info("Harvesting sources...")
         # TODO: Switch to using constant
@@ -238,7 +248,12 @@ def _harvest_sources() -> None:
             echo_info(f"Harvesting {source_str}...")
             start = timer()
             source: Harvester = source_class()
-            source_successful = source.harvest()
+            if source_str == "civic" and update_cached:
+                # Use latest civic data
+                echo_info("(civicpy cache is also being updated)")
+                source_successful = source.harvest(update_cache=True)
+            else:
+                source_successful = source.harvest()
             end = timer()
             if not source_successful:
                 echo_info(f'{source_str} harvest failed.')
diff --git a/metakb/database.py b/metakb/database.py
index 49096af2..04dd86ef 100644
--- a/metakb/database.py
+++ b/metakb/database.py
@@ -457,7 +457,7 @@ def _add_statement(tx, statement: Dict, added_ids: Set[str]):
     @staticmethod
     def get_secret():
         """Get secrets for MetaKB instances."""
-        secret_name = environ['METAKB_DB_PASSWORD']
+        secret_name = environ['METAKB_DB_SECRET']
         region_name = "us-east-2"
 
         # Create a Secrets Manager client
diff --git a/metakb/harvesters/base.py b/metakb/harvesters/base.py
index d13e2982..15973e41 100644
--- a/metakb/harvesters/base.py
+++ b/metakb/harvesters/base.py
@@ -6,18 +6,18 @@
 
 from metakb import APP_ROOT, DATE_FMT
 
-logger = logging.getLogger('metakb')
+logger = logging.getLogger("metakb.harvesters.base")
 logger.setLevel(logging.DEBUG)
 
 
 class Harvester:
     """A base class for content harvesters."""
 
-    def __init__(self):
+    def __init__(self) -> None:
         """Initialize Harvester class."""
         self.assertions = []
 
-    def harvest(self):
+    def harvest(self) -> bool:
         """
         Retrieve and store records from a resource. Records may be stored in
         any manner, but must be retrievable by :method:`iterate_records`.
@@ -27,16 +27,6 @@ def harvest(self):
         """
         raise NotImplementedError
 
-    def iter_assertions(self):
-        """
-        Yield all :class:`ClinSigAssertion` records for the resource.
-
-        :return: An iterator
-        :rtype: Iterator[:class:`ClinSigAssertion`]
-        """
-        for statement in self.assertions:
-            yield statement
-
     def create_json(self, items: Dict[str, List],
                     filename: Optional[str] = None) -> bool:
         """Create composite and individual JSON for harvested data.
@@ -59,7 +49,7 @@ def create_json(self, items: Dict[str, List],
             if filename is None:
                 filename = f"{src}_harvester_{today}.json"
             with open(src_dir / filename, "w+") as f:
-                json.dump(composite_dict, f, indent=4)
+                f.write(json.dumps(composite_dict, indent=4))
         except Exception as e:
             logger.error(f"Unable to create json: {e}")
             return False
diff --git a/metakb/harvesters/civic.py b/metakb/harvesters/civic.py
index c20c3a18..68bc7f1c 100644
--- a/metakb/harvesters/civic.py
+++ b/metakb/harvesters/civic.py
@@ -1,60 +1,68 @@
 """A module for the CIViC harvester."""
 import logging
-from typing import Optional
+from typing import Dict, List, Optional, Union
 
 from civicpy import civic as civicpy
 
-from metakb.harvesters.base import Harvester
+from metakb.harvesters.base import Harvester  # noqa: I202
 
-logger = logging.getLogger('metakb.harvesters.civic')
+logger = logging.getLogger("metakb.harvesters.civic")
 logger.setLevel(logging.DEBUG)
 
 
 class CIViCHarvester(Harvester):
     """A class for the CIViC harvester."""
 
-    def harvest(self, filename: Optional[str] = None):
+    def harvest(self, filename: Optional[str] = None,
+                update_cache: bool = False) -> bool:
         """Retrieve and store evidence, gene, variant, and assertion
         records from CIViC in composite and individual JSON files.
 
         :param Optional[str] filename: File name for composite json
+        :param bool update_cache: `True` if civicpy cache should be updated. Note
+            this will take several minutes. `False` if to use local cache.
         :return: `True` if operation was successful, `False` otherwise.
         :rtype: bool
         """
         try:
-            civicpy.load_cache(on_stale='ignore')
-            evidence = self._harvest_evidence()
-            genes = self._harvest_genes()
-            variants = self._harvest_variants()
-            assertions = self._harvest_assertions()
-            self.assertions = assertions
+            if update_cache:
+                civicpy.update_cache(from_remote_cache=False)
+
+            civicpy.load_cache(on_stale="ignore")
+
+            self.evidence = self.harvest_evidence()
+            self.genes = self.harvest_genes()
+            self.variants = self.harvest_variants()
+            self.assertions = self.harvest_assertions()
+
             json_created = self.create_json(
                 {
-                    "evidence": evidence,
-                    "genes": genes,
-                    "variants": variants,
-                    "assertions": assertions
+                    "evidence": self.evidence,
+                    "genes": self.genes,
+                    "variants": self.variants,
+                    "assertions": self.assertions
                 },
                 filename
             )
             if not json_created:
-                logger.error('CIViC Harvester was not successful.')
+                logger.error("CIViC Harvester was not successful.")
                 return False
         except Exception as e:  # noqa: E722
-            logger.error(f'CIViC Harvester was not successful: {e}')
+            logger.error(f"CIViC Harvester was not successful: {e}")
             return False
         else:
-            logger.info('CIViC Harvester was successful.')
+            logger.info("CIViC Harvester was successful.")
             return True
 
-    def _get_all_evidence(self):
+    @staticmethod
+    def _get_all_evidence() -> List[civicpy.Evidence]:
         """Return all evidence item records.
 
         :return: All civicpy evidence item records
         """
         return civicpy.get_all_evidence()
 
-    def _harvest_evidence(self):
+    def harvest_evidence(self) -> List[Dict]:
         """Harvest all CIViC evidence item records.
 
         :return: A list of all CIViC evidence item records.
@@ -63,19 +71,19 @@ def _harvest_evidence(self):
         evidence = list()
 
         for ev in evidence_items:
-            ev_record = \
-                self._evidence_item(self._get_dict(ev), is_evidence=True)
+            ev_record = self._evidence_item(self._get_dict(ev), is_evidence=True)
             evidence.append(ev_record)
         return evidence
 
-    def _get_all_genes(self):
+    @staticmethod
+    def _get_all_genes() -> List[civicpy.Gene]:
         """Return all gene records.
 
         :return: All civicpy gene records
         """
         return civicpy.get_all_genes()
 
-    def _harvest_genes(self):
+    def harvest_genes(self) -> List[Dict]:
         """Harvest all CIViC gene records.
 
         :return: A list of all CIViC gene records.
@@ -87,14 +95,15 @@ def _harvest_genes(self):
             genes_list.append(g)
         return genes_list
 
-    def _get_all_variants(self):
+    @staticmethod
+    def _get_all_variants() -> List[civicpy.Variant]:
         """Return all variant records.
 
         :return: All civicpy variant records
         """
         return civicpy.get_all_variants()
 
-    def _harvest_variants(self):
+    def harvest_variants(self) -> List[Dict]:
         """Harvest all CIViC variant records.
 
         :return: A list of all CIViC variant records.
@@ -107,14 +116,15 @@ def _harvest_variants(self):
             variants_list.append(v)
         return variants_list
 
-    def _get_all_assertions(self):
+    @staticmethod
+    def _get_all_assertions() -> List[civicpy.Assertion]:
         """Return all assertion records.
 
         :return: All civicpy assertion records
         """
         return civicpy.get_all_assertions()
 
-    def _harvest_assertions(self):
+    def harvest_assertions(self) -> List[Dict]:
         """Harvest all CIViC assertion records.
 
         :return: A list of all CIViC assertion records.
@@ -127,363 +137,341 @@ def _harvest_assertions(self):
             assertions_list.append(a)
         return assertions_list
 
-    def _harvest_gene(self, gene):
+    def _harvest_gene(self, gene: Dict) -> Dict:
         """Harvest an individual CIViC gene record.
 
-        :param Gene gene: A CIViC gene object
+        :param Dict gene: A CIViC gene object represented as a dictionary
         :return: A dictionary containing CIViC gene data
         """
         g = {
-            'id': gene['id'],
-            'name': gene['name'],
-            'entrez_id': gene['entrez_id'],
-            'description': gene['description'],
-            'variants': [
+            "id": gene["id"],
+            "name": gene["name"],
+            "entrez_id": gene["entrez_id"],
+            "description": gene["description"],
+            "variants": [
                 {
-                    'name': self._get_dict(variant)['name'],
-                    'id': self._get_dict(variant)['id'],
-                    'evidence_items':
-                        self._get_dict(variant)['_evidence_items']
+                    "name": self._get_dict(variant)["name"],
+                    "id": self._get_dict(variant)["id"],
+                    "evidence_items": self._get_dict(variant)["_evidence_items"]
                 }
-                for variant in gene['_variants']
+                for variant in gene["_variants"]
             ],
-            'aliases': gene['aliases'],
+            "aliases": gene["aliases"],
             # TODO: Add lifecycle_actions, sources
-            'type': gene['type']
+            "type": gene["type"]
         }
 
-        for v in g['variants']:
+        for v in g["variants"]:
             evidence_items = {
-                'accepted_count': 0,
-                'rejected_count': 0,
-                'submitted_count': 0
+                "accepted_count": 0,
+                "rejected_count": 0,
+                "submitted_count": 0
             }
-            for e in v['evidence_items']:
+            for e in v["evidence_items"]:
                 e = self._get_dict(e)
-                if e['status'] == 'submitted':
-                    evidence_items['submitted_count'] += 1
-                elif e['status'] == 'rejected':
-                    evidence_items['rejected_count'] += 1
-                elif e['status'] == 'accepted':
-                    evidence_items['accepted_count'] += 1
-            v['evidence_items'] = evidence_items
+                if e["status"] == "submitted":
+                    evidence_items["submitted_count"] += 1
+                elif e["status"] == "rejected":
+                    evidence_items["rejected_count"] += 1
+                elif e["status"] == "accepted":
+                    evidence_items["accepted_count"] += 1
+            v["evidence_items"] = evidence_items
 
         return g
 
-    def _harvest_variant(self, variant):
+    def _harvest_variant(self, variant: Dict) -> Dict:
         """Harvest an individual CIViC variant record.
 
-        :param Gene variant: A CIViC variant object
+        :param Dict variant: A CIViC variant object represented as a dictionary
         :return: A dictionary containing CIViC variant data
         """
         v = self._variant(variant)
 
         # Add more attributes to variant data
         v_extra = {
-            'evidence_items': [
+            "evidence_items": [
                 self._evidence_item(self._get_dict(evidence_item))
-                for evidence_item in variant['_evidence_items']
+                for evidence_item in variant["_evidence_items"]
             ],
-            'variant_groups': [
+            "variant_groups": [
                 {
-                    'id': self._get_dict(variant_group)['id'],
-                    'name': self._get_dict(variant_group)['name'],
-                    'description':
-                        self._get_dict(variant_group)['description'],
-                    'variants': [
+                    "id": self._get_dict(variant_group)["id"],
+                    "name": self._get_dict(variant_group)["name"],
+                    "description":
+                        self._get_dict(variant_group)["description"],
+                    "variants": [
                         self._variant(self._get_dict(variant))
-                        for variant in self._get_dict(variant_group)[
-                            'variants']
+                        for variant in self._get_dict(variant_group)["_variants"]
                     ],
-                    'type': self._get_dict(variant_group)['type']
+                    "type": self._get_dict(variant_group)["type"]
                 }
-                for variant_group in variant['variant_groups']
+                for variant_group in variant["_variant_groups"]
             ],
-            'assertions': [
+            "assertions": [
                 self._assertion(self._get_dict(assertion))
-                for assertion in variant['_assertions']
+                for assertion in variant["_assertions"]
             ],
-            'variant_aliases': variant['variant_aliases'],
-            'hgvs_expressions': variant['hgvs_expressions'],
-            'clinvar_entries': variant['clinvar_entries'],
+            "variant_aliases": variant["variant_aliases"],
+            "hgvs_expressions": variant["hgvs_expressions"],
+            "clinvar_entries": variant["clinvar_entries"],
             # TODO: Add lifecycle_actions
-            'allele_registry_id': variant['allele_registry_id'],
+            "allele_registry_id": variant["allele_registry_id"],
             # TODO: Add allele_registry_hgvs
         }
         v.update(v_extra)
         return v
 
-    def _harvest_assertion(self, assertion):
+    def _harvest_assertion(self, assertion: Dict) -> Dict:
         """Harvest an individual CIViC assertion record.
 
-        :param Gene assertion: A CIViC variant object
+        :param Dict assertion: A CIViC assertion object represented as a dictionary
         :return: A dictionary containing CIViC assertion data
         """
+        def _acmg_code(obj: civicpy.CivicAttribute) -> Dict:
+            """Get dictionary representation of CIViC ACMG Code
+
+            :param civicpy.CivicAttribute obj: CIViC ACMG Code
+            :return: ACMG Code represented as a dictionary
+            """
+            acmg_code = self._get_dict(obj)
+            return {
+                "id": acmg_code["id"],
+                "code": acmg_code["code"],
+                "description": acmg_code["description"]
+            }
+
         a = self._assertion(assertion)
 
         # Add more attributes to assertion data
         a_extra = {
-            'nccn_guideline': assertion['nccn_guideline'],
-            'nccn_guideline_version': assertion['nccn_guideline_version'],
-            'amp_level': assertion['amp_level'],
-            'evidence_items': [
-                self._evidence_item(self._get_dict(evidence_item),
-                                    is_assertion=True)
-                for evidence_item in assertion['evidence_items']
+            "nccn_guideline": assertion["nccn_guideline"],
+            "nccn_guideline_version": assertion["nccn_guideline_version"],
+            "amp_level": assertion["amp_level"],
+            "evidence_items": [
+                self._evidence_item(self._get_dict(evidence_item), is_assertion=True)
+                for evidence_item in assertion["_evidence_items"]
             ],
-            'acmg_codes': assertion['acmg_codes'],
-            'drug_interaction_type': assertion['drug_interaction_type'],
-            'fda_companion_test': assertion['fda_companion_test'],
-            'allele_registry_id': assertion['allele_registry_id'],
-            'phenotypes': assertion['phenotypes'],
-            'variant_origin': assertion['variant_origin']
+            "acmg_codes": [_acmg_code(acmg_code)
+                           for acmg_code in assertion["acmg_codes"]],
+            "drug_interaction_type": assertion["drug_interaction_type"],
+            "fda_companion_test": assertion["fda_companion_test"],
+            "phenotypes": self._phenotypes(assertion["phenotypes"]),
+            "variant_origin": assertion["variant_origin"]
             # TODO: Add lifecycle_actions
         }
         a.update(a_extra)
         return a
 
-    def _evidence_item(self, evidence_item,
-                       is_evidence=False, is_assertion=False):
+    def _evidence_item(self, evidence_item: Dict, is_evidence: bool = False,
+                       is_assertion: bool = False) -> Dict:
         """Get evidence item data.
 
-        :param Evidence evidence_item: A CIViC Evidence record
+        :param Dict evidence_item: A CIViC Evidence record represented as a dictionary
         :param bool is_evidence: Whether or not the evidence item is
                                  being harvested in an evidence record
         :param bool is_assertion: Whether or not the evidence item is
                                   being harvested in an assertion record
         :return: A dictionary containing evidence item data
         """
+        disease = self._get_dict(evidence_item["disease"])
+        if not disease:
+            disease = None
+        else:
+            disease = {
+                "id": disease["id"],
+                "name": disease["name"],
+                "display_name": disease["display_name"],
+                "doid": disease["doid"],
+                "disease_url": disease["disease_url"]
+            }
+
+        source = self._get_dict(evidence_item["source"])
+        source = {
+            "id": source["id"],
+            "name": source["name"],
+            "citation": source["citation"],
+            "citation_id": source["citation_id"],
+            "source_type": source["source_type"],
+            "asco_abstract_id": source["asco_abstract_id"],
+            "source_url": source["source_url"],
+            "pmc_id": source["pmc_id"],
+            "publication_date": source["publication_date"],
+            "journal": source["journal"],
+            "full_journal_title": source["full_journal_title"],
+            "clinical_trials": [ct for ct in source["clinical_trials"]]
+        }
+
         e = {
-            'id': evidence_item['id'],
-            'name': evidence_item['name'],
-            'description': evidence_item['description'],
-            'disease': self._disease(self._get_dict(evidence_item)),
-            'drugs': [
+            "id": evidence_item["id"],
+            "name": evidence_item["name"],
+            "description": evidence_item["description"],
+            "disease": disease,
+            "drugs": [
                 self._drug(self._get_dict(drug))
-                for drug in evidence_item['drugs']
+                for drug in evidence_item["drugs"]
             ],
-            'rating': evidence_item['rating'],
-            'evidence_level': evidence_item['evidence_level'],
-            'evidence_type': evidence_item['evidence_type'],
-            'clinical_significance':
-                evidence_item['clinical_significance'],
-            'evidence_direction':
-                evidence_item['evidence_direction'],
-            'variant_origin': evidence_item['variant_origin'],
-            'drug_interaction_type':
-                evidence_item['drug_interaction_type'],
-            'status': evidence_item['status'],
+            "rating": evidence_item["rating"],
+            "evidence_level": evidence_item["evidence_level"],
+            "evidence_type": evidence_item["evidence_type"],
+            "clinical_significance": evidence_item["clinical_significance"],
+            "evidence_direction": evidence_item["evidence_direction"],
+            "variant_origin": evidence_item["variant_origin"],
+            "drug_interaction_type": evidence_item["drug_interaction_type"],
+            "status": evidence_item["status"],
             # TODO: Add open_change_count
-            'type': evidence_item['type'],
-            'source': self._source(evidence_item),
-            'variant_id': evidence_item['variant_id'],
-            # TODO: Find variant w phenotypes
-            'phenotypes': []
+            "type": evidence_item["type"],
+            "source": source,
+            "variant_id": evidence_item["variant_id"],
+            "phenotypes": self._phenotypes(evidence_item["phenotypes"])
         }
 
         # Assertions and Evidence Items contain more attributes
         if is_assertion or is_evidence:
-            e['assertions'] = [
+            e["assertions"] = [
                 self._assertion(self._get_dict(assertion))
-                for assertion in evidence_item['_assertions']
+                for assertion in evidence_item["_assertions"]
             ]
             # TODO: Add lifecycle_actions, fields_with_pending_changes
-            e['gene_id'] = evidence_item['gene_id']
+            e["gene_id"] = evidence_item["gene_id"]
             if is_assertion:
                 # TODO: Add state_params
                 pass
 
         return e
 
-    def _variant(self, variant):
+    def _phenotypes(self, phenotypes: List) -> List[Dict]:
+        """Get phenotype data
+
+        :param List phenotypes: List of civic phenotype records
+        :return: List of transformed phenotypes represented as dictionaries
+        """
+        transformed_phenotypes = list()
+        for p in phenotypes:
+            p = self._get_dict(p)
+            transformed_phenotypes.append({
+                "id": p["id"],
+                "name": p["name"],
+                "hpo_id": p["hpo_id"],
+                "url": p["url"],
+                "type": p["type"]
+            })
+        return transformed_phenotypes
+
+    def _variant(self, variant: Dict) -> Dict:
         """Get basic variant data.
 
-        :param Variant variant: A CIViC Variant record
+        :param Dict variant: A CIViC Variant record represented as a dictionary
         :return: A dictionary containing variant data
         """
         return {
-            'id': variant['id'],
-            'entrez_name': variant['entrez_name'],
-            'entrez_id': variant['entrez_id'],
-            'name': variant['name'],
-            'description': variant['description'],
-            'gene_id': variant['gene_id'],
-            'type': variant['type'],
-            'variant_types': [
+            "id": variant["id"],
+            "entrez_name": variant["entrez_name"],
+            "entrez_id": variant["entrez_id"],
+            "name": variant["name"],
+            "description": variant["description"],
+            "gene_id": variant["gene_id"],
+            "type": variant["type"],
+            "variant_types": [
                 self._variant_types(self._get_dict(variant_type))
-                for variant_type in variant['variant_types']
+                for variant_type in variant["variant_types"]
             ],
-            'civic_actionability_score':
-                int(variant['civic_actionability_score']) if int(variant['civic_actionability_score']) == variant['civic_actionability_score'] else variant['civic_actionability_score'],  # noqa: E501
-            'coordinates':
-                self._variant_coordinates(variant)
+            "civic_actionability_score":
+                int(variant["civic_actionability_score"]) if int(variant["civic_actionability_score"]) == variant["civic_actionability_score"] else variant["civic_actionability_score"],  # noqa: E501
+            "coordinates": self._variant_coordinates(variant)
         }
 
-    def _assertion(self, assertion):
+    def _assertion(self, assertion: Dict) -> Dict:
         """Get assertion data.
 
-        :param Assertion assertion: A CIViC Assertion record
+        :param Dict assertion: A CIViC Assertion record represented as a dictionary
         :return: A dictionary containing assertion data
         """
-        disease = self._get_dict(assertion['disease'])
+        disease = self._get_dict(assertion["disease"])
         return {
-            'id': assertion['id'],
-            'type': assertion['type'],
-            'name': assertion['name'],
-            'summary': assertion['summary'],
-            'description': assertion['description'],
-            'gene': self._gene_name_id(assertion),
-            'variant': self._variant_name_id(assertion),
-            'disease': {
-                'id': disease['id'],
-                'name': disease['name'],
-                'display_name': disease['display_name'],
-                'doid': disease['doid'],
-                'url': disease['url']
+            "id": assertion["id"],
+            "type": assertion["type"],
+            "name": assertion["name"],
+            "summary": assertion["summary"],
+            "description": assertion["description"],
+            "gene_id": assertion["gene_id"],
+            "variant_id": assertion["variant_id"],
+            "disease": {
+                "id": disease["id"],
+                "name": disease["name"],
+                "display_name": disease["display_name"],
+                "doid": disease["doid"],
+                "disease_url": disease["disease_url"]
             },
-            'drugs': [
+            "drugs": [
                 self._drug(self._get_dict(drug))
-                for drug in assertion['drugs']
+                for drug in assertion["drugs"]
             ],
-            'evidence_type': assertion['evidence_type'],
-            'evidence_direction': assertion['evidence_direction'],
-            'clinical_significance': assertion['clinical_significance'],
+            "evidence_type": assertion["evidence_type"],
+            "evidence_direction": assertion["evidence_direction"],
+            "clinical_significance": assertion["clinical_significance"],
             # TODO: Add evidence_item_count
-            'fda_regulatory_approval':
-                assertion['fda_regulatory_approval'],
-            'status': assertion['status'],
+            "fda_regulatory_approval":
+                assertion["fda_regulatory_approval"],
+            "status": assertion["status"],
             # TODO: Add open_change_count, pending_evidence_count
         }
 
-    def _variant_coordinates(self, variant):
+    def _variant_coordinates(self, variant: Dict) -> Dict:
         """Get a variant's coordinates.
 
-        :param Variant variant: A CIViC variant record
+        :param Dict variant: A CIViC variant record represented as a dictionary
         :return: A dictionary containing a variant's coordinates
         """
-        coordinates = self._get_dict(variant['coordinates'])
+        coordinates = self._get_dict(variant["coordinates"])
         return {
-            'chromosome': coordinates['chromosome'],
-            'start': coordinates['start'],
-            'stop': coordinates['stop'],
-            'reference_bases': coordinates['reference_bases'],
-            'variant_bases': coordinates['variant_bases'],
-            'representative_transcript':
-                coordinates['representative_transcript'],
-            'chromosome2': coordinates['chromosome2'],
-            'start2': coordinates['start2'],
-            'stop2': coordinates['stop2'],
-            'representative_transcript2':
-                coordinates['representative_transcript2'],
-            'ensembl_version': coordinates['ensembl_version'],
-            'reference_build': coordinates['reference_build']
+            "chromosome": coordinates["chromosome"],
+            "start": coordinates["start"],
+            "stop": coordinates["stop"],
+            "reference_bases": coordinates["reference_bases"],
+            "variant_bases": coordinates["variant_bases"],
+            "representative_transcript": coordinates["representative_transcript"],
+            "chromosome2": coordinates["chromosome2"],
+            "start2": coordinates["start2"],
+            "stop2": coordinates["stop2"],
+            "representative_transcript2": coordinates["representative_transcript2"],
+            "ensembl_version": coordinates["ensembl_version"],
+            "reference_build": coordinates["reference_build"]
         }
 
-    def _variant_types(self, variant_type):
+    def _variant_types(self, variant_type: Dict) -> Dict:
         """Get variant_type data.
 
-        :param CivicAttribute variant_type: A CIViC variant_type record
+        :param Dict variant_type: A CIViC variant_type record represented as a
+            dictionary
         :return: A dictionary containing variant_type data
         """
         return {
-            'id': variant_type['id'],
-            'name': variant_type['name'],
-            'display_name': variant_type['display_name'],
-            'so_id': variant_type['so_id'],
-            'description': variant_type['description'],
-            'url': variant_type['url']
+            "id": variant_type["id"],
+            "name": variant_type["name"],
+            "so_id": variant_type["so_id"],
+            "description": variant_type["description"],
+            "url": variant_type["url"]
         }
 
-    def _source(self, evidence_item):
-        """Get an evidence item's source data.
-
-        :param Evidence evidence_item: A CIViC Evidence record
-        :return: A dictionary containing source data
-        """
-        source = self._get_dict(evidence_item['source'])
-        return {
-            'id': source['id'],
-            'name': source['name'],
-            'citation': source['citation'],
-            'citation_id': source['citation_id'],
-            'source_type': source['source_type'],
-            'asco_abstract_id': source['asco_abstract_id'],
-            'source_url': source['source_url'],
-            'open_access': source['open_access'],
-            'pmc_id': source['pmc_id'],
-            'publication_date': source['publication_date'],
-            'journal': source['journal'],
-            'full_journal_title': source['full_journal_title'],
-            'status': source['status'],
-            'is_review': source['is_review'],
-            'clinical_trials': [ct for ct in source['clinical_trials']]
-        }
-
-    def _disease(self, evidence_item):
-        """Get an evidence item's disease data.
-        :param Evidence evidence_item: A CIViC Evidence record
-        :return: A dictionary containing disease data
-        """
-        disease = self._get_dict(evidence_item['disease'])
-        if not disease:
-            return None
-        else:
-            return {
-                'id': disease['id'],
-                'name': disease['name'],
-                'display_name': disease['display_name'],
-                'doid': disease['doid'],
-                'url': disease['url']
-            }
-
-    def _drug(self, drug):
+    def _drug(self, drug: Dict) -> Dict:
         """Get drug data.
 
-        :param Drug drug: A CIViC Drug record
+        :param Dict drug: A CIViC Drug record represented as a dictionary
         :return: A dictionary containing drug data.
         """
         drug = self._get_dict(drug)
         return {
-            "id": drug['id'],
-            "name": drug['name'],
-            "ncit_id": drug['ncit_id'],
-            "aliases": drug['aliases']
-        }
-
-    def _gene_name_id(self, assertion):
-        """Get gene name and id.
-
-        :param Assertion assertion: A CIViC Assertion record
-        :return: A dictionary containing a gene's name and id
-        """
-        gene = self._get_dict(assertion['gene'])
-        return {
-            'name': gene['name'],
-            'id': gene['id']
+            "id": drug["id"],
+            "name": drug["name"],
+            "ncit_id": drug["ncit_id"],
+            "aliases": drug["aliases"]
         }
 
-    def _variant_name_id(self, assertion):
-        """Get variant name and id.
-
-        :param Assertion assertion: A CIViC Assertion record
-        :return: A dictionary containing a variant's name and id
-        """
-        variant = self._get_dict(assertion['variant'])
-        return {
-            'name': variant['name'],
-            'id': variant['id']
-        }
-
-    def _get_dict(self, obj):
+    def _get_dict(self, obj: Union[Dict, civicpy.CivicRecord]) -> Dict:
         """Return the __dict__ attribute for an object.
 
         :param obj: The civicpy object
+        :type obj: Dict or civicpy.CivicRecord
         :return: A dictionary for the object
         """
-        if isinstance(obj, (civicpy.Drug, civicpy.Disease,
-                            civicpy.CivicAttribute, civicpy.Evidence,
-                            civicpy.CivicRecord, civicpy.Gene,
-                            civicpy.Assertion, civicpy.Variant)):
-            return vars(obj)
-        else:
-            return obj
+        return vars(obj) if isinstance(obj, civicpy.CivicRecord) else obj
diff --git a/metakb/harvesters/moa.py b/metakb/harvesters/moa.py
index f195c7a0..816f26be 100644
--- a/metakb/harvesters/moa.py
+++ b/metakb/harvesters/moa.py
@@ -1,21 +1,21 @@
 """A module for the Molecular Oncology Almanac harvester"""
 import logging
-from typing import Optional
+from typing import Optional, List, Dict
 
 import requests
 import requests_cache
 
-from metakb.harvesters.base import Harvester
+from metakb.harvesters.base import Harvester  # noqa: I202
 
 
-logger = logging.getLogger('metakb.harvesters.moa')
+logger = logging.getLogger("metakb.harvesters.moa")
 logger.setLevel(logging.DEBUG)
 
 
 class MOAHarvester(Harvester):
     """A class for the Molecular Oncology Almanac harvester."""
 
-    def harvest(self, filename: Optional[str] = None):
+    def harvest(self, filename: Optional[str] = None) -> bool:
         """
         Retrieve and store sources, variants, and assertions
         records from MOAlmanac in composite and individual JSON files.
@@ -27,14 +27,15 @@ def harvest(self, filename: Optional[str] = None):
         try:
             assertion_resp = self._get_all_assertions()
             sources = self._harvest_sources(assertion_resp)
-            variants, variants_list = self._harvest_variants()
-            assertions = \
-                self._harvest_assertions(assertion_resp, variants_list)
+            variants, variants_list = self.harvest_variants()
+            assertions = self.harvest_assertions(assertion_resp, variants_list)
+            genes = self._harvest_genes()
             json_created = self.create_json(
                 {
                     "assertions": assertions,
                     "sources": sources,
-                    "variants": variants
+                    "variants": variants,
+                    "genes": genes
                 },
                 filename
             )
@@ -42,31 +43,44 @@ def harvest(self, filename: Optional[str] = None):
                 logger.error("MOAlmanac Harvester was not successful.")
                 return False
         except Exception as e:  # noqa: E722
-            logger.error(f'MOAlmanac Harvester was not successful: {e}')
+            logger.error(f"MOAlmanac Harvester was not successful: {e}")
             return False
         else:
-            logger.info('MOAlmanac Harvester was successful.')
+            logger.info("MOAlmanac Harvester was successful.")
             return True
 
-    def _harvest_sources(self, assertion_resp):
+    @staticmethod
+    def _harvest_genes() -> List[Dict]:
+        """Harvest all genes from MOAlamanc
+
+        :return: List of MOA gene records
+        """
+        genes = list()
+        with requests_cache.disabled():
+            r = requests.get("https://moalmanac.org/api/genes")
+            if r.status_code == 200:
+                genes = r.json()
+        return genes
+
+    def _harvest_sources(self, assertion_resp: List[Dict]) -> List[Dict]:
         """
         Harvest all MOA sources
 
-        :param: A list of MOA assertion records
+        :param List[Dict] assertion_resp: A list of MOA assertion records
         :return: A list of sources
         :rtype: list
         """
         sources = []
 
         for assertion in assertion_resp:
-            source = assertion['sources'][0]
+            source = assertion["sources"][0]
             s = self._source_item(source)
             if s not in sources:
                 sources.append(s)
 
         return sources
 
-    def _harvest_variants(self):
+    def harvest_variants(self) -> List[Dict]:
         """
         Harvest all MOA variants
 
@@ -82,12 +96,13 @@ def _harvest_variants(self):
 
         return variants, variants_list
 
-    def _harvest_assertions(self, assertion_resp, variants_list):
+    def harvest_assertions(self, assertion_resp: List[Dict],
+                           variants_list: List[Dict]) -> List[Dict]:
         """
         Harvest all MOA assertions
 
-        :param: A list of MOA assertion records
-        :param: A list of MOA variant records
+        :param List[Dict] assertion_resp: A list of MOA assertion records
+        :param List[Dict] variants_list: A list of MOA variant records
         :return: A list of assertions
         :rtype: list
         """
@@ -98,110 +113,111 @@ def _harvest_assertions(self, assertion_resp, variants_list):
 
         return assertions
 
-    def _get_all_assertions(self):
+    def _get_all_assertions(self) -> List[Dict]:
         """
         Return all assertion records.
 
         :return: All moa assertion records
         """
         with requests_cache.disabled():
-            r = requests.get('https://moalmanac.org/api/assertions')
+            r = requests.get("https://moalmanac.org/api/assertions")
             assertions = r.json()
 
         return assertions
 
-    def _get_all_variants(self):
+    def _get_all_variants(self) -> List[Dict]:
         """
         Return all variant records
 
         :return: All moa variant records
         """
         with requests_cache.disabled():
-            r = requests.get('https://moalmanac.org/api/features')
+            r = requests.get("https://moalmanac.org/api/features")
             variants = r.json()
 
         return variants
 
-    def _source_item(self, source):
+    def _source_item(self, source: Dict) -> Dict:
         """
         Harvest an individual MOA source of evidence
 
-        :param: source record of each assertion record
+        :param Dict source: source record of each assertion record
         :return: a dictionary containing MOA source of evidence data
         :rtype: dict
         """
         source_record = {
-            'id': source['source_id'],
-            'type': source['source_type'],
-            'doi': source['doi'],
-            'nct': source['nct'],
-            'pmid': source['pmid'],
-            'url': source['url'],
-            'citation': source['citation']
+            "id": source["source_id"],
+            "type": source["source_type"],
+            "doi": source["doi"],
+            "nct": source["nct"],
+            "pmid": source["pmid"],
+            "url": source["url"],
+            "citation": source["citation"]
         }
         return source_record
 
-    def _harvest_variant(self, variant):
-        """
-        Harvest an individual MOA variant record.
+    def _harvest_variant(self, variant: Dict) -> Dict:
+        """Harvest an individual MOA variant record.
 
-        :param: A MOA variant record
+        :param Dict variant: A MOA variant record
         :return: A dictionary containing MOA variant data
         :rtype: dict
         """
         variant_record = {
-            'id': variant['feature_id']
+            "id": variant["feature_id"]
         }
 
-        variant_record.update({k: v for k, v in variant['attributes'][0].items()})  # noqa: E501
+        variant_record.update({k: v for k, v in variant["attributes"][0].items()})  # noqa: E501
         variant_record.update(self._get_feature(variant_record))
 
         return variant_record
 
-    def _harvest_assertion(self, assertion, variants_list):
+    def _harvest_assertion(self, assertion: Dict, variants_list: List[Dict]) -> Dict:
         """
         Harvest an individual MOA assertion record
 
-        :param: a MOA assertion record
-        :param: a list of MOA variant records
+        :param Dict assertion: a MOA assertion record
+        :param List[Dict] variants_list: a list of MOA variant records
         :return: A dictionary containing MOA assertion data
         :rtype: dict
         """
         assertion_record = {
-            'id': assertion['assertion_id'],
-            'context': assertion['context'],
-            'description': assertion['description'],
-            'disease': {
-                'name': assertion['disease'],
-                'oncotree_code': assertion['oncotree_code'],
-                'oncotree_term': assertion['oncotree_term']
+            "id": assertion["assertion_id"],
+            "context": assertion["context"],
+            "description": assertion["description"],
+            "disease": {
+                "name": assertion["disease"],
+                "oncotree_code": assertion["oncotree_code"],
+                "oncotree_term": assertion["oncotree_term"]
             },
-            'therapy_name': assertion['therapy_name'],
-            'therapy_type': assertion['therapy_type'],
-            'clinical_significance': self._get_therapy(
-                assertion['therapy_resistance'],
-                assertion['therapy_sensitivity']),
-            'predictive_implication': assertion["predictive_implication"],
-            'favorable_prognosis': assertion['favorable_prognosis'],
-            'created_on': assertion['created_on'],
-            'last_updated': assertion['last_updated'],
-            'submitted_by': assertion['submitted_by'],
-            'validated': assertion['validated'],
-            'source_ids': assertion['sources'][0]['source_id']
+            "therapy_name": assertion["therapy_name"],
+            "therapy_type": assertion["therapy_type"],
+            "clinical_significance": self._get_therapy(
+                assertion["therapy_resistance"],
+                assertion["therapy_sensitivity"]),
+            "predictive_implication": assertion["predictive_implication"],
+            "favorable_prognosis": assertion["favorable_prognosis"],
+            "created_on": assertion["created_on"],
+            "last_updated": assertion["last_updated"],
+            "submitted_by": assertion["submitted_by"],
+            "validated": assertion["validated"],
+            "source_ids": assertion["sources"][0]["source_id"]
         }
 
         for v in variants_list:
-            if v['attributes'][0] == assertion['features'][0]['attributes'][0]:
-                assertion_record.update({'variant': self._harvest_variant(v)})
+            if v["attributes"][0] == assertion["features"][0]["attributes"][0]:
+                assertion_record.update({"variant": self._harvest_variant(v)})
 
         return assertion_record
 
-    def _get_therapy(self, resistance, sensitivity):
+    def _get_therapy(self, resistance: bool, sensitivity: bool) -> Optional[str]:
         """
         Get therapy response data.
 
-        :param: therapy_resistance
-        :param: therapy_sensitivity
+        :param bool resistance: `True` if Therapy Resistance.
+            `False` if not Therapy Resistance
+        :param bool sensitivity: `True` if Therapy Sensitivity.
+            `False` if not Therapy Sensitivity
         :return: whether the therapy response is resistance or sensitivity
         :rtype: str
         """
@@ -210,52 +226,52 @@ def _get_therapy(self, resistance, sensitivity):
         elif sensitivity:
             return "sensitivity"
         else:
-            return
+            return None
 
-    def _get_feature(self, v):
+    def _get_feature(self, v: Dict) -> Dict:
         """
         Get feature name from the harvested variants
 
-        :param: harvested MOA variant
+        :param Dict v: harvested MOA variant
         :return: feature name same format as displayed in moalmanac.org
         :rtype: dict
         """
-        feature_type = v['feature_type']
-        if feature_type == 'rearrangement':
-            feature = '{}{}{}'.format(v['gene1'],
-                                      f"--{v['gene2']}" if v['gene2'] else '',
+        feature_type = v["feature_type"]
+        if feature_type == "rearrangement":
+            feature = "{}{}{}".format(v["gene1"],
+                                      f"--{v['gene2']}" if v["gene2"] else "",
                                       f" {v['rearrangement_type']}"
-                                      if v['rearrangement_type'] else '')
-        elif feature_type == 'somatic_variant':
-            feature = '{}{}{}'.format(v['gene'],
+                                      if v["rearrangement_type"] else "")
+        elif feature_type == "somatic_variant":
+            feature = "{}{}{}".format(v["gene"],
                                       f" {v['protein_change']}"
-                                      if v['protein_change'] else '',
+                                      if v["protein_change"] else "",
                                       f" ({v['variant_annotation']})"
-                                      if v['variant_annotation'] else '')
-        elif feature_type == 'germline_variant':
-            feature = '{}{}'.format(v['gene'], ' (Pathogenic)'
-                                    if v['pathogenic'] == '1.0' else '')
-        elif feature_type == 'copy_number':
-            feature = '{} {}'.format(v['gene'], v['direction'])
-        elif feature_type == 'microsatellite_stability':
-            feature = '{}'.format(v.get('status'))
-        elif feature_type == 'mutational_signature':
-            csn = v['cosmic_signature_number']
-            feature = 'COSMIC Signature {}'.format(csn)
-        elif feature_type == 'mutational_burden':
-            clss = v['classification']
-            min_mut = v['minimum_mutations']
-            mut_per_mb = v['mutations_per_mb']
-            feature = '{}{}'.format(clss,
+                                      if v["variant_annotation"] else "")
+        elif feature_type == "germline_variant":
+            feature = "{}{}".format(v["gene"], " (Pathogenic)"
+                                    if v["pathogenic"] == "1.0" else "")
+        elif feature_type == "copy_number":
+            feature = "{} {}".format(v["gene"], v["direction"])
+        elif feature_type == "microsatellite_stability":
+            feature = "{}".format(v.get("status"))
+        elif feature_type == "mutational_signature":
+            csn = v["cosmic_signature_number"]
+            feature = "COSMIC Signature {}".format(csn)
+        elif feature_type == "mutational_burden":
+            clss = v["classification"]
+            min_mut = v["minimum_mutations"]
+            mut_per_mb = v["mutations_per_mb"]
+            feature = "{}{}".format(clss,
                                     f" (>= {min_mut} mutations)" if min_mut
                                     else (f" (>= {mut_per_mb} mutations/Mb)"
-                                          if mut_per_mb else ''))
-        elif feature_type == 'neoantigen_burden':
-            feature = '{}'.format(v['classification'])
-        elif feature_type == 'knockdown' or feature_type == 'silencing':
-            feature = '{}{}'.format(v['gene'], f" ({v['technique']})"
-                                    if v['technique'] else '')
+                                          if mut_per_mb else ""))
+        elif feature_type == "neoantigen_burden":
+            feature = "{}".format(v["classification"])
+        elif feature_type == "knockdown" or feature_type == "silencing":
+            feature = "{}{}".format(v["gene"], f" ({v['technique']})"
+                                    if v["technique"] else "")
         else:
-            feature = '{}'.format(v['event'])
+            feature = "{}".format(v["event"])
 
-        return {'feature': feature.strip()}
+        return {"feature": feature.strip()}
diff --git a/metakb/normalizers.py b/metakb/normalizers.py
index 176bc414..e6ac4766 100644
--- a/metakb/normalizers.py
+++ b/metakb/normalizers.py
@@ -1,7 +1,6 @@
 """Module for VICC normalizers."""
 from typing import Optional, Tuple
 
-from ga4gh.vrsatile.pydantic.vrs_models import VRSTypes
 from ga4gh.vrsatile.pydantic.vrsatile_models import VariationDescriptor, Extension
 from variation.query import QueryHandler as VariationQueryHandler
 from therapy.query import QueryHandler as TherapyQueryHandler
@@ -30,23 +29,20 @@ async def normalize_variation(self,
                                   queries) -> Optional[VariationDescriptor]:
         """Normalize variation queries.
 
-        :param list queries: Possible query strings to try to normalize
+        :param List[str] queries: Possible query strings to try to normalize
             which are used in the event that a MANE transcript cannot be found
         :return: A normalized variation
         """
         for query in queries:
             if not query:
                 continue
-
             try:
-                variation_norm_resp = \
-                    await self.variation_normalizer.normalize(query)
-                if variation_norm_resp:
-                    if variation_norm_resp.variation.type != VRSTypes.TEXT:
-                        return variation_norm_resp
+                variation_norm_resp = await self.variation_normalizer.normalize_handler.normalize(query)  # noqa: E501
+                if variation_norm_resp and variation_norm_resp.variation_descriptor:
+                    return variation_norm_resp.variation_descriptor
             except Exception as e:  # noqa: E722
-                logger.warning(f"Variation Normalizer raised an exception "
-                               f"using query {query}: {e}")
+                logger.warning(f"Variation Normalizer raised an exception using query"
+                               f" {query}: {e}")
         return None
 
     def normalize_gene(self, queries)\
@@ -66,8 +62,8 @@ def normalize_gene(self, queries)\
             try:
                 gene_norm_resp = self.gene_query_handler.normalize(query_str)
             except Exception as e:
-                logger.warning(f"Gene Normalizer raised an exception using "
-                               f"query {query_str}: {e}")
+                logger.warning(f"Gene Normalizer raised an exception using query "
+                               f"{query_str}: {e}")
             else:
                 if gene_norm_resp.match_type > highest_match:
                     highest_match = gene_norm_resp.match_type
@@ -95,8 +91,8 @@ def normalize_disease(self, queries)\
             try:
                 disease_norm_resp = self.disease_query_handler.normalize(query)
             except Exception as e:
-                logger.warning(f"Disease Normalizer raised an exception using "
-                               f"query {query}: {e}")
+                logger.warning(f"Disease Normalizer raised an exception using query "
+                               f"{query}: {e}")
             else:
                 if disease_norm_resp.match_type > highest_match:
                     highest_match = disease_norm_resp.match_type
diff --git a/metakb/query.py b/metakb/query.py
index ae2e9dd5..ec8db654 100644
--- a/metakb/query.py
+++ b/metakb/query.py
@@ -8,8 +8,7 @@
 from ga4gh.vrsatile.pydantic.vrsatile_models import Extension, Expression
 from neo4j.graph import Node
 from neo4j.data import Record
-from neo4j.work.transaction import Transaction
-from neo4j.work.simple import Session
+from neo4j import Transaction, Session
 
 from metakb.database import Graph
 from metakb.normalizers import VICCNormalizers
diff --git a/metakb/transform/civic.py b/metakb/transform/civic.py
index a882e546..c96d347a 100644
--- a/metakb/transform/civic.py
+++ b/metakb/transform/civic.py
@@ -2,6 +2,7 @@
 from typing import Optional, Dict, List, Set
 from pathlib import Path
 import logging
+import re
 
 from ga4gh.vrsatile.pydantic.vrsatile_models import VariationDescriptor, \
     Extension, Expression, GeneDescriptor, ValueObjectDescriptor
@@ -51,13 +52,17 @@ async def transform(self):
         variants = data['variants']
         genes = data['genes']
 
-        # Filter Variant IDs for
-        # Prognostic, Predictive, and Diagnostic evidence
-        supported_evidence_types = ['Prognostic', 'Predictive', 'Diagnostic']
-        vids = {e['variant_id'] for e in evidence_items
-                if e['evidence_type'] in supported_evidence_types}
-        vids |= {a['variant']['id'] for a in assertions
-                 if a['evidence_type'] in supported_evidence_types}
+        # Only want evidence with approved status
+        evidence_items = [e for e in evidence_items if e["status"] == "accepted"]
+
+        # Filter Variant IDs for Prognostic, Predictive, and Diagnostic evidence
+        supported_evidence_types = ['PROGNOSTIC', 'PREDICTIVE', 'DIAGNOSTIC']
+        evidence_items = [e for e in evidence_items
+                          if e["evidence_type"].upper() in supported_evidence_types]
+        assertions = [a for a in assertions
+                      if a["evidence_type"].upper() in supported_evidence_types]
+        vids = {e["variant_id"] for e in evidence_items}
+        vids |= {a["variant_id"] for a in assertions}
 
         await self._add_variation_descriptors(variants, vids)
         self._add_gene_descriptors(genes)
@@ -86,15 +91,15 @@ def _transform_evidence_and_assertions(self, records: List[Dict],
                 logger.warning(f"{civic_id} has status: {r['status']}")
                 continue
 
-            if r['evidence_type'] not in ['Predictive', 'Prognostic',
-                                          'Diagnostic']:
+            if r['evidence_type'] not in ['PREDICTIVE', 'PROGNOSTIC',
+                                          'DIAGNOSTIC']:
                 continue
             else:
                 # Functional Evidence types do not have a disease
                 if not r['disease']:
                     continue
 
-            if r['evidence_type'] == 'Predictive':
+            if r['evidence_type'] == 'PREDICTIVE':
                 if len(r['drugs']) != 1:
                     continue
                 else:
@@ -118,10 +123,7 @@ def _transform_evidence_and_assertions(self, records: List[Dict],
             if disease_descriptor not in self.disease_descriptors:
                 self.disease_descriptors.append(disease_descriptor)
 
-            if is_evidence:
-                variant_id = f"civic.vid:{r['variant_id']}"
-            else:
-                variant_id = f"civic.vid:{r['variant']['id']}"
+            variant_id = f"civic.vid:{r['variant_id']}"
             variation_descriptor = \
                 self.valid_ids['variation_descriptors'].get(variant_id)
             if not variation_descriptor:
@@ -201,9 +203,10 @@ def _get_evidence_direction(self, direction) -> Optional[str]:
         :param str direction: The civic evidence_direction value
         :return: `supports` or `does_not_support` or None
         """
-        if direction == 'Supports':
+        direction_upper = direction.upper()
+        if direction_upper == "SUPPORTS":
             return schemas.Direction.SUPPORTS.value
-        elif direction == 'Does Not Support':
+        elif direction_upper == "DOES_NOT_SUPPORT":
             return schemas.Direction.DOES_NOT_SUPPORT.value
         else:
             return None
@@ -220,18 +223,27 @@ def _get_assertion_evidence_level(self, assertion) -> Optional[str]:
             if assertion['amp_level'] == 'Not Applicable':
                 evidence_level = None
             else:
-                tier, level = assertion['amp_level'].split(' - ')
-                tier = tier.split()[1]
-                if tier == 'I':
-                    tier = 1
-                elif tier == 'II':
-                    tier = 2
-                elif tier == 'III':
-                    tier = 3
-                elif tier == 'IV':
-                    tier = 4
-                evidence_level = f"amp_asco_cap_2017_level:" \
-                                 f"{tier}{level.split()[1]}"
+                amp_level = assertion["amp_level"]
+                regex = re.compile(r"TIER_(?P<tier>\w+)_LEVEL_(?P<level>\w+)")
+                match = regex.match(amp_level)
+                if match:
+                    match = match.groupdict()
+                    tier = match["tier"]
+                    level = match["level"]
+
+                    if tier == 'I':
+                        tier = 1
+                    elif tier == 'II':
+                        tier = 2
+                    elif tier == 'III':
+                        tier = 3
+                    elif tier == 'IV':
+                        tier = 4
+
+                    evidence_level = f"amp_asco_cap_2017_level:" \
+                                     f"{tier}{level}"
+                else:
+                    raise Exception(f"{amp_level} not supported with regex")
         return evidence_level
 
     def _get_proposition(self, record, variation_descriptor,
@@ -333,11 +345,12 @@ def _get_variation_origin(self, variant_origin) -> Optional[str]:
         :param str variant_origin: CIViC variant origin
         :return: Variation origin
         """
-        if variant_origin == 'Somatic':
+        variant_origin = variant_origin.upper()
+        if variant_origin == "SOMATIC":
             origin = schemas.VariationOrigin.SOMATIC.value
-        elif variant_origin in ['Rare Germline', 'Common Germline']:
+        elif variant_origin in ["RARE_GERMLINE", "COMMON_GERMLINE"]:
             origin = schemas.VariationOrigin.GERMLINE.value
-        elif variant_origin == 'N/A':
+        elif variant_origin == "NA":
             origin = schemas.VariationOrigin.NOT_APPLICABLE.value
         else:
             origin = None
@@ -355,10 +368,13 @@ def _get_predicate(self, proposition_type,
             return None
 
         clin_sig = '_'.join(clin_sig.upper().split())
+        if clin_sig == "NA":
+            logger.info("NA predicate not supported")
+            return None
         predicate = None
 
         if proposition_type == schemas.PropositionType.PREDICTIVE:
-            if clin_sig == 'SENSITIVITY/RESPONSE':
+            if clin_sig == 'SENSITIVITYRESPONSE':
                 predicate = schemas.PredictivePredicate.SENSITIVITY
             elif clin_sig == 'RESISTANCE':
                 predicate = schemas.PredictivePredicate.RESISTANCE
@@ -416,7 +432,7 @@ async def _add_variation_descriptors(self, variants: List, vids: Set) -> None:
                     continue
 
             unable_to_normalize = {
-                "mutation", "amplification", "exon", "overexpression",
+                "mutation", "exon", "overexpression",
                 "frameshift", "promoter", "deletion", "type", "insertion",
                 "expression", "duplication", "copy", "underexpression",
                 "number", "variation", "repeat", "rearrangement", "activation",
@@ -431,12 +447,12 @@ async def _add_variation_descriptors(self, variants: List, vids: Set) -> None:
                                f"{variant_id}: {variant_query}")
                 continue
 
-            variation_norm_resp = await self.vicc_normalizers.normalize_variation(
+            variation_descriptor = await self.vicc_normalizers.normalize_variation(
                 [variant_query]
             )
 
             # Couldn't find normalized concept
-            if not variation_norm_resp:
+            if not variation_descriptor:
                 logger.warning("Variation Normalizer unable to normalize "
                                f"civic.vid:{variant['id']} using query "
                                f"{variant_query}")
@@ -451,8 +467,8 @@ async def _add_variation_descriptors(self, variants: List, vids: Set) -> None:
                 id=variant_id,
                 label=variant["name"],
                 description=variant["description"] if variant["description"] else None,  # noqa: E501
-                variation_id=variation_norm_resp.variation_id,
-                variation=variation_norm_resp.variation,
+                variation_id=variation_descriptor.variation_id,
+                variation=variation_descriptor.variation,
                 gene_context=f"civic.gid:{variant['gene_id']}",
                 structural_type=structural_type,
                 expressions=hgvs_exprs,
@@ -618,11 +634,20 @@ def _get_disease_descriptors(self, disease) \
         doid = disease['doid']
 
         if not doid:
-            logger.warning(f"{disease_id} ({display_name}) has null DOID")
+            logger.debug(f"{disease_id} ({display_name}) has null DOID")
             queries = [display_name]
             xrefs = []
         else:
-            doid = f"DOID:{disease['doid']}"
+            doid = f"DOID:{doid}"
+            # TODO: DOIDs might be wrong if there are leading zeros
+            # Will be fixed in https://github.com/griffithlab/civic-v2/issues/653
+            # Once fixed, we can remove this code
+            if "DOID:" in disease["disease_url"]:
+                if not disease["disease_url"].endswith(doid):
+                    logger.debug(f"DOID mismatch for civic disease id, {disease['id']}."
+                                 f" DOID={doid}. Name={display_name}")
+                    doid = disease["disease_url"].split("?id=")[-1]
+
             queries = [doid, display_name]
             xrefs = [doid]
 
@@ -779,7 +804,8 @@ def _get_aid_document(self, assertion: Dict) -> List[schemas.Document]:
         """
         # NCCN Guidlines
         documents = list()
-        label = assertion["nccn_guideline"]
+        nccn_guideline = assertion["nccn_guideline"] or dict()
+        label = nccn_guideline.get("name")
         version = assertion["nccn_guideline_version"]
         if label and version:
             doc_id = "https://www.nccn.org/professionals/physician_gls/default.aspx"  # noqa: E501
diff --git a/metakb/transform/moa.py b/metakb/transform/moa.py
index 622d0369..bee74e5c 100644
--- a/metakb/transform/moa.py
+++ b/metakb/transform/moa.py
@@ -234,15 +234,15 @@ async def _get_variation_descriptors(self, variant, g_descriptors):
         vrs_ref_allele_seq = variant['protein_change'][2] \
             if 'protein_change' in variant and variant['protein_change'] else None  # noqa: E501
 
-        v_norm_resp = None
+        variation_descriptor = None
         # For now, the normalizer only support a.a substitution
         if g_descriptors and 'protein_change' in variant and variant['protein_change']:  # noqa: E501
             gene = g_descriptors[0]['label']
             query = f"{gene} {variant['protein_change'][2:]}"
-            v_norm_resp = \
+            variation_descriptor = \
                 await self.vicc_normalizers.normalize_variation([query])
 
-            if not v_norm_resp:
+            if not variation_descriptor:
                 logger.warning(f"Variant Normalizer unable to normalize: "
                                f"moa.variant:{variant['id']}.")
                 return []
@@ -256,8 +256,8 @@ async def _get_variation_descriptors(self, variant, g_descriptors):
         variation_descriptor = VariationDescriptor(
             id=f"moa.variant:{variant['id']}",
             label=variant['feature'],
-            variation_id=v_norm_resp.variation_id,
-            variation=v_norm_resp.variation,
+            variation_id=variation_descriptor.variation_id,
+            variation=variation_descriptor.variation,
             gene_context=gene_context,
             vrs_ref_allele_seq=vrs_ref_allele_seq,
             extensions=self._get_variant_extensions(variant)
@@ -327,7 +327,7 @@ def _get_documents(self, source):
         :param: An evidence source
         :param: Keeps track of proposition and documents indexes
         """
-        if source['pmid'] != "None":
+        if source['pmid']:
             documents_id = f"pmid:{source['pmid']}"
         else:
             documents_id = source['url']
@@ -335,7 +335,7 @@ def _get_documents(self, source):
         xrefs = []
         if source['doi']:
             xrefs.append(f"doi:{source['doi']}")
-        if source['nct'] != "None":
+        if source['nct']:
             xrefs.append(f"nct:{source['nct']}")
 
         documents = schemas.Document(
diff --git a/metakb/version.py b/metakb/version.py
index a60bab27..0d6b9718 100644
--- a/metakb/version.py
+++ b/metakb/version.py
@@ -1,4 +1,4 @@
 """MetaKB version"""
 # REQ: EACH TIME VERSION IS UPDATED, MUST ALSO UPDATE LAST_UPDATED
-__version__ = "1.1.0-alpha.9"
-LAST_UPDATED = "2022-06-13"
+__version__ = "1.1.0"
+LAST_UPDATED = "2022-11-08"
diff --git a/requirements-dev.txt b/requirements-dev.txt
index 04936d7e..665c7b7d 100644
--- a/requirements-dev.txt
+++ b/requirements-dev.txt
@@ -1,213 +1,223 @@
 -i https://pypi.org/simple
-aiofiles==0.8.0
-anyio==3.6.1
+aiofiles==22.1.0 ; python_version >= '3.7' and python_version < '4.0'
+anyio==3.6.2 ; python_full_version >= '3.6.2'
 appdirs==1.4.4
-appnope==0.1.3
-argcomplete==2.0.0
+appnope==0.1.3 ; platform_system == 'Darwin'
+argcomplete==2.0.0 ; python_version >= '3.6'
 argh==0.26.2
-asgiref==3.5.2
-asttokens==2.0.5
-asyncclick==8.1.3.2
-asyncpg==0.25.0
-attrs==21.4.0
+argon2-cffi==21.3.0 ; python_version >= '3.6'
+argon2-cffi-bindings==21.2.0 ; python_version >= '3.6'
+asttokens==2.1.0
+asyncclick==8.1.3.4
+asyncpg==0.27.0 ; python_full_version >= '3.7.0'
+attrs==22.1.0 ; python_version >= '3.5'
+babel==2.11.0 ; python_version >= '3.6'
 backcall==0.2.0
-backoff==2.1.2
+backoff==2.1.2 ; python_version >= '3.7' and python_version < '4.0'
 backports-datetime-fromisoformat==1.0.0
-beautifulsoup4==4.11.1
+beautifulsoup4==4.11.1 ; python_full_version >= '3.6.0'
 biocommons.seqrepo==0.6.5
-bioregistry[align]==0.5.21
-bioutils==0.5.6
-bioversions==0.5.21
-boto3==1.24.8
-botocore==1.27.8
+bioregistry[align]==0.6.8 ; python_version >= '3.7'
+bioutils==0.5.7 ; python_version >= '3.6'
+bioversions==0.5.79
+bleach==5.0.1 ; python_version >= '3.7'
+boto3==1.26.4
+botocore==1.29.4
 bs4==0.0.1
 cachier==1.5.4
-canonicaljson==1.6.2
-cattrs==1.10.0
-certifi==2022.5.18.1
-charset-normalizer==2.0.12
-chembl-downloader==0.3.0
-civicpy==1.1.3
+canonicaljson==1.6.4 ; python_version >= '3.7'
+cattrs==22.2.0 ; python_version >= '3.7'
+certifi==2022.9.24 ; python_version >= '3.6'
+cffi==1.15.1
+cfgv==3.3.1 ; python_full_version >= '3.6.1'
+charset-normalizer==2.1.1 ; python_full_version >= '3.6.0'
+chembl-downloader==0.4.0
+civicpy==2.0.0
 class-resolver==0.3.10
 click==8.1.3
 click-default-group==1.2.2
-coloredlogs==15.0.1
-configparser==5.2.0
-cssselect==1.1.0
-cython==0.29.30
-dataclasses-json==0.5.7
-decorator==5.1.1
+coloredlogs==15.0.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+configparser==5.3.0 ; python_version >= '3.7'
+coverage==6.5.0
+coveralls==3.3.1
+cssselect==1.2.0 ; python_version >= '3.7'
+curies==0.4.0 ; python_version >= '3.7'
+dataclasses-json==0.5.7 ; python_version >= '3.6'
+debugpy==1.6.3 ; python_version >= '3.7'
+decorator==5.1.1 ; python_version >= '3.5'
 defusedxml==0.7.1
 deprecation==2.1.0
-disease-normalizer==0.2.12
-executing==0.8.3
-fake-useragent==0.1.11
-fastapi==0.78.0
-ga4gh.vrs[extras]==0.8a0
+disease-normalizer[dev]==0.2.15
+distlib==0.3.6
+docopt==0.6.2
+entrypoints==0.4 ; python_version >= '3.6'
+exceptiongroup==1.0.1 ; python_version < '3.11'
+executing==1.2.0
+fake-useragent==0.1.14
+fastapi==0.86.0
+fastjsonschema==2.16.2
+filelock==3.8.0 ; python_version >= '3.7'
+flake8==5.0.4
+flake8-annotations==2.9.1
+flake8-docstrings==1.6.0
+flake8-import-order==0.18.1
+flake8-quotes==3.3.1
+ga4gh.vrs==0.8.0dev0
 ga4gh.vrsatile.pydantic==0.0.11
-gene-normalizer==0.1.27
-gffutils==0.11.0
-h11==0.13.0
+gene-normalizer[dev]==0.1.30
+gffutils==0.11.1
+h11==0.14.0 ; python_version >= '3.7'
 hgvs==1.5.2
-httptools==0.4.0
-humanfriendly==10.0
-idna==3.3
-importlib-metadata==4.11.4
-inflection==0.5.1
-ipython==8.4.0
+humanfriendly==10.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+identify==2.5.8 ; python_version >= '3.7'
+idna==3.4 ; python_version >= '3.5'
+importlib-metadata==5.0.0 ; python_version >= '3.7'
+inflection==0.5.1 ; python_version >= '3.5'
+iniconfig==1.1.1
+ipykernel==6.17.0
+ipython==8.6.0 ; python_version >= '3.8'
+ipython-genutils==0.2.0
+ipywidgets==8.0.2 ; python_version >= '3.7'
 isodate==0.6.1
-jedi==0.18.1
-jmespath==1.0.0
+jedi==0.18.1 ; python_version >= '3.6'
+jinja2==3.1.2 ; python_version >= '3.7'
+jmespath==1.0.1 ; python_version >= '3.7'
+json5==0.9.10
 jsondiff==2.0.0
 jsonschema==3.2.0
-lxml==4.9.0
-markdown==3.3.7
-marshmallow==3.16.0
+jupyter==1.0.0
+jupyter-client==7.4.4 ; python_version >= '3.7'
+jupyter-console==6.4.4 ; python_version >= '3.7'
+jupyter-core==4.11.2 ; python_version >= '3.7'
+jupyter-server==1.23.0 ; python_version >= '3.7'
+jupyterlab==3.5.0
+jupyterlab-pygments==0.2.2 ; python_version >= '3.7'
+jupyterlab-server==2.16.2 ; python_version >= '3.7'
+jupyterlab-widgets==3.0.3 ; python_version >= '3.7'
+lxml==4.9.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+markdown==3.4.1 ; python_version >= '3.7'
+markupsafe==2.1.1 ; python_version >= '3.7'
+marshmallow==3.18.0 ; python_version >= '3.7'
 marshmallow-enum==1.5.1
-matplotlib-inline==0.1.3
-more-click==0.1.1
+matplotlib-inline==0.1.6 ; python_version >= '3.5'
+mccabe==0.7.0 ; python_version >= '3.6'
+-e .
+mistune==2.0.4
+mock==4.0.3
+more-click==0.1.1 ; python_version >= '3.7'
 mwoauth==0.3.8
+mypy==0.990
 mypy-extensions==0.4.3
-neo4j==4.4.4
-networkx==2.8.3
-numpy==1.22.4
-oauthlib==3.2.0
-obonet==0.3.0
-owlready2==0.38
-packaging==21.3
-pandas==1.4.2
+nbclassic==0.4.8 ; python_version >= '3.7'
+nbclient==0.7.0 ; python_full_version >= '3.7.0'
+nbconvert==7.2.3 ; python_version >= '3.7'
+nbformat==5.7.0 ; python_version >= '3.7'
+neo4j==5.2.0
+nest-asyncio==1.5.6 ; python_version >= '3.5'
+networkx==2.8.8 ; python_version >= '3.8'
+nodeenv==1.7.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6'
+notebook==6.5.2 ; python_version >= '3.7'
+notebook-shim==0.2.2 ; python_version >= '3.7'
+numpy==1.23.4 ; python_version >= '3.8'
+oauthlib==3.2.2 ; python_version >= '3.6'
+obonet==0.3.0 ; python_version >= '3.5'
+owlready2==0.39
+packaging==21.3 ; python_version >= '3.6'
+pandas==1.5.1 ; python_version >= '3.8'
+pandocfilters==1.5.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
 parse==1.19.0
 parsley==1.3
-parso==0.8.3
+parso==0.8.3 ; python_version >= '3.6'
 pathtools==0.1.2
-pexpect==4.8.0
+pexpect==4.8.0 ; sys_platform != 'win32'
 pickleshare==0.7.5
-portalocker==2.4.0
-prompt-toolkit==3.0.29
-psycopg2==2.9.3
+platformdirs==2.5.3 ; python_version >= '3.7'
+pluggy==1.0.0 ; python_version >= '3.6'
+portalocker==2.6.0 ; python_version >= '3.5'
+pre-commit==2.20.0
+prometheus-client==0.15.0 ; python_version >= '3.6'
+prompt-toolkit==3.0.32 ; python_full_version >= '3.6.2'
+psutil==5.9.4 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+psycopg2==2.9.5 ; python_version >= '3.6'
+psycopg2-binary==2.9.5
 ptyprocess==0.7.0
 pure-eval==0.2.2
-pydantic==1.9.1
+py==1.11.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+pycodestyle==2.9.1 ; python_version >= '3.6'
+pycparser==2.21
+pydantic==1.10.2
+pydocstyle==6.1.1 ; python_version >= '3.6'
 pyee==8.2.2
-pyfaidx==0.7.0
-pygments==2.12.0
-pyjwt==2.4.0
+pyfaidx==0.7.1
+pyflakes==2.5.0 ; python_version >= '3.6'
+pygments==2.13.0 ; python_version >= '3.6'
+pyjwt==2.6.0 ; python_version >= '3.7'
 pyliftover==0.4
-pyparsing==2.4.7
-pyppeteer==1.0.2
+pyparsing==3.0.9 ; python_full_version >= '3.6.8'
+pyppeteer==1.0.2 ; python_version >= '3.7' and python_version < '4.0'
 pyquery==1.4.3
-pyrsistent==0.18.1
-pysam==0.19.1
-pystow==0.4.4
-python-dateutil==2.8.2
+pyrsistent==0.19.2 ; python_version >= '3.7'
+pysam==0.20.0
+pystow==0.4.7 ; python_version >= '3.7'
+pytest==7.2.0
+pytest-asyncio==0.20.1
+pytest-cov==4.0.0
+python-dateutil==2.8.2 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2'
 python-jsonschema-objects==0.4.1
-pytz==2022.1
-pyyaml==6.0
-rdflib==6.1.1
-requests==2.28.0
-requests-cache==0.9.4
+pytrie==0.4.0
+pytz==2022.6
+pyyaml==6.0 ; python_version >= '3.6'
+pyzmq==24.0.1 ; python_version >= '3.6'
+qtconsole==5.4.0 ; python_version >= '3.7'
+qtpy==2.3.0 ; python_version >= '3.7'
+rdflib==6.2.0
+requests==2.28.1
+requests-cache==0.9.7
 requests-ftp==0.3.1
-requests-html==0.10.0
-requests-oauthlib==1.3.1
-s3transfer==0.6.0
-setuptools==62.4.0
-simplejson==3.17.6
-six==1.16.0
-sniffio==1.2.0
-soupsieve==2.3.2.post1
-sqlparse==0.4.2
-stack-data==0.2.0
-starlette==0.19.1
-tabulate==0.8.9
-thera-py==0.3.5
-tqdm==4.64.0
-traitlets==5.2.2.post1
-typing-extensions==4.2.0
-typing-inspect==0.7.1
-url-normalize==1.4.3
-urllib3==1.26.9
-uta-tools==0.1.1
-uvicorn==0.17.6
-uvloop==0.16.0
-variation-normalizer==0.4.0a7
-vcfpy==0.13.4
-w3lib==1.22.0
-watchdog==2.1.9
-wcwidth==0.2.5
-websockets==10.3
-wikibaseintegrator==0.11.0
-yoyo-migrations==7.3.2
-zipp==3.8.0
-argon2-cffi==21.3.0
-argon2-cffi-bindings==21.2.0
-babel==2.10.1
-bleach==5.0.0
-cffi==1.15.0
-cfgv==3.3.1
-coverage==6.4.1
-coveralls==3.3.1
-debugpy==1.6.0
-distlib==0.3.4
-docopt==0.6.2
-entrypoints==0.4
-fastjsonschema==2.15.3
-filelock==3.7.1
-flake8==4.0.1
-flake8-docstrings==1.6.0
-identify==2.5.1
-iniconfig==1.1.1
-ipykernel==6.14.0
-ipython-genutils==0.2.0
-ipywidgets==7.7.0
-jinja2==3.1.2
-json5==0.9.8
-jupyter==1.0.0
-jupyter-client==7.3.4
-jupyter-console==6.4.3
-jupyter-core==4.10.0
-jupyter-server==1.17.1
-jupyterlab==3.4.3
-jupyterlab-pygments==0.2.2
-jupyterlab-server==2.14.0
-jupyterlab-widgets==1.1.0
-markupsafe==2.1.1
-mccabe==0.6.1
--e .
-mistune==0.8.4
-mock==4.0.3
-nbclassic==0.3.7
-nbclient==0.6.4
-nbconvert==6.5.0
-nbformat==5.4.0
-nest-asyncio==1.5.5
-nodeenv==1.6.0
-notebook==6.4.12
-notebook-shim==0.1.0
-pandocfilters==1.5.0
-platformdirs==2.5.2
-pluggy==1.0.0
-pre-commit==2.19.0
-prometheus-client==0.14.1
-psutil==5.9.1
-py==1.11.0
-pycodestyle==2.8.0
-pycparser==2.21
-pydocstyle==6.1.1
-pyflakes==2.4.0
-pytest==7.1.2
-pytest-asyncio==0.18.3
-pytest-cov==3.0.0
-pyzmq==23.1.0
-qtconsole==5.3.1
-qtpy==2.1.0
+requests-html==0.10.0 ; python_full_version >= '3.6.0'
+requests-oauthlib==1.3.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+s3transfer==0.6.0 ; python_version >= '3.7'
 send2trash==1.8.0
+setuptools==65.5.1 ; python_version >= '3.7'
+simplejson==3.17.6 ; python_version >= '2.5' and python_version not in '3.0, 3.1, 3.2'
+six==1.16.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2'
+sniffio==1.3.0 ; python_version >= '3.7'
 snowballstemmer==2.2.0
-terminado==0.15.0
-tinycss2==1.1.1
-toml==0.10.2
-tomli==2.0.1
-tornado==6.1
-virtualenv==20.14.1
+sortedcontainers==2.4.0
+soupsieve==2.3.2.post1 ; python_version >= '3.6'
+sqlparse==0.4.3 ; python_version >= '3.5'
+stack-data==0.6.0
+starlette==0.20.4 ; python_version >= '3.7'
+tabulate==0.9.0 ; python_version >= '3.7'
+terminado==0.17.0 ; python_version >= '3.7'
+thera-py[dev]==0.3.7
+tinycss2==1.2.1 ; python_version >= '3.7'
+toml==0.10.2 ; python_version >= '2.6' and python_version not in '3.0, 3.1, 3.2'
+tomli==2.0.1 ; python_version < '3.11'
+tornado==6.2 ; python_version >= '3.7'
+tox==3.27.0
+tqdm==4.64.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+traitlets==5.5.0 ; python_version >= '3.7'
+types-pyyaml==6.0.12.1
+types-requests==2.28.11.3
+types-urllib3==1.26.25.2
+typing-extensions==4.4.0 ; python_version >= '3.7'
+typing-inspect==0.8.0
+ujson==5.4.0 ; python_version >= '3.7'
+url-normalize==1.4.3 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5'
+urllib3==1.26.12 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5' and python_version < '4'
+uta-tools==0.1.3 ; python_version >= '3.8'
+uvicorn==0.19.0
+variation-normalizer==0.5.1
+vcfpy==0.13.5
+virtualenv==20.16.6 ; python_version >= '3.6'
+w3lib==2.0.1 ; python_version >= '3.6'
+watchdog==2.1.9 ; python_version >= '3.6'
+wcwidth==0.2.5
 webencodings==0.5.1
-websocket-client==1.3.2
-widgetsnbextension==3.6.0
+websocket-client==1.4.2 ; python_version >= '3.7'
+websockets==10.4 ; python_version >= '3.7'
+widgetsnbextension==4.0.3 ; python_version >= '3.7'
+wikibaseintegrator==0.12.1
+yoyo-migrations==8.1.0
+zipp==3.10.0 ; python_version >= '3.7'
diff --git a/requirements.txt b/requirements.txt
index 576d16cc..033a55b3 100644
--- a/requirements.txt
+++ b/requirements.txt
@@ -1,140 +1,178 @@
 -i https://pypi.org/simple
-aiofiles==0.8.0
-anyio==3.6.1
+aiofiles==22.1.0 ; python_version >= '3.7' and python_version < '4.0'
+anyio==3.6.2 ; python_full_version >= '3.6.2'
 appdirs==1.4.4
-appnope==0.1.3
-argcomplete==2.0.0
+appnope==0.1.3 ; platform_system == 'Darwin'
+argcomplete==2.0.0 ; python_version >= '3.6'
 argh==0.26.2
-asgiref==3.5.2
-asttokens==2.0.5
-asyncclick==8.1.3.2
-asyncpg==0.25.0
-attrs==21.4.0
+asttokens==2.1.0
+asyncclick==8.1.3.4
+asyncpg==0.27.0 ; python_full_version >= '3.7.0'
+attrs==22.1.0 ; python_version >= '3.5'
 backcall==0.2.0
-backoff==2.1.2
+backoff==2.1.2 ; python_version >= '3.7' and python_version < '4.0'
 backports-datetime-fromisoformat==1.0.0
-beautifulsoup4==4.11.1
+beautifulsoup4==4.11.1 ; python_full_version >= '3.6.0'
 biocommons.seqrepo==0.6.5
-bioregistry[align]==0.5.21
-bioutils==0.5.6
-bioversions==0.5.21
-boto3==1.24.8
-botocore==1.27.8
+bioregistry[align]==0.6.8 ; python_version >= '3.7'
+bioutils==0.5.7 ; python_version >= '3.6'
+bioversions==0.5.79
+boto3==1.26.4
+botocore==1.29.4
 bs4==0.0.1
 cachier==1.5.4
-canonicaljson==1.6.2
-cattrs==1.10.0
-certifi==2022.5.18.1
-charset-normalizer==2.0.12
-chembl-downloader==0.3.0
-civicpy==1.1.3
+canonicaljson==1.6.4 ; python_version >= '3.7'
+cattrs==22.2.0 ; python_version >= '3.7'
+certifi==2022.9.24 ; python_version >= '3.6'
+cfgv==3.3.1 ; python_full_version >= '3.6.1'
+charset-normalizer==2.1.1 ; python_full_version >= '3.6.0'
+chembl-downloader==0.4.0
+civicpy==2.0.0
 class-resolver==0.3.10
 click==8.1.3
 click-default-group==1.2.2
-coloredlogs==15.0.1
-configparser==5.2.0
-cssselect==1.1.0
-cython==0.29.30
-dataclasses-json==0.5.7
-decorator==5.1.1
+coloredlogs==15.0.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+configparser==5.3.0 ; python_version >= '3.7'
+cssselect==1.2.0 ; python_version >= '3.7'
+curies==0.4.0 ; python_version >= '3.7'
+dataclasses-json==0.5.7 ; python_version >= '3.6'
+debugpy==1.6.3 ; python_version >= '3.7'
+decorator==5.1.1 ; python_version >= '3.5'
 defusedxml==0.7.1
 deprecation==2.1.0
-disease-normalizer==0.2.12
-executing==0.8.3
-fake-useragent==0.1.11
-fastapi==0.78.0
-ga4gh.vrs[extras]==0.8a0
+disease-normalizer[dev]==0.2.15
+distlib==0.3.6
+entrypoints==0.4 ; python_version >= '3.6'
+exceptiongroup==1.0.1 ; python_version < '3.11'
+executing==1.2.0
+fake-useragent==0.1.14
+fastapi==0.86.0
+filelock==3.8.0 ; python_version >= '3.7'
+flake8==5.0.4
+flake8-annotations==2.9.1
+flake8-docstrings==1.6.0
+flake8-import-order==0.18.1
+flake8-quotes==3.3.1
+ga4gh.vrs==0.8.0dev0
 ga4gh.vrsatile.pydantic==0.0.11
-gene-normalizer==0.1.27
-gffutils==0.11.0
-h11==0.13.0
+gene-normalizer[dev]==0.1.30
+gffutils==0.11.1
+h11==0.14.0 ; python_version >= '3.7'
 hgvs==1.5.2
-httptools==0.4.0
-humanfriendly==10.0
-idna==3.3
-importlib-metadata==4.11.4
-inflection==0.5.1
-ipython==8.4.0
+humanfriendly==10.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+identify==2.5.8 ; python_version >= '3.7'
+idna==3.4 ; python_version >= '3.5'
+importlib-metadata==5.0.0 ; python_version >= '3.7'
+inflection==0.5.1 ; python_version >= '3.5'
+ipykernel==6.17.0
+ipython==8.6.0 ; python_version >= '3.8'
 isodate==0.6.1
-jedi==0.18.1
-jmespath==1.0.0
+jedi==0.18.1 ; python_version >= '3.6'
+jmespath==1.0.1 ; python_version >= '3.7'
 jsondiff==2.0.0
 jsonschema==3.2.0
-lxml==4.9.0
-markdown==3.3.7
-marshmallow==3.16.0
+jupyter-client==7.4.4 ; python_version >= '3.7'
+jupyter-core==4.11.2 ; python_version >= '3.7'
+lxml==4.9.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+markdown==3.4.1 ; python_version >= '3.7'
+marshmallow==3.18.0 ; python_version >= '3.7'
 marshmallow-enum==1.5.1
-matplotlib-inline==0.1.3
-more-click==0.1.1
+matplotlib-inline==0.1.6 ; python_version >= '3.5'
+mccabe==0.7.0 ; python_version >= '3.6'
+more-click==0.1.1 ; python_version >= '3.7'
 mwoauth==0.3.8
+mypy==0.990
 mypy-extensions==0.4.3
-neo4j==4.4.4
-networkx==2.8.3
-numpy==1.22.4
-oauthlib==3.2.0
-obonet==0.3.0
-owlready2==0.38
-packaging==21.3
-pandas==1.4.2
+neo4j==5.2.0
+nest-asyncio==1.5.6 ; python_version >= '3.5'
+networkx==2.8.8 ; python_version >= '3.8'
+nodeenv==1.7.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6'
+numpy==1.23.4 ; python_version >= '3.8'
+oauthlib==3.2.2 ; python_version >= '3.6'
+obonet==0.3.0 ; python_version >= '3.5'
+owlready2==0.39
+packaging==21.3 ; python_version >= '3.6'
+pandas==1.5.1 ; python_version >= '3.8'
 parse==1.19.0
 parsley==1.3
-parso==0.8.3
+parso==0.8.3 ; python_version >= '3.6'
 pathtools==0.1.2
-pexpect==4.8.0
+pexpect==4.8.0 ; sys_platform != 'win32'
 pickleshare==0.7.5
-portalocker==2.4.0
-prompt-toolkit==3.0.29
-psycopg2==2.9.3
+platformdirs==2.5.3 ; python_version >= '3.7'
+pluggy==1.0.0 ; python_version >= '3.6'
+portalocker==2.6.0 ; python_version >= '3.5'
+pre-commit==2.20.0
+prompt-toolkit==3.0.32 ; python_full_version >= '3.6.2'
+psutil==5.9.4 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+psycopg2==2.9.5 ; python_version >= '3.6'
+psycopg2-binary==2.9.5
 ptyprocess==0.7.0
 pure-eval==0.2.2
-pydantic==1.9.1
+py==1.11.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4'
+pycodestyle==2.9.1 ; python_version >= '3.6'
+pydantic==1.10.2
+pydocstyle==6.1.1 ; python_version >= '3.6'
 pyee==8.2.2
-pyfaidx==0.7.0
-pygments==2.12.0
-pyjwt==2.4.0
+pyfaidx==0.7.1
+pyflakes==2.5.0 ; python_version >= '3.6'
+pygments==2.13.0 ; python_version >= '3.6'
+pyjwt==2.6.0 ; python_version >= '3.7'
 pyliftover==0.4
-pyparsing==2.4.7
-pyppeteer==1.0.2
+pyparsing==3.0.9 ; python_full_version >= '3.6.8'
+pyppeteer==1.0.2 ; python_version >= '3.7' and python_version < '4.0'
 pyquery==1.4.3
-pyrsistent==0.18.1
-pysam==0.19.1
-pystow==0.4.4
-python-dateutil==2.8.2
+pyrsistent==0.19.2 ; python_version >= '3.7'
+pysam==0.20.0
+pystow==0.4.7 ; python_version >= '3.7'
+python-dateutil==2.8.2 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2'
 python-jsonschema-objects==0.4.1
-pytz==2022.1
-pyyaml==6.0
-rdflib==6.1.1
-requests==2.28.0
-requests-cache==0.9.4
+pytrie==0.4.0
+pytz==2022.6
+pyyaml==6.0 ; python_version >= '3.6'
+pyzmq==24.0.1 ; python_version >= '3.6'
+rdflib==6.2.0
+requests==2.28.1
+requests-cache==0.9.7
 requests-ftp==0.3.1
-requests-html==0.10.0
-requests-oauthlib==1.3.1
-s3transfer==0.6.0
-setuptools==62.4.0
-simplejson==3.17.6
-six==1.16.0
-sniffio==1.2.0
-soupsieve==2.3.2.post1
-sqlparse==0.4.2
-stack-data==0.2.0
-starlette==0.19.1
-tabulate==0.8.9
-thera-py==0.3.5
-tqdm==4.64.0
-traitlets==5.2.2.post1
-typing-extensions==4.2.0
-typing-inspect==0.7.1
-url-normalize==1.4.3
-urllib3==1.26.9
-uta-tools==0.1.1
-uvicorn==0.17.6
-uvloop==0.16.0
-variation-normalizer==0.4.0a7
-vcfpy==0.13.4
-w3lib==1.22.0
-watchdog==2.1.9
+requests-html==0.10.0 ; python_full_version >= '3.6.0'
+requests-oauthlib==1.3.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+s3transfer==0.6.0 ; python_version >= '3.7'
+setuptools==65.5.1 ; python_version >= '3.7'
+simplejson==3.17.6 ; python_version >= '2.5' and python_version not in '3.0, 3.1, 3.2'
+six==1.16.0 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2'
+sniffio==1.3.0 ; python_version >= '3.7'
+snowballstemmer==2.2.0
+sortedcontainers==2.4.0
+soupsieve==2.3.2.post1 ; python_version >= '3.6'
+sqlparse==0.4.3 ; python_version >= '3.5'
+stack-data==0.6.0
+starlette==0.20.4 ; python_version >= '3.7'
+tabulate==0.9.0 ; python_version >= '3.7'
+thera-py[dev]==0.3.7
+toml==0.10.2 ; python_version >= '2.6' and python_version not in '3.0, 3.1, 3.2'
+tomli==2.0.1 ; python_version < '3.11'
+tornado==6.2 ; python_version >= '3.7'
+tox==3.27.0
+tqdm==4.64.1 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3'
+traitlets==5.5.0 ; python_version >= '3.7'
+types-pyyaml==6.0.12.1
+types-requests==2.28.11.3
+types-urllib3==1.26.25.2
+typing-extensions==4.4.0 ; python_version >= '3.7'
+typing-inspect==0.8.0
+ujson==5.4.0 ; python_version >= '3.7'
+url-normalize==1.4.3 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5'
+urllib3==1.26.12 ; python_version >= '2.7' and python_version not in '3.0, 3.1, 3.2, 3.3, 3.4, 3.5' and python_version < '4'
+uta-tools==0.1.3 ; python_version >= '3.8'
+uvicorn==0.19.0
+variation-normalizer==0.5.1
+vcfpy==0.13.5
+virtualenv==20.16.6 ; python_version >= '3.6'
+w3lib==2.0.1 ; python_version >= '3.6'
+watchdog==2.1.9 ; python_version >= '3.6'
 wcwidth==0.2.5
-websockets==10.3
-wikibaseintegrator==0.11.0
-yoyo-migrations==7.3.2
-zipp==3.8.0
+websockets==10.4 ; python_version >= '3.7'
+wikibaseintegrator==0.12.1
+yoyo-migrations==8.1.0
+zipp==3.10.0 ; python_version >= '3.7'
diff --git a/setup.cfg b/setup.cfg
index 55689764..2bb48687 100644
--- a/setup.cfg
+++ b/setup.cfg
@@ -24,24 +24,23 @@ python_requires = >=3.8
 zip_safe = False
 
 install_requires =
-    ga4gh.vrs[extras] >=0.7.5.dev1
-    civicpy
+    ga4gh.vrs ==0.8.0dev0
+    civicpy >=2.0.0
     requests
     jsondiff
     pydantic
     requests-cache
-    gene-normalizer >=0.1.25
-    disease-normalizer >=0.2.12
-    thera-py >= 0.3.4
+    gene-normalizer[dev] ==0.1.30
+    disease-normalizer[dev] ==0.2.15
+    thera-py[dev] ==0.3.7
     neo4j
     uvicorn
     fastapi
     asyncclick
-    typing-extensions
     boto3
     botocore
-    variation-normalizer >=0.4.0a7
-    ga4gh.vrsatile.pydantic >=0.0.11
+    variation-normalizer ==0.5.1
+    ga4gh.vrsatile.pydantic ==0.0.11
 
 tests_require =
     pytest
diff --git a/tests/conftest.py b/tests/conftest.py
index 15210b7e..8a9e9b18 100644
--- a/tests/conftest.py
+++ b/tests/conftest.py
@@ -140,17 +140,17 @@ def civic_gid19():
         "id": "civic.gid:19",
         "type": "GeneDescriptor",
         "label": "EGFR",
-        "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. \nOverproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).",  # noqa: E501
+        "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).",  # noqa: E501
         "gene_id": "hgnc:3236",
         "alternate_labels": [
-            "ERRP",
             "EGFR",
-            "mENA",
-            "PIG61",
-            "NISBD2",
-            "HER1",
+            "ERBB",
             "ERBB1",
-            "ERBB"
+            "ERRP",
+            "HER1",
+            "NISBD2",
+            "PIG61",
+            "mENA"
         ],
         "xrefs": [
             "ncbigene:1956"
@@ -933,7 +933,7 @@ def civic_eid1756_statement():
     """Create test fixture for CIViC EID1756 statement."""
     return {
         "id": "civic.eid:1756",
-        "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",  # noqa: E501
+        "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai. Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",  # noqa: E501
         "direction": "supports",
         "evidence_level": "civic.evidence_level:B",
         "proposition": "proposition:cDLAt3AJPrHQPQ--JpKU4MkU528_kE-a",
@@ -1181,13 +1181,13 @@ def moa_vid71():
                 "name": "moa_representative_coordinate",
                 "value": {
                     "chromosome": "9",
-                    "start_position": "133747580.0",
-                    "end_position": "133747580.0",
+                    "start_position": "133747580",
+                    "end_position": "133747580",
                     "reference_allele": "C",
                     "alternate_allele": "T",
                     "cdna_change": "c.944C>T",
                     "protein_change": "p.T315I",
-                    "exon": "5.0"
+                    "exon": "5"
                 },
                 "type": "Extension"
             }
diff --git a/tests/data/deltas/main_moa.json b/tests/data/deltas/main_moa.json
index 76c06de0..ee3d6095 100644
--- a/tests/data/deltas/main_moa.json
+++ b/tests/data/deltas/main_moa.json
@@ -1,73 +1,73 @@
 {
 	"assertions": [
 		{
-			"id": 3, 
-			"context": null, 
-			"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", 
+			"id": 3,
+			"context": null,
+			"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
 			"disease": {
-				"name": "Acute Lymphoid Leukemia", 
-				"oncotree_code": null, 
+				"name": "Acute Lymphoid Leukemia",
+				"oncotree_code": null,
 				"oncotree_term": null
-			}, 
-			"therapy_name": "Dasatinib", 
-			"therapy_type": "Targeted therapy", 
+			},
+			"therapy_name": "Dasatinib",
+			"therapy_type": "Targeted therapy",
 			"clinical_significance": "sensitivity",
-			"predictive_implication": "FDA-Approved", 
-			"feature_ids": [3], 
-			"favorable_prognosis": null, 
-			"created_on": "01/07/21", 
-			"last_updated": "2020-11-12", 
-			"submitted_by": "breardon@broadinstitute.org", 
-			"validated": true, 
-			"source_ids": [2], 
+			"predictive_implication": "FDA-Approved",
+			"feature_ids": [3],
+			"favorable_prognosis": null,
+			"created_on": "01/07/21",
+			"last_updated": "2020-11-12",
+			"submitted_by": "breardon@broadinstitute.org",
+			"validated": true,
+			"source_ids": [2],
 			"variant": {
-				"id": 3, 
+				"id": 3,
 				"feature_type": "rearrangement",
-				"rearrangement_type": "Fusion", 
-				"gene1": "BCR", 
-				"gene2": "ABL1", 
-				"locus": null, 
+				"rearrangement_type": "Fusion",
+				"gene1": "BCR",
+				"gene2": "ABL1",
+				"locus": null,
 				"feature": "BCR--ABL1 Fusion"
 			},
 			"test update delete": "delete"
 		}
-	], 
+	],
 	"sources": [
 		{
-			"id": 2, 
-			"type": "FDA", 
-			"assertion_id": [2], 
-			"doi": null, 
-			"nct": null, 
-			"pmid": "None", 
-			"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", 
+			"id": 2,
+			"type": "FDA",
+			"assertion_id": [2],
+			"doi": null,
+			"nct": null,
+			"pmid": "None",
+			"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
 			"citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020."
 		}
-	], 
+	],
 	"variants": [
 		{
 			"id": 3,
-			"feature_type": "rearrangement",  
-			"rearrangement_type": "Fusion", 
-			"gene1": "BCR", 
-			"gene2": "ABL1", 
-			"locus": null, 
+			"feature_type": "rearrangement",
+			"rearrangement_type": "Fusion",
+			"gene1": "BCR",
+			"gene2": "ABL1",
+			"locus": null,
 			"feature": "BCR--ABL1 Fusion"
 		},
 		{
 			"id": 296,
-			"feature_type": "somatic_variant", 
-			"gene": "EZH2", 
-			"chromosome": "7", 
-			"start_position": "148508728.0", 
-			"end_position": "148508728.0", 
-			"reference_allele": "A", 
-			"alternate_allele": "T", 
-			"cdna_change": "c.1936T>A", 
-			"protein_change": "p.Y646N", 
-			"variant_annotation": "Missense", 
-			"exon": "16.0", 
-			"rsid": null, 
+			"feature_type": "somatic_variant",
+			"gene": "EZH2",
+			"chromosome": "7",
+			"start_position": "148508728.0",
+			"end_position": "148508728.0",
+			"reference_allele": "A",
+			"alternate_allele": "T",
+			"cdna_change": "c.1936T>A",
+			"protein_change": "p.Y646N",
+			"variant_annotation": "Missense",
+			"exon": "16.0",
+			"rsid": null,
 			"feature": "EZH2 p.Y646N (Missense)"
 		},
 		{
diff --git a/tests/data/harvesters/civic/assertions.json b/tests/data/harvesters/civic/assertions.json
index a04c37de..db62745a 100644
--- a/tests/data/harvesters/civic/assertions.json
+++ b/tests/data/harvesters/civic/assertions.json
@@ -5,20 +5,14 @@
         "name": "AID40",
         "summary": "FLT3 tyrosine kinase domain mutations at residue I836 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
         "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), including at the residue I836. FLT3 TKD mutations, such as I836 are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib (an oral inhibitor of FLT3 and AXL) demonstrated significant single-agent activity in R/R (Relapsed or Refractory) AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
-        "gene": {
-            "name": "FLT3",
-            "id": 24
-        },
-        "variant": {
-            "name": "I836",
-            "id": 3232
-        },
+        "gene_id": 24,
+        "variant_id": 3232,
         "disease": {
             "id": 3,
             "name": "Acute Myeloid Leukemia",
             "display_name": "Acute Myeloid Leukemia",
             "doid": "9119",
-            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
         },
         "drugs": [
             {
@@ -46,7 +40,7 @@
         "nccn_guideline": "Acute Myeloid Leukemia",
         "nccn_guideline_version": "v1.2020",
         "amp_level": "Tier I - Level A",
-        "evidence_items": [
+        "_evidence_items": [
             {
                 "id": 7283,
                 "name": "EID7283",
@@ -56,7 +50,7 @@
                     "name": "Acute Myeloid Leukemia",
                     "display_name": "Acute Myeloid Leukemia",
                     "doid": "9119",
-                    "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                    "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                 },
                 "drugs": [
                     {
@@ -118,20 +112,14 @@
                         "name": "AID33",
                         "summary": "FLT3 tyrosine kinase domain mutations at residue D835 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), particularly at the residue D835. FLT3 TKD mutations at the D835 residue are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib, an oral inhibitor of FLT3 and AXL demonstrated preclinical activity against type II FLT3 inhibitor resistance-conferring D835 mutations and clinical activity as monotherapy in Relapsed/Refractory (R/R) FLT3-mutated AML. In the phase 1/2 CHRYSALIS clinical trial (Perl AE, et al., 2017), Gilteritinib demonstrated significant single-agent activity in R/R AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "D835",
-                            "id": 437
-                        },
+                        "gene_id": 24,
+                        "variant_id": 437,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
@@ -163,20 +151,14 @@
                         "name": "AID40",
                         "summary": "FLT3 tyrosine kinase domain mutations at residue I836 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), including at the residue I836. FLT3 TKD mutations, such as I836 are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib (an oral inhibitor of FLT3 and AXL) demonstrated significant single-agent activity in R/R (Relapsed or Refractory) AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "I836",
-                            "id": 3232
-                        },
+                        "gene_id": 24,
+                        "variant_id": 3232,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
@@ -208,20 +190,14 @@
                         "name": "AID38",
                         "summary": "FLT3 internal tandem duplication (ITD) mutations in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "The constitutively activating FLT3 internal tandem duplication (ITD) mutation appears in approximately 20-30% of AML patients and are associated with high risk, high relapse rates and poor clinical outcome. The type I selective second-generation oral inhibitor, gilteritinib, received initial global approval for use to treat adults with relapsed or refractory (R/R) FLT3 ITD positive AML in Japan in September 2018. Based on interim results of the ADMIRAL trail (Perl AE, et al., 2019), the FDA approved the drug for treatment of adult R/R AML with FLT3 ITD mutations in November 2018. The FDA approved companion diagnostic, LeukoStrat CDx FLT3 Mutation assay. NCCN AML guidelines classify gilteritinib as a category 1 recommendation for R/R AML patients harboring FLT3 ITD.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "ITD",
-                            "id": 55
-                        },
+                        "gene_id": 24,
+                        "variant_id": 55,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
@@ -989,7 +965,7 @@
                     "name": "Acute Myeloid Leukemia",
                     "display_name": "Acute Myeloid Leukemia",
                     "doid": "9119",
-                    "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                    "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                 },
                 "drugs": [
                     {
@@ -1052,20 +1028,14 @@
                         "name": "AID33",
                         "summary": "FLT3 tyrosine kinase domain mutations at residue D835 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), particularly at the residue D835. FLT3 TKD mutations at the D835 residue are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib, an oral inhibitor of FLT3 and AXL demonstrated preclinical activity against type II FLT3 inhibitor resistance-conferring D835 mutations and clinical activity as monotherapy in Relapsed/Refractory (R/R) FLT3-mutated AML. In the phase 1/2 CHRYSALIS clinical trial (Perl AE, et al., 2017), Gilteritinib demonstrated significant single-agent activity in R/R AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "D835",
-                            "id": 437
-                        },
+                        "gene_id": 24,
+                        "variant_id": 437,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
@@ -1097,20 +1067,14 @@
                         "name": "AID40",
                         "summary": "FLT3 tyrosine kinase domain mutations at residue I836 in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most common mutations in acute myeloid leukemia (AML). 5 to 10% of AML is associated with activating point mutations in the FLT3 tyrosine kinase domain (TKD), including at the residue I836. FLT3 TKD mutations, such as I836 are a commonly reported mechanism of clinical resistance to type II FLT3 inhibitors (sorafenib, quizartinib and ponatinib), which bind only the inactive kinase conformation. However, Gilteritinib (an oral inhibitor of FLT3 and AXL) demonstrated significant single-agent activity in R/R (Relapsed or Refractory) AML with FLT3 ITD, D835, I836 mutations, achieving an overall response rate of 40%. A randomized phase 3 study of Gilteritinib (ADMIRAL trial, NCT02421939) compared with salvage chemotherapy in AML demonstrated a significant overall survival benefit in the gilteritinib arm (9.3 months) compared with chemotherapy (5.6 months). Event-free survival in the gilteritinib arm was also superior (Perl AE, et al., 2019). Based on findings from this study, the US Food and Drug Administration (FDA) approved Gilteritinib as the first FLT3 inhibitor indicated for use as monotherapy R/R AML with FLT3 ITD mutations or TKD D835 or I836 mutations.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "I836",
-                            "id": 3232
-                        },
+                        "gene_id": 24,
+                        "variant_id": 3232,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
@@ -1142,20 +1106,14 @@
                         "name": "AID38",
                         "summary": "FLT3 internal tandem duplication (ITD) mutations in relapsed / refractory acute myeloid leukemia (AML) are sensitive to Gilteritinib, a Type I FLT3 inhibitor.",
                         "description": "The constitutively activating FLT3 internal tandem duplication (ITD) mutation appears in approximately 20-30% of AML patients and are associated with high risk, high relapse rates and poor clinical outcome. The type I selective second-generation oral inhibitor, gilteritinib, received initial global approval for use to treat adults with relapsed or refractory (R/R) FLT3 ITD positive AML in Japan in September 2018. Based on interim results of the ADMIRAL trail (Perl AE, et al., 2019), the FDA approved the drug for treatment of adult R/R AML with FLT3 ITD mutations in November 2018. The FDA approved companion diagnostic, LeukoStrat CDx FLT3 Mutation assay. NCCN AML guidelines classify gilteritinib as a category 1 recommendation for R/R AML patients harboring FLT3 ITD.",
-                        "gene": {
-                            "name": "FLT3",
-                            "id": 24
-                        },
-                        "variant": {
-                            "name": "ITD",
-                            "id": 55
-                        },
+                        "gene_id": 24,
+                        "variant_id": 55,
                         "disease": {
                             "id": 3,
                             "name": "Acute Myeloid Leukemia",
                             "display_name": "Acute Myeloid Leukemia",
                             "doid": "9119",
-                            "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                            "disease_url": "http://www.disease-ontology.org/?id=DOID:9119"
                         },
                         "drugs": [
                             {
diff --git a/tests/data/harvesters/civic/evidence.json b/tests/data/harvesters/civic/evidence.json
index a9f877c1..45dd7bb2 100644
--- a/tests/data/harvesters/civic/evidence.json
+++ b/tests/data/harvesters/civic/evidence.json
@@ -8,7 +8,7 @@
             "name": "Lung Non-small Cell Carcinoma",
             "display_name": "Lung Non-small Cell Carcinoma",
             "doid": "3908",
-            "url": "http://www.disease-ontology.org/?id=DOID:3908"
+            "disease_url": "http://www.disease-ontology.org/?id=DOID:3908"
         },
         "drugs": [
             {
@@ -54,7 +54,6 @@
             "source_type": "PubMed",
             "asco_abstract_id": null,
             "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27283860",
-            "open_access": true,
             "pmc_id": "PMC4993103",
             "publication_date": {
                 "year": 2016,
@@ -62,8 +61,6 @@
             },
             "journal": "Lancet Oncol.",
             "full_journal_title": "The Lancet. Oncology",
-            "status": "partially curated",
-            "is_review": false,
             "clinical_trials": [
                 {
                     "nct_id": "NCT01336634",
diff --git a/tests/data/harvesters/civic/variants.json b/tests/data/harvesters/civic/variants.json
index 5246188f..0fccd606 100644
--- a/tests/data/harvesters/civic/variants.json
+++ b/tests/data/harvesters/civic/variants.json
@@ -11,7 +11,6 @@
             {
                 "id": 47,
                 "name": "missense_variant",
-                "display_name": "Missense Variant",
                 "so_id": "SO:0001583",
                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -48,7 +47,7 @@
                     "name": "Gastrointestinal Stromal Tumor",
                     "display_name": "Gastrointestinal Stromal Tumor",
                     "doid": "9253",
-                    "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                    "disease_url": "http://www.disease-ontology.org/?id=DOID:9253"
                 },
                 "drugs": [
                     {
@@ -82,7 +81,6 @@
                     "source_type": "PubMed",
                     "asco_abstract_id": null,
                     "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22745105",
-                    "open_access": null,
                     "pmc_id": null,
                     "publication_date": {
                         "year": 2012,
@@ -91,8 +89,6 @@
                     },
                     "journal": "Clin. Cancer Res.",
                     "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                    "status": "fully curated",
-                    "is_review": false,
                     "clinical_trials": []
                 },
                 "flagged": false,
@@ -101,12 +97,12 @@
                 "updated_at": "2016-02-17T19:50:06.701Z"
             }
         ],
-        "variant_groups": [
+        "_variant_groups": [
             {
                 "id": 1,
                 "name": "Imatinib Resistance",
                 "description": "While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. ",
-                "variants": [
+                "_variants": [
                     {
                         "id": 2,
                         "entrez_name": "ABL1",
@@ -119,7 +115,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -131,7 +126,6 @@
                             {
                                 "id": 120,
                                 "name": "transcript_fusion",
-                                "display_name": "Transcript Fusion",
                                 "so_id": "SO:0001886",
                                 "description": "A feature fusion where the deletion brings together transcript regions.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886",
@@ -171,7 +165,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -183,7 +176,6 @@
                             {
                                 "id": 120,
                                 "name": "transcript_fusion",
-                                "display_name": "Transcript Fusion",
                                 "so_id": "SO:0001886",
                                 "description": "A feature fusion where the deletion brings together transcript regions.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886",
@@ -223,7 +215,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -263,7 +254,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -303,7 +293,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -343,7 +332,6 @@
                             {
                                 "id": 107,
                                 "name": "inframe_deletion",
-                                "display_name": "Inframe Deletion",
                                 "so_id": "SO:0001822",
                                 "description": "An inframe non synonymous variant that deletes bases from the coding sequence.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001822",
@@ -383,7 +371,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -423,7 +410,6 @@
                             {
                                 "id": 47,
                                 "name": "missense_variant",
-                                "display_name": "Missense Variant",
                                 "so_id": "SO:0001583",
                                 "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583",
@@ -435,7 +421,6 @@
                             {
                                 "id": 120,
                                 "name": "transcript_fusion",
-                                "display_name": "Transcript Fusion",
                                 "so_id": "SO:0001886",
                                 "description": "A feature fusion where the deletion brings together transcript regions.",
                                 "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886",
diff --git a/tests/data/harvesters/moa/assertions.json b/tests/data/harvesters/moa/assertions.json
index c56a1f17..3adc3172 100644
--- a/tests/data/harvesters/moa/assertions.json
+++ b/tests/data/harvesters/moa/assertions.json
@@ -1,106 +1,106 @@
 [
 	{
-		"assertion_id": 168, 
-		"context": null, 
-		"created_on": "03/31/21", 
-		"description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", 
-		"disease": "Melanoma", 
-		"favorable_prognosis": null, 
+		"assertion_id": 170,
+		"context": "",
+		"created_on": "09/08/22",
+		"description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.",
+		"disease": "Melanoma",
+		"favorable_prognosis": false,
 		"features": [
 			{
 				"attributes": [
 					{
-						"alternate_allele": "T", 
-						"cdna_change": "c.1799T>A", 
-						"chromosome": "7", 
-						"end_position": "140453136.0", 
-						"exon": "15.0", 
-						"feature_type": "somatic_variant", 
-						"gene": "BRAF", 
-						"protein_change": "p.V600E", 
-						"reference_allele": "A", 
-						"rsid": "rs113488022", 
-						"start_position": "140453136.0", 
+						"alternate_allele": "T",
+						"cdna_change": "c.1799T>A",
+						"chromosome": "7",
+						"end_position": "140453136",
+						"exon": "15",
+						"feature_type": "somatic_variant",
+						"gene": "BRAF",
+						"protein_change": "p.V600E",
+						"reference_allele": "A",
+						"rsid": "rs113488022",
+						"start_position": "140453136",
 						"variant_annotation": "Missense"
 					}
-				], 
-				"feature_id": 168, 
+				],
+				"feature_id": 170,
 				"feature_type": "somatic_variant"
 			}
-		], 
-		"last_updated": "2019-06-13", 
-		"oncotree_code": "MEL", 
-		"oncotree_term": "Melanoma", 
-		"predictive_implication": "Preclinical", 
+		],
+		"last_updated": "2019-06-13",
+		"oncotree_code": "MEL",
+		"oncotree_term": "Melanoma",
+		"predictive_implication": "Preclinical",
 		"sources": [
 			{
-				"citation": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", 
-				"doi": "10.3892/ijo.2016.3594", 
-				"nct": "None", 
-				"pmid": 27572939, 
-				"source_id": 67, 
-				"source_type": "Journal", 
+				"citation": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.",
+				"doi": "10.3892/ijo.2016.3594",
+				"nct": "",
+				"pmid": 27572939,
+				"source_id": 69,
+				"source_type": "Journal",
 				"url": "https://doi.org/10.3892/ijo.2016.3594"
 			}
-		], 
-		"submitted_by": "breardon@broadinstitute.org", 
-		"therapy_name": "Bevacizumab", 
-		"therapy_resistance": null, 
-		"therapy_sensitivity": true, 
-		"therapy_strategy": "VEGF/VEGFR inhibition", 
-		"therapy_type": "Targeted therapy", 
+		],
+		"submitted_by": "breardon@broadinstitute.org",
+		"therapy_name": "Bevacizumab",
+		"therapy_resistance": false,
+		"therapy_sensitivity": true,
+		"therapy_strategy": "VEGF/VEGFR inhibition",
+		"therapy_type": "Targeted therapy",
 		"validated": true
 	},
 	{
-		"assertion_id": 166, 
-		"context": null, 
-		"created_on": "03/31/21", 
-		"description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", 
-		"disease": "Melanoma", 
-		"favorable_prognosis": null, 
+		"assertion_id": 168,
+		"context": "",
+		"created_on": "09/08/22",
+		"description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.",
+		"disease": "Melanoma",
+		"favorable_prognosis": false,
 		"features": [
 			{
 				"attributes": [
 					{
-						"alternate_allele": "T", 
-						"cdna_change": "c.1799T>A", 
-						"chromosome": "7", 
-						"end_position": "140453136.0", 
-						"exon": "15.0", 
-						"feature_type": "somatic_variant", 
-						"gene": "BRAF", 
-						"protein_change": "p.V600E", 
-						"reference_allele": "A", 
-						"rsid": "rs113488022", 
-						"start_position": "140453136.0", 
+						"alternate_allele": "T",
+						"cdna_change": "c.1799T>A",
+						"chromosome": "7",
+						"end_position": "140453136",
+						"exon": "15",
+						"feature_type": "somatic_variant",
+						"gene": "BRAF",
+						"protein_change": "p.V600E",
+						"reference_allele": "A",
+						"rsid": "rs113488022",
+						"start_position": "140453136",
 						"variant_annotation": "Missense"
 					}
-				], 
-				"feature_id": 166, 
+				],
+				"feature_id": 168,
 				"feature_type": "somatic_variant"
 			}
-		], 
-		"last_updated": "2019-06-13", 
-		"oncotree_code": "MEL", 
-		"oncotree_term": "Melanoma", 
-		"predictive_implication": "Clinical trial", 
+		],
+		"last_updated": "2019-06-13",
+		"oncotree_code": "MEL",
+		"oncotree_term": "Melanoma",
+		"predictive_implication": "Clinical trial",
 		"sources": [
 			{
-				"citation": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", 
-				"doi": "10.1186/s40425-016-0148-7", 
-				"nct": "NCT01673854", 
-				"pmid": 27532019, 
-				"source_id": 66, 
-				"source_type": "Journal", 
+				"citation": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.",
+				"doi": "10.1186/s40425-016-0148-7",
+				"nct": "NCT01673854",
+				"pmid": 27532019,
+				"source_id": 68,
+				"source_type": "Journal",
 				"url": "https://doi.org/10.1186/s40425-016-0148-7"
 			}
-		], 
-		"submitted_by": "breardon@broadinstitute.org", 
-		"therapy_name": "Ipilimumab + Vemurafenib", 
-		"therapy_resistance": null, 
-		"therapy_sensitivity": true, 
-		"therapy_strategy": "CTLA-4 inhibition + B-RAF inhibition", 
-		"therapy_type": "Combination therapy", 
+		],
+		"submitted_by": "breardon@broadinstitute.org",
+		"therapy_name": "Ipilimumab + Vemurafenib",
+		"therapy_resistance": false,
+		"therapy_sensitivity": true,
+		"therapy_strategy": "CTLA-4 inhibition + B-RAF inhibition",
+		"therapy_type": "Combination therapy",
 		"validated": true
-		}
+	}
 ]
\ No newline at end of file
diff --git a/tests/data/harvesters/moa/variants.json b/tests/data/harvesters/moa/variants.json
index a8d85d26..a79e5595 100644
--- a/tests/data/harvesters/moa/variants.json
+++ b/tests/data/harvesters/moa/variants.json
@@ -1,22 +1,22 @@
 [
-    {
-        "attributes": [
-            {
-                "alternate_allele": "T", 
-                "cdna_change": "c.1799T>A", 
-                "chromosome": "7", 
-                "end_position": "140453136.0", 
-                "exon": "15.0", 
-                "feature_type": "somatic_variant", 
-                "gene": "BRAF", 
-                "protein_change": "p.V600E", 
-                "reference_allele": "A", 
-                "rsid": "rs113488022", 
-                "start_position": "140453136.0", 
-                "variant_annotation": "Missense"
-            }
-        ], 
-        "feature_id": 147, 
-        "feature_type": "somatic_variant"
-    }
+	{
+		"attributes": [
+			{
+				"alternate_allele": "T",
+				"cdna_change": "c.1799T>A",
+				"chromosome": "7",
+				"end_position": "140453136",
+				"exon": "15",
+				"feature_type": "somatic_variant",
+				"gene": "BRAF",
+				"protein_change": "p.V600E",
+				"reference_allele": "A",
+				"rsid": "rs113488022",
+				"start_position": "140453136",
+				"variant_annotation": "Missense"
+			}
+		],
+		"feature_id": 149,
+		"feature_type": "somatic_variant"
+	}
 ]
\ No newline at end of file
diff --git a/tests/data/transform/diagnostic/civic_harvester.json b/tests/data/transform/diagnostic/civic_harvester.json
index 45c50f06..eed7b35d 100644
--- a/tests/data/transform/diagnostic/civic_harvester.json
+++ b/tests/data/transform/diagnostic/civic_harvester.json
@@ -8,16 +8,16 @@
                 "id": 2,
                 "name": "Gastrointestinal Stromal Tumor",
                 "display_name": "Gastrointestinal Stromal Tumor",
-                "doid": "9253",
-                "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                "doid": 9253,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
             },
             "drugs": [],
             "rating": 3,
             "evidence_level": "B",
-            "evidence_type": "Diagnostic",
-            "clinical_significance": "Negative",
-            "evidence_direction": "Supports",
-            "variant_origin": "Somatic",
+            "evidence_type": "DIAGNOSTIC",
+            "clinical_significance": "NEGATIVE",
+            "evidence_direction": "SUPPORTS",
+            "variant_origin": "SOMATIC",
             "drug_interaction_type": null,
             "status": "accepted",
             "type": "evidence",
@@ -25,20 +25,14 @@
                 "id": 52,
                 "name": "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.",
                 "citation": "Lasota et al., 2004, Lab. Invest.",
-                "citation_id": "15146165",
-                "source_type": "PubMed",
+                "citation_id": 15146165,
+                "source_type": "PUBMED",
                 "asco_abstract_id": null,
                 "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15146165",
-                "open_access": null,
                 "pmc_id": null,
-                "publication_date": {
-                    "year": 2004,
-                    "month": 7
-                },
+                "publication_date": "2004-7",
                 "journal": "Lab. Invest.",
                 "full_journal_title": "Laboratory investigation; a journal of technical methods and pathology",
-                "status": "fully curated",
-                "is_review": false,
                 "clinical_trials": []
             },
             "variant_id": 99,
@@ -54,16 +48,16 @@
                 "id": 15,
                 "name": "Thyroid Gland Medullary Carcinoma",
                 "display_name": "Thyroid Gland Medullary Carcinoma",
-                "doid": "3973",
-                "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                "doid": 3973,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
             },
             "drugs": [],
             "rating": 5,
             "evidence_level": "B",
-            "evidence_type": "Diagnostic",
-            "clinical_significance": "Positive",
-            "evidence_direction": "Supports",
-            "variant_origin": "Somatic",
+            "evidence_type": "DIAGNOSTIC",
+            "clinical_significance": "POSITIVE",
+            "evidence_direction": "SUPPORTS",
+            "variant_origin": "SOMATIC",
             "drug_interaction_type": null,
             "status": "accepted",
             "type": "evidence",
@@ -71,20 +65,14 @@
                 "id": 44,
                 "name": "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.",
                 "citation": "Elisei et al., 2008, J. Clin. Endocrinol. Metab.",
-                "citation_id": "18073307",
-                "source_type": "PubMed",
+                "citation_id": 18073307,
+                "source_type": "PUBMED",
                 "asco_abstract_id": null,
                 "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18073307",
-                "open_access": null,
                 "pmc_id": null,
-                "publication_date": {
-                    "year": 2008,
-                    "month": 3
-                },
+                "publication_date": "2008-3",
                 "journal": "J. Clin. Endocrinol. Metab.",
                 "full_journal_title": "The Journal of clinical endocrinology and metabolism",
-                "status": "fully curated",
-                "is_review": false,
                 "clinical_trials": []
             },
             "variant_id": 113,
@@ -100,30 +88,24 @@
             "name": "AID9",
             "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
             "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
-            "gene": {
-                "name": "ACVR1",
-                "id": 154
-            },
-            "variant": {
-                "name": "G328V",
-                "id": 1686
-            },
+            "gene_id": 154,
+            "variant_id": 1686,
             "disease": {
                 "id": 2950,
                 "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                 "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                "doid": "0080684",
-                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                "doid": 80684,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
             },
             "drugs": [],
-            "evidence_type": "Diagnostic",
-            "evidence_direction": "Supports",
-            "clinical_significance": "Positive",
+            "evidence_type": "DIAGNOSTIC",
+            "evidence_direction": "SUPPORTS",
+            "clinical_significance": "POSITIVE",
             "fda_regulatory_approval": false,
             "status": "accepted",
             "nccn_guideline": null,
             "nccn_guideline_version": "",
-            "amp_level": "Tier II - Level C",
+            "amp_level": "TIER_II_LEVEL_C",
             "evidence_items": [
                 {
                     "id": 4846,
@@ -133,16 +115,16 @@
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Positive",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -150,20 +132,14 @@
                         "id": 2149,
                         "name": "Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.",
                         "citation": "Fontebasso et al., 2014, Nat. Genet.",
-                        "citation_id": "24705250",
-                        "source_type": "PubMed",
+                        "citation_id": 24705250,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705250",
-                        "open_access": true,
                         "pmc_id": "PMC4282994",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
+                        "publication_date": "2014-5",
                         "journal": "Nat. Genet.",
                         "full_journal_title": "Nature genetics",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 1686,
@@ -175,25 +151,19 @@
                             "name": "AID9",
                             "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                             "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
-                            "gene": {
-                                "name": "ACVR1",
-                                "id": 154
-                            },
-                            "variant": {
-                                "name": "G328V",
-                                "id": 1686
-                            },
+                            "gene_id": 154,
+                            "variant_id": 1686,
                             "disease": {
                                 "id": 2950,
                                 "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                 "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                                "doid": "0080684",
-                                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                                "doid": 80684,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                             },
                             "drugs": [],
-                            "evidence_type": "Diagnostic",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Positive",
+                            "evidence_type": "DIAGNOSTIC",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "POSITIVE",
                             "fda_regulatory_approval": false,
                             "status": "accepted"
                         }
@@ -208,16 +178,16 @@
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Positive",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -225,20 +195,14 @@
                         "id": 2680,
                         "name": "Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.",
                         "citation": "Buczkowicz et al., 2014, Nat. Genet.",
-                        "citation_id": "24705254",
-                        "source_type": "PubMed",
+                        "citation_id": 24705254,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705254",
-                        "open_access": true,
                         "pmc_id": "PMC3997489",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
+                        "publication_date": "2014-5",
                         "journal": "Nat. Genet.",
                         "full_journal_title": "Nature genetics",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 1686,
@@ -250,25 +214,19 @@
                             "name": "AID9",
                             "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                             "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
-                            "gene": {
-                                "name": "ACVR1",
-                                "id": 154
-                            },
-                            "variant": {
-                                "name": "G328V",
-                                "id": 1686
-                            },
+                            "gene_id": 154,
+                            "variant_id": 1686,
                             "disease": {
                                 "id": 2950,
                                 "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                 "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                                "doid": "0080684",
-                                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                                "doid": 80684,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                             },
                             "drugs": [],
-                            "evidence_type": "Diagnostic",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Positive",
+                            "evidence_type": "DIAGNOSTIC",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "POSITIVE",
                             "fda_regulatory_approval": false,
                             "status": "accepted"
                         }
@@ -279,9 +237,8 @@
             "acmg_codes": [],
             "drug_interaction_type": null,
             "fda_companion_test": false,
-            "allele_registry_id": "CA16602802",
             "phenotypes": [],
-            "variant_origin": "Somatic"
+            "variant_origin": "SOMATIC"
         }
     ],
     "genes": [
@@ -292,8 +249,8 @@
             "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.",
             "variants": [
                 {
-                    "name": "Exon 18 Mutation",
-                    "id": 2623,
+                    "name": "Amplification",
+                    "id": 716,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -301,44 +258,44 @@
                     }
                 },
                 {
-                    "name": "Fusion",
-                    "id": 567,
+                    "name": "BCR::PDGFRA",
+                    "id": 2971,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Amplification",
-                    "id": 716,
+                    "name": "D842I",
+                    "id": 98,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "D842_M844del",
-                    "id": 1518,
+                    "name": "D842V",
+                    "id": 99,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 11,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "Overexpression",
-                    "id": 2944,
+                    "name": "D842Y",
+                    "id": 100,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Mutation",
-                    "id": 3274,
+                    "name": "D842_H845DELDIMH",
+                    "id": 943,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -346,62 +303,62 @@
                     }
                 },
                 {
-                    "name": "FIP1L1-PDGFRA T674I",
-                    "id": 577,
+                    "name": "D842_I843delinsVM",
+                    "id": 102,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "TNKS2-PDGFRA",
-                    "id": 774,
+                    "name": "D842_M844del",
+                    "id": 1518,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "P577S",
-                    "id": 862,
+                    "name": "Exon 18 Mutation",
+                    "id": 2623,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D842I",
-                    "id": 98,
+                    "name": "FIP1L1::PDGFRA",
+                    "id": 574,
                     "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 0
+                        "accepted_count": 5,
+                        "rejected_count": 1,
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V561A",
-                    "id": 247,
+                    "name": "FIP1L1::PDGFRA T674I",
+                    "id": 577,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 3,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D842Y",
-                    "id": 100,
+                    "name": "Fusion",
+                    "id": 567,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "R841K",
-                    "id": 863,
+                    "name": "G853D",
+                    "id": 865,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -418,21 +375,21 @@
                     }
                 },
                 {
-                    "name": "G853D",
-                    "id": 865,
+                    "name": "I843DEL",
+                    "id": 101,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "V561D",
-                    "id": 941,
+                    "name": "K385",
+                    "id": 4177,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
@@ -445,26 +402,26 @@
                     }
                 },
                 {
-                    "name": "W559_R560DELWR",
-                    "id": 1539,
+                    "name": "Mutation",
+                    "id": 3274,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "I843DEL",
-                    "id": 101,
+                    "name": "Overexpression",
+                    "id": 2944,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D842_H845DELDIMH",
-                    "id": 943,
+                    "name": "P577S",
+                    "id": 862,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -472,26 +429,26 @@
                     }
                 },
                 {
-                    "name": "D842V",
-                    "id": 99,
+                    "name": "R841K",
+                    "id": 863,
                     "evidence_items": {
-                        "accepted_count": 11,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "FIP1L1-PDGFRA",
-                    "id": 574,
+                    "name": "TNKS2::PDGFRA",
+                    "id": 774,
                     "evidence_items": {
-                        "accepted_count": 5,
-                        "rejected_count": 1,
-                        "submitted_count": 1
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "BCR-PDGFRA",
-                    "id": 2971,
+                    "name": "V561A",
+                    "id": 247,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -499,10 +456,10 @@
                     }
                 },
                 {
-                    "name": "D842_I843delinsVM",
-                    "id": 102,
+                    "name": "V561D",
+                    "id": 941,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 4,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
@@ -515,13 +472,22 @@
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
+                },
+                {
+                    "name": "W559_R560DELWR",
+                    "id": 1539,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 1
+                    }
                 }
             ],
             "aliases": [
-                "PDGFRA",
-                "PDGFR2",
+                "CD140A",
                 "PDGFR-2",
-                "CD140A"
+                "PDGFR2",
+                "PDGFRA"
             ],
             "type": "gene"
         },
@@ -532,35 +498,53 @@
             "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.",
             "variants": [
                 {
-                    "name": "Fusion",
-                    "id": 1687,
+                    "name": "C609Y",
+                    "id": 1260,
                     "evidence_items": {
-                        "accepted_count": 6,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Mutation",
-                    "id": 1690,
+                    "name": "C634R",
+                    "id": 1700,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Overexpression",
-                    "id": 597,
+                    "name": "C634W",
+                    "id": 112,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "KIF5B-RET V804L",
-                    "id": 1688,
+                    "name": "CCDC6::RET",
+                    "id": 626,
+                    "evidence_items": {
+                        "accepted_count": 2,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "Fusion",
+                    "id": 1687,
+                    "evidence_items": {
+                        "accepted_count": 6,
+                        "rejected_count": 0,
+                        "submitted_count": 3
+                    }
+                },
+                {
+                    "name": "G810",
+                    "id": 3033,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -568,17 +552,17 @@
                     }
                 },
                 {
-                    "name": "KIF5B-RET G810A",
-                    "id": 1689,
+                    "name": "G810C",
+                    "id": 3226,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "C634R",
-                    "id": 1700,
+                    "name": "G810S",
+                    "id": 3227,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -586,7 +570,7 @@
                     }
                 },
                 {
-                    "name": "KIF5B-RET",
+                    "name": "KIF5B::RET",
                     "id": 273,
                     "evidence_items": {
                         "accepted_count": 2,
@@ -595,21 +579,21 @@
                     }
                 },
                 {
-                    "name": "CCDC6-RET",
-                    "id": 626,
+                    "name": "KIF5B::RET G810A",
+                    "id": 1689,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "V804M",
-                    "id": 2568,
+                    "name": "KIF5B::RET V804L",
+                    "id": 1688,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 2
                     }
                 },
                 {
@@ -622,53 +606,44 @@
                     }
                 },
                 {
-                    "name": "C609Y",
-                    "id": 1260,
+                    "name": "Mutation",
+                    "id": 1690,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "C634W",
-                    "id": 112,
+                    "name": "Overexpression",
+                    "id": 597,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 3,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "G810",
-                    "id": 3033,
+                    "name": "V738A",
+                    "id": 3230,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "G810C",
-                    "id": 3226,
+                    "name": "V804M",
+                    "id": 2568,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "G810S",
-                    "id": 3227,
-                    "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
-                    }
-                },
-                {
-                    "name": "Y806C",
-                    "id": 3228,
+                    "name": "Y806C",
+                    "id": 3228,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -683,27 +658,18 @@
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
-                },
-                {
-                    "name": "V738A",
-                    "id": 3230,
-                    "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
-                    }
                 }
             ],
             "aliases": [
-                "RET",
-                "RET-ELE1",
-                "PTC",
-                "MTC1",
-                "MEN2B",
-                "MEN2A",
-                "HSCR1",
+                "CDHF12",
                 "CDHR16",
-                "CDHF12"
+                "HSCR1",
+                "MEN2A",
+                "MEN2B",
+                "MTC1",
+                "PTC",
+                "RET",
+                "RET-ELE1"
             ],
             "type": "gene"
         },
@@ -714,8 +680,8 @@
             "description": "",
             "variants": [
                 {
-                    "name": "Gain-of-Function",
-                    "id": 2061,
+                    "name": "G328E",
+                    "id": 2283,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -723,17 +689,26 @@
                     }
                 },
                 {
-                    "name": "MUTATION",
-                    "id": 2983,
+                    "name": "G328V",
+                    "id": 1686,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 3,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "G328W",
+                    "id": 2280,
+                    "evidence_items": {
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "G328E",
-                    "id": 2283,
+                    "name": "G356D",
+                    "id": 3662,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -741,21 +716,30 @@
                     }
                 },
                 {
-                    "name": "G328V",
-                    "id": 1686,
+                    "name": "Gain-of-Function",
+                    "id": 2061,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "G328W",
-                    "id": 2280,
+                    "name": "Mutation",
+                    "id": 2983,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 3
+                    }
+                },
+                {
+                    "name": "R206H",
+                    "id": 3661,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
                     }
                 },
                 {
@@ -769,14 +753,14 @@
                 }
             ],
             "aliases": [
+                "ACTRI",
                 "ACVR1",
-                "TSRI",
-                "SKR1",
-                "FOP",
-                "ALK2",
-                "ACVRLK2",
                 "ACVR1A",
-                "ACTRI"
+                "ACVRLK2",
+                "ALK2",
+                "FOP",
+                "SKR1",
+                "TSRI"
             ],
             "type": "gene"
         }
@@ -793,8 +777,7 @@
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -817,112 +800,94 @@
             },
             "evidence_items": [
                 {
-                    "id": 4059,
-                    "name": "EID4059",
-                    "description": "In an in vitro study, Ba/F3 cells expressing PDGFRA D842V mutation (overexpression) demonstrated resistance to sunitinib treatment. Sensitivity was determined by assessing PDGFRA auto-phosphorylation and cell proliferation.",
+                    "id": 15,
+                    "name": "EID15",
+                    "description": "GIST cancer with D842V mutation is resistant to imatinib.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 157,
-                            "name": "Sunitinib",
-                            "ncit_id": "C71622",
+                            "id": 5,
+                            "name": "Imatinib",
+                            "ncit_id": "C62035",
                             "aliases": [
-                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 192,
-                        "name": "Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.",
-                        "citation": "Prenen et al., 2006, Clin. Cancer Res.",
-                        "citation_id": "16638875",
-                        "source_type": "PubMed",
+                        "id": 61,
+                        "name": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",
+                        "citation": "Corless et al., 2005, J. Clin. Oncol.",
+                        "citation_id": 15928335,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16638875",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15928335",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 4,
-                            "day": 15
-                        },
-                        "journal": "Clin. Cancer Res.",
-                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2005-8-10",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 4057,
-                    "name": "EID4057",
-                    "description": "In an in vitro study, gastrointestinal tumor (GIST) cells (endogenous expression) and Ba/F3 murine cells (overexpression) with the PDGFRA D842V mutation were associated with sensitivity to dasatinib treatment (GIST IC50: 47nM, Ba/F3 IC50: 62 nM). Sensitivity was determined by assessing cell proliferation, apoptosis and PDGFRA auto-phosphorylation.",
+                    "id": 16,
+                    "name": "EID16",
+                    "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 20,
-                            "name": "Dasatinib",
-                            "ncit_id": "C38713",
+                            "id": 5,
+                            "name": "Imatinib",
+                            "ncit_id": "C62035",
                             "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
-                                "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2041,
-                        "name": "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.",
-                        "citation": "Dewaele et al., 2008, Clin. Cancer Res.",
-                        "citation_id": "18794084",
-                        "source_type": "PubMed",
+                        "id": 62,
+                        "name": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.",
+                        "citation": "Heinrich et al., 2006, J. Clin. Oncol.",
+                        "citation_id": 16954519,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18794084",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16954519",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 9,
-                            "day": 15
-                        },
-                        "journal": "Clin. Cancer Res.",
-                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2006-10-10",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
@@ -936,8 +901,8 @@
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
@@ -951,10 +916,10 @@
                     ],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -962,25 +927,72 @@
                         "id": 486,
                         "name": "Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.",
                         "citation": "Yoo et al., 2016, Cancer Res Treat",
-                        "citation_id": "26130666",
-                        "source_type": "PubMed",
+                        "citation_id": 26130666,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26130666",
-                        "open_access": true,
                         "pmc_id": "PMC4843750",
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 4
-                        },
+                        "publication_date": "2016-4",
                         "journal": "Cancer Res Treat",
                         "full_journal_title": "Cancer research and treatment : official journal of Korean Cancer Association",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
+                {
+                    "id": 7479,
+                    "name": "EID7479",
+                    "description": "In a phase 2 trial, patients with gastrointestinal stromal tumor (GIST) harboring with PDGFRA D842V or other exon 18 mutation were treated with Avapritinib which have broad activity against oncogenic KIT/PDGFRA mutations including secondary resistance mutations.\nThis trial included 62 patients with PDGRFA exon 18 mutations 56 D842V, 6 non-D842V).\nThe response rate in evaluable patients with PDGFRA exon 18 mutations were 86% (37/43).",
+                    "disease": {
+                        "id": 2,
+                        "name": "Gastrointestinal Stromal Tumor",
+                        "display_name": "Gastrointestinal Stromal Tumor",
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
+                    },
+                    "drugs": [
+                        {
+                            "id": 671,
+                            "name": "Avapritinib",
+                            "ncit_id": "C123827",
+                            "aliases": [
+                                "(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine",
+                                "AYVAKIT",
+                                "BLU-285",
+                                "CS3007",
+                                "PDGFR Alpha/KIT Mutant-specific Inhibitor BLU-285"
+                            ]
+                        }
+                    ],
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 2968,
+                        "name": "Clinical activity of avapritinib in &#x2265; fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).",
+                        "citation": "Michael C. Heinrich, 2019, ASCO Annual Meeting, Abstract 11022",
+                        "citation_id": 174900,
+                        "source_type": "ASCO",
+                        "asco_abstract_id": 11022,
+                        "source_url": "https://meetinglibrary.asco.org/record/174900/abstract",
+                        "pmc_id": null,
+                        "publication_date": "2019-10",
+                        "journal": "J Clin Oncol 37, 2019 (suppl; abstr 11022)",
+                        "full_journal_title": "Journal of Clinical Oncology",
+                        "clinical_trials": [
+                            {}
+                        ]
+                    },
+                    "variant_id": 99,
+                    "phenotypes": []
+                },
                 {
                     "id": 2,
                     "name": "EID2",
@@ -989,16 +1001,16 @@
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Negative",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "NEGATIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -1006,255 +1018,221 @@
                         "id": 52,
                         "name": "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.",
                         "citation": "Lasota et al., 2004, Lab. Invest.",
-                        "citation_id": "15146165",
-                        "source_type": "PubMed",
+                        "citation_id": 15146165,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15146165",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2004,
-                            "month": 7
-                        },
+                        "publication_date": "2004-7",
                         "journal": "Lab. Invest.",
                         "full_journal_title": "Laboratory investigation; a journal of technical methods and pathology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 651,
-                    "name": "EID651",
-                    "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.",
+                    "id": 4058,
+                    "name": "EID4058",
+                    "description": "In a prospective study of  137 gastrointestinal stromal tumor patients who failed imatinib treatment, patients with PDGFRA mutation (12/89; 11/12 tumors genotyped as D842V) treated with sunitinib were associated with shorter progression free survival (9wk vs. 50.5wk, HR= 1.8753, P=0.049) and shorter overall survival (40wk vs. 121wk, no statistics) as compared to patients with wild-type PDGFRA (n=10).",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 5,
-                            "name": "Imatinib",
-                            "ncit_id": "C62035",
+                            "id": 157,
+                            "name": "Sunitinib",
+                            "ncit_id": "C71622",
                             "aliases": [
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
+                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                             ]
                         }
                     ],
                     "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 411,
-                        "name": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.",
-                        "citation": "Hirota et al., 2003, Gastroenterology",
-                        "citation_id": "12949711",
-                        "source_type": "PubMed",
+                        "id": 846,
+                        "name": "The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.",
+                        "citation": "Rutkowski et al., 2012, BMC Cancer",
+                        "citation_id": 22439647,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/12949711",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2003,
-                            "month": 9
-                        },
-                        "journal": "Gastroenterology",
-                        "full_journal_title": "Gastroenterology",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22439647",
+                        "pmc_id": "PMC3361487",
+                        "publication_date": "2012",
+                        "journal": "BMC Cancer",
+                        "full_journal_title": "BMC cancer",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 15,
-                    "name": "EID15",
-                    "description": "GIST cancer with D842V mutation is resistant to imatinib.",
+                    "id": 4597,
+                    "name": "EID4597",
+                    "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 5,
-                            "name": "Imatinib",
-                            "ncit_id": "C62035",
+                            "id": 157,
+                            "name": "Sunitinib",
+                            "ncit_id": "C71622",
                             "aliases": [
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
+                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 61,
-                        "name": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",
-                        "citation": "Corless et al., 2005, J. Clin. Oncol.",
-                        "citation_id": "15928335",
-                        "source_type": "PubMed",
+                        "id": 965,
+                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
+                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
+                        "citation_id": 18955458,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15928335",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2005,
-                            "month": 8,
-                            "day": 10
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
+                        "pmc_id": "PMC2651076",
+                        "publication_date": "2008-11-20",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 5346,
-                    "name": "EID5346",
-                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
-                    "disease": {
-                        "id": 216,
-                        "name": "Cancer",
-                        "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                    "id": 2478,
+                    "name": "EID2478",
+                    "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.",
+                    "disease": {
+                        "id": 2,
+                        "name": "Gastrointestinal Stromal Tumor",
+                        "display_name": "Gastrointestinal Stromal Tumor",
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 537,
-                            "name": "Imatinib Mesylate",
-                            "ncit_id": "C1687",
+                            "id": 5,
+                            "name": "Imatinib",
+                            "ncit_id": "C62035",
                             "aliases": [
-                                "STI571",
-                                "STI-571",
-                                "STI 571",
-                                "Glivec",
-                                "Gleevec",
-                                "CGP57148B",
-                                "CGP 57148",
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
                         }
                     ],
                     "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 965,
-                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
-                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
-                        "citation_id": "18955458",
-                        "source_type": "PubMed",
+                        "id": 412,
+                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
+                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
+                        "citation_id": 14645423,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
-                        "open_access": true,
-                        "pmc_id": "PMC2651076",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 11,
-                            "day": 20
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
+                        "pmc_id": null,
+                        "publication_date": "2003-12-1",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 4058,
-                    "name": "EID4058",
-                    "description": "In a prospective study of  137 gastrointestinal stromal tumor patients who failed imatinib treatment, patients with PDGFRA mutation (12/89; 11/12 tumors genotyped as D842V) treated with sunitinib were associated with shorter progression free survival (9wk vs. 50.5wk, HR= 1.8753, P=0.049) and shorter overall survival (40wk vs. 121wk, no statistics) as compared to patients with wild-type PDGFRA (n=10).",
+                    "id": 4057,
+                    "name": "EID4057",
+                    "description": "In an in vitro study, gastrointestinal tumor (GIST) cells (endogenous expression) and Ba/F3 murine cells (overexpression) with the PDGFRA D842V mutation were associated with sensitivity to dasatinib treatment (GIST IC50: 47nM, Ba/F3 IC50: 62 nM). Sensitivity was determined by assessing cell proliferation, apoptosis and PDGFRA auto-phosphorylation.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 157,
-                            "name": "Sunitinib",
-                            "ncit_id": "C71622",
+                            "id": 20,
+                            "name": "Dasatinib",
+                            "ncit_id": "C38713",
                             "aliases": [
-                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
+                                "BMS-354825",
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
                             ]
                         }
                     ],
                     "rating": null,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 846,
-                        "name": "The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.",
-                        "citation": "Rutkowski et al., 2012, BMC Cancer",
-                        "citation_id": "22439647",
-                        "source_type": "PubMed",
+                        "id": 2041,
+                        "name": "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.",
+                        "citation": "Dewaele et al., 2008, Clin. Cancer Res.",
+                        "citation_id": 18794084,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22439647",
-                        "open_access": true,
-                        "pmc_id": "PMC3361487",
-                        "publication_date": {
-                            "year": 2012
-                        },
-                        "journal": "BMC Cancer",
-                        "full_journal_title": "BMC cancer",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18794084",
+                        "pmc_id": null,
+                        "publication_date": "2008-9-15",
+                        "journal": "Clin. Cancer Res.",
+                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 4597,
-                    "name": "EID4597",
-                    "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.",
+                    "id": 4059,
+                    "name": "EID4059",
+                    "description": "In an in vitro study, Ba/F3 cells expressing PDGFRA D842V mutation (overexpression) demonstrated resistance to sunitinib treatment. Sensitivity was determined by assessing PDGFRA auto-phosphorylation and cell proliferation.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
@@ -1266,167 +1244,93 @@
                             ]
                         }
                     ],
-                    "rating": 3,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": null,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 965,
-                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
-                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
-                        "citation_id": "18955458",
-                        "source_type": "PubMed",
+                        "id": 192,
+                        "name": "Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.",
+                        "citation": "Prenen et al., 2006, Clin. Cancer Res.",
+                        "citation_id": 16638875,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
-                        "open_access": true,
-                        "pmc_id": "PMC2651076",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 11,
-                            "day": 20
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16638875",
+                        "pmc_id": null,
+                        "publication_date": "2006-4-15",
+                        "journal": "Clin. Cancer Res.",
+                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 7479,
-                    "name": "EID7479",
-                    "description": "In a phase 2 trial, patients with gastrointestinal stromal tumor (GIST) harboring with PDGFRA D842V or other exon 18 mutation were treated with Avapritinib which have broad activity against oncogenic KIT/PDGFRA mutations including secondary resistance mutations.\nThis trial included 62 patients with PDGRFA exon 18 mutations 56 D842V, 6 non-D842V).\nThe response rate in evaluable patients with PDGFRA exon 18 mutations were 86% (37/43).",
+                    "id": 44,
+                    "name": "EID44",
+                    "description": "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 671,
-                            "name": "Avapritinib",
-                            "ncit_id": "C123827",
+                            "id": 21,
+                            "name": "Crenolanib",
+                            "ncit_id": "C64639",
                             "aliases": [
-                                "CS3007",
-                                "AYVAKIT",
-                                "(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine",
-                                "PDGFR Alpha/KIT Mutant-specific Inhibitor BLU-285",
-                                "BLU-285"
+                                "4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-",
+                                "CP-868,596",
+                                "CP-868596",
+                                "PDGFR Inhibitor CP-868596",
+                                "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"
                             ]
                         }
                     ],
                     "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "submitted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 2968,
-                        "name": "Clinical activity of avapritinib in &#x2265; fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).",
-                        "citation": "Michael C. Heinrich, 2019, ASCO Annual Meeting, Abstract 11022",
-                        "citation_id": "174900",
-                        "source_type": "ASCO",
-                        "asco_abstract_id": 11022,
-                        "source_url": "https://meetinglibrary.asco.org/record/174900/abstract",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2019,
-                            "month": 10
-                        },
-                        "journal": "J Clin Oncol 37, 2019 (suppl; abstr 11022)",
-                        "full_journal_title": "Endocrinologia japonica",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT02508532",
-                                "name": "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors",
-                                "description": "This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT02508532"
-                            }
-                        ]
-                    },
-                    "variant_id": 99,
-                    "phenotypes": []
-                },
-                {
-                    "id": 4060,
-                    "name": "EID4060",
-                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
-                    "disease": {
-                        "id": 216,
-                        "name": "Cancer",
-                        "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
-                    },
-                    "drugs": [
-                        {
-                            "id": 157,
-                            "name": "Sunitinib",
-                            "ncit_id": "C71622",
-                            "aliases": [
-                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
-                            ]
-                        }
-                    ],
-                    "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 965,
-                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
-                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
-                        "citation_id": "18955458",
-                        "source_type": "PubMed",
+                        "id": 80,
+                        "name": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.",
+                        "citation": "Heinrich et al., 2012, Clin. Cancer Res.",
+                        "citation_id": 22745105,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
-                        "open_access": true,
-                        "pmc_id": "PMC2651076",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 11,
-                            "day": 20
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22745105",
+                        "pmc_id": null,
+                        "publication_date": "2012-8-15",
+                        "journal": "Clin. Cancer Res.",
+                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 16,
-                    "name": "EID16",
-                    "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.",
+                    "id": 651,
+                    "name": "EID651",
+                    "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.",
                     "disease": {
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
@@ -1438,200 +1342,175 @@
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 62,
-                        "name": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.",
-                        "citation": "Heinrich et al., 2006, J. Clin. Oncol.",
-                        "citation_id": "16954519",
-                        "source_type": "PubMed",
+                        "id": 411,
+                        "name": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.",
+                        "citation": "Hirota et al., 2003, Gastroenterology",
+                        "citation_id": 12949711,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16954519",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/12949711",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 10,
-                            "day": 10
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "publication_date": "2003-9",
+                        "journal": "Gastroenterology",
+                        "full_journal_title": "Gastroenterology",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 44,
-                    "name": "EID44",
-                    "description": "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",
+                    "id": 2463,
+                    "name": "EID2463",
+                    "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).",
                     "disease": {
-                        "id": 2,
-                        "name": "Gastrointestinal Stromal Tumor",
-                        "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
-                            "id": 21,
-                            "name": "Crenolanib",
-                            "ncit_id": "C64639",
+                            "id": 5,
+                            "name": "Imatinib",
+                            "ncit_id": "C62035",
                             "aliases": [
-                                "PDGFR Inhibitor CP-868596",
-                                "CP-868596",
-                                "CP-868,596",
-                                "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine",
-                                "4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
                         }
                     ],
-                    "rating": 4,
+                    "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 80,
-                        "name": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.",
-                        "citation": "Heinrich et al., 2012, Clin. Cancer Res.",
-                        "citation_id": "22745105",
-                        "source_type": "PubMed",
+                        "id": 412,
+                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
+                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
+                        "citation_id": 14645423,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22745105",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 8,
-                            "day": 15
-                        },
-                        "journal": "Clin. Cancer Res.",
-                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2003-12-1",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 2478,
-                    "name": "EID2478",
-                    "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.",
+                    "id": 4060,
+                    "name": "EID4060",
+                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
                     "disease": {
-                        "id": 2,
-                        "name": "Gastrointestinal Stromal Tumor",
-                        "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
-                            "id": 5,
-                            "name": "Imatinib",
-                            "ncit_id": "C62035",
+                            "id": 157,
+                            "name": "Sunitinib",
+                            "ncit_id": "C71622",
                             "aliases": [
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
+                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                             ]
                         }
                     ],
                     "rating": 2,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 412,
-                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
-                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
-                        "citation_id": "14645423",
-                        "source_type": "PubMed",
+                        "id": 965,
+                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
+                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
+                        "citation_id": 18955458,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2003,
-                            "month": 12,
-                            "day": 1
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
+                        "pmc_id": "PMC2651076",
+                        "publication_date": "2008-11-20",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
                     "phenotypes": []
                 },
                 {
-                    "id": 2463,
-                    "name": "EID2463",
-                    "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).",
+                    "id": 5346,
+                    "name": "EID5346",
+                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
                     "disease": {
                         "id": 216,
                         "name": "Cancer",
                         "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
-                            "id": 5,
-                            "name": "Imatinib",
-                            "ncit_id": "C62035",
+                            "id": 537,
+                            "name": "Imatinib Mesylate",
+                            "ncit_id": "C1687",
                             "aliases": [
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate",
+                                "CGP 57148",
+                                "CGP57148B",
+                                "Gleevec",
+                                "Glivec",
+                                "STI 571",
+                                "STI-571",
+                                "STI571"
                             ]
                         }
                     ],
                     "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 412,
-                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
-                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
-                        "citation_id": "14645423",
-                        "source_type": "PubMed",
+                        "id": 965,
+                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
+                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
+                        "citation_id": 18955458,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2003,
-                            "month": 12,
-                            "day": 1
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
+                        "pmc_id": "PMC2651076",
+                        "publication_date": "2008-11-20",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 99,
@@ -1645,8 +1524,8 @@
                         "id": 4,
                         "name": "Chronic Myeloid Leukemia",
                         "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
@@ -1654,155 +1533,79 @@
                             "name": "Bosutinib",
                             "ncit_id": "C60809",
                             "aliases": [
-                                "SKI-606",
-                                "SKI 606",
-                                "Bosulif",
-                                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
                                 "4-Anilino-3-quinolinecarbonitrile",
-                                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile"
+                                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
+                                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile",
+                                "Bosulif",
+                                "SKI 606",
+                                "SKI-606"
                             ]
                         }
                     ],
                     "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 1994,
-                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
-                        "citation": "Remsing Rix et al., 2009, Leukemia",
-                        "citation_id": "19039322",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 3
-                        },
-                        "journal": "Leukemia",
-                        "full_journal_title": "Leukemia",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 99,
-                    "phenotypes": []
-                }
-            ],
-            "variant_groups": [
-                {
-                    "id": 1,
-                    "name": "Imatinib Resistance",
-                    "description": "While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. ",
-                    "variants": [
-                        {
-                            "id": 98,
-                            "entrez_name": "PDGFRA",
-                            "entrez_id": 5156,
-                            "name": "D842I",
-                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
-                            "gene_id": 38,
-                            "type": "variant",
-                            "variant_types": [
-                                {
-                                    "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
-                                    "so_id": "SO:0001583",
-                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
-                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
-                                }
-                            ],
-                            "civic_actionability_score": 4,
-                            "coordinates": {
-                                "chromosome": "4",
-                                "start": 55152092,
-                                "stop": 55152093,
-                                "reference_bases": "GA",
-                                "variant_bases": "AT",
-                                "representative_transcript": "ENST00000257290.5",
-                                "chromosome2": null,
-                                "start2": null,
-                                "stop2": null,
-                                "representative_transcript2": null,
-                                "ensembl_version": 75,
-                                "reference_build": "GRCh37"
-                            }
-                        },
-                        {
-                            "id": 101,
-                            "entrez_name": "PDGFRA",
-                            "entrez_id": 5156,
-                            "name": "I843DEL",
-                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
-                            "gene_id": 38,
-                            "type": "variant",
-                            "variant_types": [
-                                {
-                                    "id": 107,
-                                    "name": "inframe_deletion",
-                                    "display_name": "Inframe Deletion",
-                                    "so_id": "SO:0001822",
-                                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence.",
-                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001822"
-                                }
-                            ],
-                            "civic_actionability_score": 5,
-                            "coordinates": {
-                                "chromosome": "4",
-                                "start": 55152095,
-                                "stop": 55152097,
-                                "reference_bases": "ATC",
-                                "variant_bases": null,
-                                "representative_transcript": "ENST00000257290.5",
-                                "chromosome2": null,
-                                "start2": null,
-                                "stop2": null,
-                                "representative_transcript2": null,
-                                "ensembl_version": 75,
-                                "reference_build": "GRCh37"
-                            }
-                        },
+                        "id": 1994,
+                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
+                        "citation": "Remsing Rix et al., 2009, Leukemia",
+                        "citation_id": 19039322,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
+                        "pmc_id": null,
+                        "publication_date": "2009-3",
+                        "journal": "Leukemia",
+                        "full_journal_title": "Leukemia",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 99,
+                    "phenotypes": []
+                }
+            ],
+            "variant_groups": [
+                {
+                    "id": 1,
+                    "name": "Imatinib Resistance",
+                    "description": "While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. ",
+                    "variants": [
                         {
-                            "id": 2,
+                            "id": 3,
                             "entrez_name": "ABL1",
                             "entrez_id": 25,
-                            "name": "BCR-ABL T315I",
-                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
+                            "name": "BCR::ABL E255K",
+                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
                             "gene_id": 4,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 },
                                 {
                                     "id": 120,
-                                    "name": "transcript_fusion",
-                                    "display_name": "Transcript Fusion",
+                                    "name": "Transcript Fusion",
                                     "so_id": "SO:0001886",
                                     "description": "A feature fusion where the deletion brings together transcript regions.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                                 }
                             ],
-                            "civic_actionability_score": 146,
+                            "civic_actionability_score": 83,
                             "coordinates": {
                                 "chromosome": "9",
-                                "start": 133748283,
-                                "stop": 133748283,
-                                "reference_bases": "C",
-                                "variant_bases": "T",
+                                "start": 133738363,
+                                "stop": 133738363,
+                                "reference_bases": "G",
+                                "variant_bases": "A",
                                 "representative_transcript": "ENST00000318560.5",
                                 "chromosome2": null,
                                 "start2": null,
@@ -1816,23 +1619,21 @@
                             "id": 241,
                             "entrez_name": "ABL1",
                             "entrez_id": 25,
-                            "name": "BCR-ABL F317L",
+                            "name": "BCR::ABL F317L",
                             "description": "BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.",
                             "gene_id": 4,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 },
                                 {
                                     "id": 120,
-                                    "name": "transcript_fusion",
-                                    "display_name": "Transcript Fusion",
+                                    "name": "Transcript Fusion",
                                     "so_id": "SO:0001886",
                                     "description": "A feature fusion where the deletion brings together transcript regions.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
@@ -1855,38 +1656,36 @@
                             }
                         },
                         {
-                            "id": 3,
+                            "id": 2,
                             "entrez_name": "ABL1",
                             "entrez_id": 25,
-                            "name": "BCR-ABL E255K",
-                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
+                            "name": "BCR::ABL T315I",
+                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
                             "gene_id": 4,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 },
                                 {
                                     "id": 120,
-                                    "name": "transcript_fusion",
-                                    "display_name": "Transcript Fusion",
+                                    "name": "Transcript Fusion",
                                     "so_id": "SO:0001886",
                                     "description": "A feature fusion where the deletion brings together transcript regions.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                                 }
                             ],
-                            "civic_actionability_score": 73,
+                            "civic_actionability_score": 146,
                             "coordinates": {
                                 "chromosome": "9",
-                                "start": 133738363,
-                                "stop": 133738363,
-                                "reference_bases": "G",
-                                "variant_bases": "A",
+                                "start": 133748283,
+                                "stop": 133748283,
+                                "reference_bases": "C",
+                                "variant_bases": "T",
                                 "representative_transcript": "ENST00000318560.5",
                                 "chromosome2": null,
                                 "start2": null,
@@ -1896,6 +1695,39 @@
                                 "reference_build": "GRCh37"
                             }
                         },
+                        {
+                            "id": 98,
+                            "entrez_name": "PDGFRA",
+                            "entrez_id": 5156,
+                            "name": "D842I",
+                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
+                            "gene_id": 38,
+                            "type": "variant",
+                            "variant_types": [
+                                {
+                                    "id": 47,
+                                    "name": "Missense Variant",
+                                    "so_id": "SO:0001583",
+                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
+                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
+                                }
+                            ],
+                            "civic_actionability_score": 4,
+                            "coordinates": {
+                                "chromosome": "4",
+                                "start": 55152092,
+                                "stop": 55152093,
+                                "reference_bases": "GA",
+                                "variant_bases": "AT",
+                                "representative_transcript": "ENST00000257290.5",
+                                "chromosome2": null,
+                                "start2": null,
+                                "stop2": null,
+                                "representative_transcript2": null,
+                                "ensembl_version": 75,
+                                "reference_build": "GRCh37"
+                            }
+                        },
                         {
                             "id": 99,
                             "entrez_name": "PDGFRA",
@@ -1907,8 +1739,7 @@
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1941,8 +1772,7 @@
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1975,8 +1805,7 @@
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1997,6 +1826,39 @@
                                 "ensembl_version": 75,
                                 "reference_build": "GRCh37"
                             }
+                        },
+                        {
+                            "id": 101,
+                            "entrez_name": "PDGFRA",
+                            "entrez_id": 5156,
+                            "name": "I843DEL",
+                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
+                            "gene_id": 38,
+                            "type": "variant",
+                            "variant_types": [
+                                {
+                                    "id": 107,
+                                    "name": "Inframe Deletion",
+                                    "so_id": "SO:0001822",
+                                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence.",
+                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001822"
+                                }
+                            ],
+                            "civic_actionability_score": 5,
+                            "coordinates": {
+                                "chromosome": "4",
+                                "start": 55152095,
+                                "stop": 55152097,
+                                "reference_bases": "ATC",
+                                "variant_bases": null,
+                                "representative_transcript": "ENST00000257290.5",
+                                "chromosome2": null,
+                                "start2": null,
+                                "stop2": null,
+                                "representative_transcript2": null,
+                                "ensembl_version": 75,
+                                "reference_build": "GRCh37"
+                            }
                         }
                     ],
                     "type": "variant_group"
@@ -2029,8 +1891,7 @@
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2053,52 +1914,38 @@
             },
             "evidence_items": [
                 {
-                    "id": 77,
-                    "name": "EID77",
-                    "description": "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.",
+                    "id": 74,
+                    "name": "EID74",
+                    "description": "In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.",
                     "disease": {
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
-                    "drugs": [
-                        {
-                            "id": 24,
-                            "name": "JAK2 Inhibitor AZD1480",
-                            "ncit_id": "C91394",
-                            "aliases": [
-                                "AZD1480"
-                            ]
-                        }
-                    ],
-                    "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "drugs": [],
+                    "rating": 5,
+                    "evidence_level": "B",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 91,
-                        "name": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
-                        "citation": "Couto et al., 2012, PLoS ONE",
-                        "citation_id": "23056499",
-                        "source_type": "PubMed",
+                        "id": 44,
+                        "name": "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.",
+                        "citation": "Elisei et al., 2008, J. Clin. Endocrinol. Metab.",
+                        "citation_id": 18073307,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23056499",
-                        "open_access": true,
-                        "pmc_id": "PMC3462763",
-                        "publication_date": {
-                            "year": 2012
-                        },
-                        "journal": "PLoS ONE",
-                        "full_journal_title": "PloS one",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18073307",
+                        "pmc_id": null,
+                        "publication_date": "2008-3",
+                        "journal": "J. Clin. Endocrinol. Metab.",
+                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
                         "clinical_trials": []
                     },
                     "variant_id": 113,
@@ -2112,16 +1959,16 @@
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
                     "drugs": [],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Prognostic",
-                    "clinical_significance": "Poor Outcome",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PROGNOSTIC",
+                    "clinical_significance": "POOR_OUTCOME",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2129,127 +1976,62 @@
                         "id": 92,
                         "name": "Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.",
                         "citation": "Egawa et al., 1998, Jpn. J. Clin. Oncol.",
-                        "citation_id": "9839497",
-                        "source_type": "PubMed",
+                        "citation_id": 9839497,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/9839497",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 1998,
-                            "month": 10
-                        },
+                        "publication_date": "1998-10",
                         "journal": "Jpn. J. Clin. Oncol.",
                         "full_journal_title": "Japanese journal of clinical oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 113,
-                    "phenotypes": []
-                },
-                {
-                    "id": 76,
-                    "name": "EID76",
-                    "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.",
-                    "disease": {
-                        "id": 15,
-                        "name": "Thyroid Gland Medullary Carcinoma",
-                        "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
-                    },
-                    "drugs": [
-                        {
-                            "id": 23,
-                            "name": "Motesanib",
-                            "ncit_id": "C71896",
-                            "aliases": []
-                        }
-                    ],
-                    "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "accepted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 90,
-                        "name": "Anti-tumor activity of motesanib in a medullary thyroid cancer model.",
-                        "citation": "Coxon et al., 2012, J. Endocrinol. Invest.",
-                        "citation_id": "21422803",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21422803",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 2
-                        },
-                        "journal": "J. Endocrinol. Invest.",
-                        "full_journal_title": "Journal of endocrinological investigation",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 113,
                     "phenotypes": []
                 },
                 {
-                    "id": 3696,
-                    "name": "EID3696",
-                    "description": "In an in vitro study, a MZ-CRC-1 cell line expressing RET M918T mutation (endogenous) demonstrated resistance to axitinib treatment (IC50> 5uM). Resistance was determined by assessing cell viability.",
+                    "id": 7710,
+                    "name": "EID7710",
+                    "description": "In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\u2009<\u2009.0001). \nPatients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53).\nThe RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).",
                     "disease": {
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
                     "drugs": [
                         {
-                            "id": 519,
-                            "name": "Axitinib",
-                            "ncit_id": "C38718",
+                            "id": 144,
+                            "name": "Cabozantinib",
+                            "ncit_id": "C52200",
                             "aliases": [
-                                "N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide",
-                                "Inlyta",
-                                "AG013736",
-                                "AG-013736"
+                                "1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-",
+                                "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"
                             ]
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1921,
-                        "name": "The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.",
-                        "citation": "Verbeek et al., 2011, J. Clin. Endocrinol. Metab.",
-                        "citation_id": "21470995",
-                        "source_type": "PubMed",
+                        "id": 3061,
+                        "name": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",
+                        "citation": "Sherman et al., 2016, Cancer",
+                        "citation_id": 27525386,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21470995",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27525386",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2011,
-                            "month": 6
-                        },
-                        "journal": "J. Clin. Endocrinol. Metab.",
-                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2016-12-15",
+                        "journal": "Cancer",
+                        "full_journal_title": "Cancer",
                         "clinical_trials": []
                     },
                     "variant_id": 113,
@@ -2263,8 +2045,8 @@
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
                     "drugs": [
                         {
@@ -2272,18 +2054,18 @@
                             "name": "Sorafenib",
                             "ncit_id": "C61948",
                             "aliases": [
-                                "Bay-439006",
+                                "BA4 43 9006",
                                 "BAY 43-9006",
-                                "BA4 43 9006"
+                                "Bay-439006"
                             ]
                         }
                     ],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2291,21 +2073,14 @@
                         "id": 928,
                         "name": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.",
                         "citation": "Lam et al., 2010, J. Clin. Oncol.",
-                        "citation_id": "20368568",
-                        "source_type": "PubMed",
+                        "citation_id": 20368568,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20368568",
-                        "open_access": true,
                         "pmc_id": "PMC2881718",
-                        "publication_date": {
-                            "year": 2010,
-                            "month": 5,
-                            "day": 10
-                        },
+                        "publication_date": "2010-5-10",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 113,
@@ -2319,8 +2094,8 @@
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
                     "drugs": [
                         {
@@ -2328,21 +2103,21 @@
                             "name": "Selpercatinib",
                             "ncit_id": "C134987",
                             "aliases": [
-                                "WHO 10967",
-                                "Retevmo",
                                 "6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril",
+                                "LOXO-292",
                                 "RET Inhibitor LOXO-292",
                                 "RET Kinase Inhibitor LOXO-292",
-                                "LOXO-292"
+                                "Retevmo",
+                                "WHO 10967"
                             ]
                         }
                     ],
                     "rating": 4,
                     "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -2350,119 +2125,157 @@
                         "id": 2677,
                         "name": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                         "citation": "Subbiah et al., 2018, Ann. Oncol.",
-                        "citation_id": "29912274",
-                        "source_type": "PubMed",
+                        "citation_id": 29912274,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274",
+                        "pmc_id": "PMC6096733",
+                        "publication_date": "2018",
+                        "journal": "Ann. Oncol.",
+                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 113,
+                    "phenotypes": []
+                },
+                {
+                    "id": 3696,
+                    "name": "EID3696",
+                    "description": "In an in vitro study, a MZ-CRC-1 cell line expressing RET M918T mutation (endogenous) demonstrated resistance to axitinib treatment (IC50> 5uM). Resistance was determined by assessing cell viability.",
+                    "disease": {
+                        "id": 15,
+                        "name": "Thyroid Gland Medullary Carcinoma",
+                        "display_name": "Thyroid Gland Medullary Carcinoma",
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
+                    },
+                    "drugs": [
+                        {
+                            "id": 519,
+                            "name": "Axitinib",
+                            "ncit_id": "C38718",
+                            "aliases": [
+                                "AG-013736",
+                                "AG013736",
+                                "Inlyta",
+                                "N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide"
+                            ]
+                        }
+                    ],
+                    "rating": null,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 1921,
+                        "name": "The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.",
+                        "citation": "Verbeek et al., 2011, J. Clin. Endocrinol. Metab.",
+                        "citation_id": 21470995,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274",
-                        "open_access": true,
-                        "pmc_id": "PMC6096733",
-                        "publication_date": {
-                            "year": 2018,
-                            "day": 1
-                        },
-                        "journal": "Ann. Oncol.",
-                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21470995",
+                        "pmc_id": null,
+                        "publication_date": "2011-6",
+                        "journal": "J. Clin. Endocrinol. Metab.",
+                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
                         "clinical_trials": []
                     },
                     "variant_id": 113,
                     "phenotypes": []
                 },
                 {
-                    "id": 74,
-                    "name": "EID74",
-                    "description": "In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.",
+                    "id": 76,
+                    "name": "EID76",
+                    "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.",
                     "disease": {
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
-                    "drugs": [],
-                    "rating": 5,
-                    "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Positive",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "drugs": [
+                        {
+                            "id": 23,
+                            "name": "Motesanib",
+                            "ncit_id": "C71896",
+                            "aliases": []
+                        }
+                    ],
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 44,
-                        "name": "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.",
-                        "citation": "Elisei et al., 2008, J. Clin. Endocrinol. Metab.",
-                        "citation_id": "18073307",
-                        "source_type": "PubMed",
+                        "id": 90,
+                        "name": "Anti-tumor activity of motesanib in a medullary thyroid cancer model.",
+                        "citation": "Coxon et al., 2012, J. Endocrinol. Invest.",
+                        "citation_id": 21422803,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18073307",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21422803",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 3
-                        },
-                        "journal": "J. Clin. Endocrinol. Metab.",
-                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2012-2",
+                        "journal": "J. Endocrinol. Invest.",
+                        "full_journal_title": "Journal of endocrinological investigation",
                         "clinical_trials": []
                     },
                     "variant_id": 113,
                     "phenotypes": []
                 },
                 {
-                    "id": 7710,
-                    "name": "EID7710",
-                    "description": "In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\u2009<\u2009.0001). \nPatients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53).\nThe RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).",
+                    "id": 77,
+                    "name": "EID77",
+                    "description": "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.",
                     "disease": {
                         "id": 15,
                         "name": "Thyroid Gland Medullary Carcinoma",
                         "display_name": "Thyroid Gland Medullary Carcinoma",
-                        "doid": "3973",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
+                        "doid": 3973,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3973"
                     },
                     "drugs": [
                         {
-                            "id": 144,
-                            "name": "Cabozantinib",
-                            "ncit_id": "C52200",
+                            "id": 24,
+                            "name": "JAK2 Inhibitor AZD1480",
+                            "ncit_id": "C91394",
                             "aliases": [
-                                "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide",
-                                "1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-"
+                                "AZD-1480",
+                                "AZD1480"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 3061,
-                        "name": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",
-                        "citation": "Sherman et al., 2016, Cancer",
-                        "citation_id": "27525386",
-                        "source_type": "PubMed",
+                        "id": 91,
+                        "name": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
+                        "citation": "Couto et al., 2012, PLoS ONE",
+                        "citation_id": 23056499,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27525386",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 12,
-                            "day": 15
-                        },
-                        "journal": "Cancer",
-                        "full_journal_title": "Cancer",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23056499",
+                        "pmc_id": "PMC3462763",
+                        "publication_date": "2012",
+                        "journal": "PLoS ONE",
+                        "full_journal_title": "PloS one",
                         "clinical_trials": []
                     },
                     "variant_id": 113,
@@ -2486,8 +2299,7 @@
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2520,8 +2332,7 @@
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2549,8 +2360,8 @@
             ],
             "assertions": [],
             "variant_aliases": [
-                "RS74799832",
-                "MET918THR"
+                "MET918THR",
+                "RS74799832"
             ],
             "hgvs_expressions": [
                 "NM_020975.4:c.2753T>C",
@@ -2568,14 +2379,13 @@
             "entrez_name": "ACVR1",
             "entrez_id": 90,
             "name": "G328V",
-            "description": "",
+            "description": null,
             "gene_id": 154,
             "type": "variant",
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2597,60 +2407,6 @@
                 "reference_build": "GRCh37"
             },
             "evidence_items": [
-                {
-                    "id": 8035,
-                    "name": "EID8035",
-                    "description": "Using mouse models, the authors demonstrated that Acvr1G328V arrested the differentiation of oligodendroglial lineage cells to generate high-grade diffuse gliomas. Using a cellular NanoBRET target engagement assay, they identified the binding between E6201 and ACVR1 with half maximal inhibitory concen- tration [IC50] \u2248 0.25 mM). Furthermore, in primary brainstem glial cells, they demonstrated that E6201 had a larger suppressive effect on BMP signaling pathway activation induced by mutant ACVR1 than by wild-type ACVR1. In addition, to obtain mechanistic insights into the inhibitory effect of E6201 on ACVR1, they solved the 1.5-A \u030a structure of ACVR1 in complex with its interacting partner E6201 by X-ray crystallography. And they showed that E6201 occupied the ATP-binding pocket of ACVR1 with a binding position similar to that in the equivalent MEK1 complex.",
-                    "disease": {
-                        "id": 2950,
-                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
-                    },
-                    "drugs": [
-                        {
-                            "id": 15211,
-                            "name": "MEK-1/MEKK-1 Inhibitor E6201",
-                            "ncit_id": "C79848",
-                            "aliases": [
-                                "E6201"
-                            ]
-                        }
-                    ],
-                    "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "submitted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 3226,
-                        "name": "Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.",
-                        "citation": "Fortin et al., 2020, Cancer Cell",
-                        "citation_id": "32142668",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32142668",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2020,
-                            "month": 2,
-                            "day": 21
-                        },
-                        "journal": "Cancer Cell",
-                        "full_journal_title": "Cancer cell",
-                        "status": "submitted",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 1686,
-                    "phenotypes": []
-                },
                 {
                     "id": 4846,
                     "name": "EID4846",
@@ -2659,16 +2415,16 @@
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Positive",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2676,20 +2432,14 @@
                         "id": 2149,
                         "name": "Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.",
                         "citation": "Fontebasso et al., 2014, Nat. Genet.",
-                        "citation_id": "24705250",
-                        "source_type": "PubMed",
+                        "citation_id": 24705250,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705250",
-                        "open_access": true,
                         "pmc_id": "PMC4282994",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
+                        "publication_date": "2014-5",
                         "journal": "Nat. Genet.",
                         "full_journal_title": "Nature genetics",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 1686,
@@ -2703,16 +2453,16 @@
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Diagnostic",
-                    "clinical_significance": "Positive",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2720,20 +2470,52 @@
                         "id": 2680,
                         "name": "Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.",
                         "citation": "Buczkowicz et al., 2014, Nat. Genet.",
-                        "citation_id": "24705254",
-                        "source_type": "PubMed",
+                        "citation_id": 24705254,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705254",
-                        "open_access": true,
                         "pmc_id": "PMC3997489",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
+                        "publication_date": "2014-5",
+                        "journal": "Nat. Genet.",
+                        "full_journal_title": "Nature genetics",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 1686,
+                    "phenotypes": []
+                },
+                {
+                    "id": 10011,
+                    "name": "EID10011",
+                    "description": "It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52) of DIPG samples. The mutations were highly specific to DIPG, with an overall frequency of 0.3% in other tumors present in the Catalogue of Somatic Mutations in Cancer database. Data was collected from whole genome sequencing on 20 pre-treated biopsy samples of DIPG as well as whole exome sequencing from 1 biopsy sample and five samples obtained at autopsy. An additional 26 DIPG biopsy samples were screened via Sanger sequencing and identified the variant (G328W). DIPG cases with somatic mutations of ACVR1 (R206H, R258G, G328E/V/W, G356D) had longer overall survival (n=11 versus 41; median of 14.9 versus 10.9 months; p=0.05, log-rank test).",
+                    "disease": {
+                        "id": 2950,
+                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
+                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
+                    },
+                    "drugs": [],
+                    "rating": 2,
+                    "evidence_level": "C",
+                    "evidence_type": "DIAGNOSTIC",
+                    "clinical_significance": "POSITIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "accepted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 2448,
+                        "name": "Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.",
+                        "citation": "Taylor et al., 2014, Nat. Genet.",
+                        "citation_id": 24705252,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705252",
+                        "pmc_id": "PMC4018681",
+                        "publication_date": "2014-5",
                         "journal": "Nat. Genet.",
                         "full_journal_title": "Nature genetics",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 1686,
@@ -2747,8 +2529,8 @@
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [
                         {
@@ -2760,10 +2542,10 @@
                     ],
                     "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -2771,20 +2553,62 @@
                         "id": 2448,
                         "name": "Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.",
                         "citation": "Taylor et al., 2014, Nat. Genet.",
-                        "citation_id": "24705252",
-                        "source_type": "PubMed",
+                        "citation_id": 24705252,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705252",
-                        "open_access": true,
                         "pmc_id": "PMC4018681",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
+                        "publication_date": "2014-5",
                         "journal": "Nat. Genet.",
                         "full_journal_title": "Nature genetics",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "clinical_trials": []
+                    },
+                    "variant_id": 1686,
+                    "phenotypes": []
+                },
+                {
+                    "id": 8035,
+                    "name": "EID8035",
+                    "description": "Using mouse models, the authors demonstrated that Acvr1G328V arrested the differentiation of oligodendroglial lineage cells to generate high-grade diffuse gliomas. Using a cellular NanoBRET target engagement assay, they identified the binding between E6201 and ACVR1 with half maximal inhibitory concen- tration [IC50] \u2248 0.25 mM). Furthermore, in primary brainstem glial cells, they demonstrated that E6201 had a larger suppressive effect on BMP signaling pathway activation induced by mutant ACVR1 than by wild-type ACVR1. In addition, to obtain mechanistic insights into the inhibitory effect of E6201 on ACVR1, they solved the 1.5-A \u030a structure of ACVR1 in complex with its interacting partner E6201 by X-ray crystallography. And they showed that E6201 occupied the ATP-binding pocket of ACVR1 with a binding position similar to that in the equivalent MEK1 complex.",
+                    "disease": {
+                        "id": 2950,
+                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
+                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
+                    },
+                    "drugs": [
+                        {
+                            "id": 15211,
+                            "name": "MEK-1/MEKK-1 Inhibitor E6201",
+                            "ncit_id": "C79848",
+                            "aliases": [
+                                "E-6201",
+                                "E6201"
+                            ]
+                        }
+                    ],
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 3226,
+                        "name": "Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.",
+                        "citation": "Fortin et al., 2020, Cancer Cell",
+                        "citation_id": 32142668,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32142668",
+                        "pmc_id": null,
+                        "publication_date": "2020-2-21",
+                        "journal": "Cancer Cell",
+                        "full_journal_title": "Cancer cell",
                         "clinical_trials": []
                     },
                     "variant_id": 1686,
@@ -2798,65 +2622,70 @@
                     "description": "",
                     "variants": [
                         {
-                            "id": 1686,
+                            "id": 2283,
                             "entrez_name": "ACVR1",
                             "entrez_id": 90,
-                            "name": "G328V",
-                            "description": "",
+                            "name": "G328E",
+                            "description": "This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.",
                             "gene_id": 154,
                             "type": "variant",
                             "variant_types": [
+                                {
+                                    "id": 160,
+                                    "name": "Gain Of Function Variant",
+                                    "so_id": "SO:0002053",
+                                    "description": "A sequence variant whereby new or enhanced function is conferred on the gene product.",
+                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002053"
+                                },
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 30,
+                            "civic_actionability_score": 7.5,
                             "coordinates": {
-                                "chromosome": "2",
-                                "start": 158622516,
-                                "stop": 158622516,
-                                "reference_bases": "C",
-                                "variant_bases": "A",
-                                "representative_transcript": "ENST00000434821.1",
+                                "chromosome": null,
+                                "start": null,
+                                "stop": null,
+                                "reference_bases": null,
+                                "variant_bases": null,
+                                "representative_transcript": null,
                                 "chromosome2": null,
                                 "start2": null,
                                 "stop2": null,
                                 "representative_transcript2": null,
-                                "ensembl_version": 75,
-                                "reference_build": "GRCh37"
+                                "ensembl_version": null,
+                                "reference_build": null
                             }
                         },
                         {
-                            "id": 2280,
+                            "id": 1686,
                             "entrez_name": "ACVR1",
                             "entrez_id": 90,
-                            "name": "G328W",
-                            "description": "",
+                            "name": "G328V",
+                            "description": null,
                             "gene_id": 154,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 0,
+                            "civic_actionability_score": 30,
                             "coordinates": {
                                 "chromosome": "2",
-                                "start": 158622517,
-                                "stop": 158622517,
+                                "start": 158622516,
+                                "stop": 158622516,
                                 "reference_bases": "C",
                                 "variant_bases": "A",
-                                "representative_transcript": "ENST00000263640.3",
+                                "representative_transcript": "ENST00000434821.1",
                                 "chromosome2": null,
                                 "start2": null,
                                 "stop2": null,
@@ -2866,45 +2695,36 @@
                             }
                         },
                         {
-                            "id": 2283,
+                            "id": 2280,
                             "entrez_name": "ACVR1",
                             "entrez_id": 90,
-                            "name": "G328E",
-                            "description": "This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.",
+                            "name": "G328W",
+                            "description": null,
                             "gene_id": 154,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
-                                },
-                                {
-                                    "id": 160,
-                                    "name": "gain_of_function_variant",
-                                    "display_name": "Gain Of Function Variant",
-                                    "so_id": "SO:0002053",
-                                    "description": "A sequence variant whereby new or enhanced function is conferred on the gene product.",
-                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002053"
                                 }
                             ],
-                            "civic_actionability_score": 7.5,
+                            "civic_actionability_score": 0,
                             "coordinates": {
-                                "chromosome": null,
-                                "start": null,
-                                "stop": null,
-                                "reference_bases": null,
-                                "variant_bases": null,
-                                "representative_transcript": null,
+                                "chromosome": "2",
+                                "start": 158622517,
+                                "stop": 158622517,
+                                "reference_bases": "C",
+                                "variant_bases": "A",
+                                "representative_transcript": "ENST00000263640.3",
                                 "chromosome2": null,
                                 "start2": null,
                                 "stop2": null,
                                 "representative_transcript2": null,
-                                "ensembl_version": null,
-                                "reference_build": null
+                                "ensembl_version": 75,
+                                "reference_build": "GRCh37"
                             }
                         }
                     ],
@@ -2918,25 +2738,19 @@
                     "name": "AID9",
                     "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                     "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
-                    "gene": {
-                        "name": "ACVR1",
-                        "id": 154
-                    },
-                    "variant": {
-                        "name": "G328V",
-                        "id": 1686
-                    },
+                    "gene_id": 154,
+                    "variant_id": 1686,
                     "disease": {
                         "id": 2950,
                         "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                         "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
-                        "doid": "0080684",
-                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
+                        "doid": 80684,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:0080684"
                     },
                     "drugs": [],
-                    "evidence_type": "Diagnostic",
-                    "evidence_direction": "Supports",
-                    "clinical_significance": "Positive",
+                    "evidence_type": "DIAGNOSTIC",
+                    "evidence_direction": "SUPPORTS",
+                    "clinical_significance": "POSITIVE",
                     "fda_regulatory_approval": false,
                     "status": "accepted"
                 }
diff --git a/tests/data/transform/moa_harvester.json b/tests/data/transform/moa_harvester.json
index 3281eeaf..a24ace34 100644
--- a/tests/data/transform/moa_harvester.json
+++ b/tests/data/transform/moa_harvester.json
@@ -1,69 +1,72 @@
 {
-    "assertions": [
-    	{
-	        "id": 71,
-	        "context": null,
-	        "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.",
-	        "disease": {
-	            "name": "Chronic Myelogenous Leukemia",
-	            "oncotree_code": "CML",
-	            "oncotree_term": "Chronic Myelogenous Leukemia"
-	        },
-	        "therapy_name": "Imatinib",
-	        "therapy_type": "Targeted therapy",
-	        "clinical_significance": "resistance",
-	        "predictive_implication": "Preclinical",
-	        "favorable_prognosis": null,
-	        "created_on": "03/31/21",
-	        "last_updated": "2019-06-13",
-	        "submitted_by": "breardon@broadinstitute.org",
-	        "validated": true,
-	        "source_ids": 41,
-	        "variant": {
-	            "id": 71,
-	            "alternate_allele": "T",
-	            "cdna_change": "c.944C>T",
-	            "chromosome": "9",
-	            "end_position": "133747580.0",
-	            "exon": "5.0",
-	            "feature_type": "somatic_variant",
-	            "gene": "ABL1",
-	            "protein_change": "p.T315I",
-	            "reference_allele": "C",
-	            "rsid": null,
-	            "start_position": "133747580.0",
-	            "variant_annotation": "Missense",
-	            "feature": "ABL1 p.T315I (Missense)"
-	        }
-	    }
+	"assertions": [
+		{
+			"id": 71,
+			"context": "",
+			"description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.",
+			"disease": {
+				"name": "Chronic Myelogenous Leukemia",
+				"oncotree_code": "CML",
+				"oncotree_term": "Chronic Myelogenous Leukemia"
+			},
+			"therapy_name": "Imatinib",
+			"therapy_type": "Targeted therapy",
+			"clinical_significance": "resistance",
+			"predictive_implication": "Preclinical",
+			"favorable_prognosis": false,
+			"created_on": "09/08/22",
+			"last_updated": "2019-06-13",
+			"submitted_by": "breardon@broadinstitute.org",
+			"validated": true,
+			"source_ids": 44,
+			"variant": {
+				"id": 71,
+				"alternate_allele": "T",
+				"cdna_change": "c.944C>T",
+				"chromosome": "9",
+				"end_position": "133747580",
+				"exon": "5",
+				"feature_type": "somatic_variant",
+				"gene": "ABL1",
+				"protein_change": "p.T315I",
+				"reference_allele": "C",
+				"rsid": null,
+				"start_position": "133747580",
+				"variant_annotation": "Missense",
+				"feature": "ABL1 p.T315I (Missense)"
+			}
+		}
 	],
-    "sources": [
-    	{
-	        "id": 41,
-	        "type": "Journal",
-	        "doi": "10.1126/science.1062538",
-	        "nct": "None",
-	        "pmid": 11423618,
-	        "url": "https://doi.org/10.1126/science.1062538",
-	        "citation": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880."
-	    }
+	"sources": [
+		{
+			"id": 44,
+			"type": "Journal",
+			"doi": "10.1126/science.1062538",
+			"nct": "",
+			"pmid": 11423618,
+			"url": "https://doi.org/10.1126/science.1062538",
+			"citation": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880."
+		}
 	],
-    "variants": [
-    	{
-	        "id": 71,
-	        "alternate_allele": "T",
-	        "cdna_change": "c.944C>T",
-	        "chromosome": "9",
-	        "end_position": "133747580.0",
-	        "exon": "5.0",
-	        "feature_type": "somatic_variant",
-	        "gene": "ABL1",
-	        "protein_change": "p.T315I",
-	        "reference_allele": "C",
-	        "rsid": null,
-	        "start_position": "133747580.0",
-	        "variant_annotation": "Missense",
-	        "feature": "ABL1 p.T315I (Missense)"
-	    }
+	"variants": [
+		{
+			"id": 71,
+			"alternate_allele": "T",
+			"cdna_change": "c.944C>T",
+			"chromosome": "9",
+			"end_position": "133747580",
+			"exon": "5",
+			"feature_type": "somatic_variant",
+			"gene": "ABL1",
+			"protein_change": "p.T315I",
+			"reference_allele": "C",
+			"rsid": null,
+			"start_position": "133747580",
+			"variant_annotation": "Missense",
+			"feature": "ABL1 p.T315I (Missense)"
+		}
+	],
+	"genes": [
+		"ABL1"
 	]
-}
+}
\ No newline at end of file
diff --git a/tests/data/transform/prognostic/civic_harvester.json b/tests/data/transform/prognostic/civic_harvester.json
index b0e8beb6..f4f0f0b1 100644
--- a/tests/data/transform/prognostic/civic_harvester.json
+++ b/tests/data/transform/prognostic/civic_harvester.json
@@ -8,16 +8,16 @@
                 "id": 3,
                 "name": "Acute Myeloid Leukemia",
                 "display_name": "Acute Myeloid Leukemia",
-                "doid": "9119",
-                "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                "doid": 9119,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:9119"
             },
             "drugs": [],
             "rating": 4,
             "evidence_level": "B",
-            "evidence_type": "Prognostic",
-            "clinical_significance": "Poor Outcome",
-            "evidence_direction": "Supports",
-            "variant_origin": "Somatic",
+            "evidence_type": "PROGNOSTIC",
+            "clinical_significance": "POOR_OUTCOME",
+            "evidence_direction": "SUPPORTS",
+            "variant_origin": "SOMATIC",
             "drug_interaction_type": null,
             "status": "accepted",
             "type": "evidence",
@@ -25,21 +25,14 @@
                 "id": 69,
                 "name": "Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.",
                 "citation": "Cairoli et al., 2006, Blood",
-                "citation_id": "16384925",
-                "source_type": "PubMed",
+                "citation_id": 16384925,
+                "source_type": "PUBMED",
                 "asco_abstract_id": null,
                 "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16384925",
-                "open_access": null,
                 "pmc_id": null,
-                "publication_date": {
-                    "year": 2006,
-                    "month": 5,
-                    "day": 1
-                },
+                "publication_date": "2006-5-1",
                 "journal": "Blood",
                 "full_journal_title": "Blood",
-                "status": "fully curated",
-                "is_review": false,
                 "clinical_trials": []
             },
             "variant_id": 65,
@@ -50,21 +43,21 @@
         {
             "id": 1756,
             "name": "EID1756",
-            "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",
+            "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai. Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",
             "disease": {
                 "id": 556,
                 "name": "Pancreatic Cancer",
                 "display_name": "Pancreatic Cancer",
-                "doid": "1793",
-                "url": "http://www.disease-ontology.org/?id=DOID:1793"
+                "doid": 1793,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:1793"
             },
             "drugs": [],
             "rating": 4,
             "evidence_level": "B",
-            "evidence_type": "Prognostic",
-            "clinical_significance": "Better Outcome",
-            "evidence_direction": "Supports",
-            "variant_origin": "Rare Germline",
+            "evidence_type": "PROGNOSTIC",
+            "clinical_significance": "BETTER_OUTCOME",
+            "evidence_direction": "SUPPORTS",
+            "variant_origin": "COMMON_GERMLINE",
             "drug_interaction_type": null,
             "status": "accepted",
             "type": "evidence",
@@ -72,21 +65,14 @@
                 "id": 1218,
                 "name": "MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.",
                 "citation": "Wu et al., 2016, Sci Rep",
-                "citation_id": "27819322",
-                "source_type": "PubMed",
+                "citation_id": 27819322,
+                "source_type": "PUBMED",
                 "asco_abstract_id": null,
                 "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27819322",
-                "open_access": true,
                 "pmc_id": "PMC5098242",
-                "publication_date": {
-                    "year": 2016,
-                    "month": 11,
-                    "day": 7
-                },
+                "publication_date": "2016-11-7",
                 "journal": "Sci Rep",
                 "full_journal_title": "Scientific reports",
-                "status": "fully curated",
-                "is_review": false,
                 "clinical_trials": []
             },
             "variant_id": 258,
@@ -104,116 +90,125 @@
             "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.",
             "variants": [
                 {
-                    "name": "D579del",
-                    "id": 977,
+                    "name": "A502_Y503insAY",
+                    "id": 1558,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 3,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Internal Duplication",
-                    "id": 67,
+                    "name": "A829P",
+                    "id": 990,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Exon 11 Mutation",
-                    "id": 66,
+                    "name": "Amplification",
+                    "id": 586,
                     "evidence_items": {
-                        "accepted_count": 13,
-                        "rejected_count": 1,
+                        "accepted_count": 1,
+                        "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Amplification",
-                    "id": 586,
+                    "name": "C809G",
+                    "id": 1264,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "W557_E561del",
-                    "id": 962,
+                    "name": "D419del",
+                    "id": 855,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "WILDTYPE",
-                    "id": 2651,
+                    "name": "D579_H580insIDPTQLPYD",
+                    "id": 1547,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Exon 13 Mutation",
-                    "id": 2643,
+                    "name": "D579del",
+                    "id": 977,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "Exon 9 Mutation",
-                    "id": 509,
+                    "name": "D816E",
+                    "id": 1559,
                     "evidence_items": {
-                        "accepted_count": 8,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "W557_K558del",
-                    "id": 961,
+                    "name": "D816G",
+                    "id": 1402,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "A502_Y503insAY",
-                    "id": 1558,
+                    "name": "D816H",
+                    "id": 983,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "F504A",
-                    "id": 3240,
+                    "name": "D816V",
+                    "id": 65,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 5,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 9
                     }
                 },
                 {
-                    "name": "Y503A",
-                    "id": 3239,
+                    "name": "D816Y",
+                    "id": 984,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "N505R",
-                    "id": 3238,
+                    "name": "D820A",
+                    "id": 1265,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "D820E",
+                    "id": 2736,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -221,26 +216,35 @@
                     }
                 },
                 {
-                    "name": "N505I",
-                    "id": 3237,
+                    "name": "D820G",
+                    "id": 1266,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "D820Y",
+                    "id": 986,
+                    "evidence_items": {
+                        "accepted_count": 3,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V559",
-                    "id": 1316,
+                    "name": "DEL 554-558",
+                    "id": 954,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "K642R",
-                    "id": 2592,
+                    "name": "E554D",
+                    "id": 955,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -248,17 +252,26 @@
                     }
                 },
                 {
-                    "name": "T417_D419delinsY",
-                    "id": 2620,
+                    "name": "EXPRESSION",
+                    "id": 429,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 4,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "F506_F508DUP",
-                    "id": 2621,
+                    "name": "Exon 11 Mutation",
+                    "id": 66,
+                    "evidence_items": {
+                        "accepted_count": 13,
+                        "rejected_count": 1,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "Exon 13 Mutation",
+                    "id": 2643,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -266,8 +279,8 @@
                     }
                 },
                 {
-                    "name": "K484_G487DEL",
-                    "id": 2622,
+                    "name": "Exon 14 Mutation",
+                    "id": 69,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -275,35 +288,44 @@
                     }
                 },
                 {
-                    "name": "RS3733542",
-                    "id": 482,
+                    "name": "Exon 9 Mutation",
+                    "id": 509,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 8,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "MUTATION",
-                    "id": 388,
+                    "name": "F504A",
+                    "id": 3240,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V560D",
-                    "id": 971,
+                    "name": "F506_F508DUP",
+                    "id": 2621,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "3' UTR MUTATION",
-                    "id": 256,
+                    "name": "G3BP2::KIT",
+                    "id": 3742,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 1
+                    }
+                },
+                {
+                    "name": "Internal Duplication",
+                    "id": 67,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -311,8 +333,8 @@
                     }
                 },
                 {
-                    "name": "EXON 14 MUTATION",
-                    "id": 69,
+                    "name": "K484_G487DEL",
+                    "id": 2622,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -320,39 +342,39 @@
                     }
                 },
                 {
-                    "name": "EXPRESSION",
-                    "id": 429,
+                    "name": "K550_K558del",
+                    "id": 949,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
                 },
                 {
-                    "name": "EXON 8 MUTATION",
-                    "id": 855,
+                    "name": "K550_K559DEL",
+                    "id": 2696,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "A829P",
-                    "id": 990,
+                    "name": "K550_W557del",
+                    "id": 948,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Y553_K558DEL",
-                    "id": 953,
+                    "name": "K558NP",
+                    "id": 1549,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 1
                     }
                 },
                 {
@@ -365,35 +387,35 @@
                     }
                 },
                 {
-                    "name": "D816Y",
-                    "id": 984,
+                    "name": "K558R",
+                    "id": 965,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V569_L576DEL",
-                    "id": 1551,
+                    "name": "K558_V559del",
+                    "id": 964,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "D579_H580insIDPTQLPYD",
-                    "id": 1547,
+                    "name": "K642E",
+                    "id": 978,
                     "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
+                        "accepted_count": 4,
+                        "rejected_count": 1,
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "V555_I571DEL",
-                    "id": 1543,
+                    "name": "K642R",
+                    "id": 2592,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -401,26 +423,35 @@
                     }
                 },
                 {
-                    "name": "Y570_L576DEL",
-                    "id": 1548,
+                    "name": "L576P",
+                    "id": 72,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 5,
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
                 },
                 {
-                    "name": "V560_L576DEL",
-                    "id": 1550,
+                    "name": "M541L",
+                    "id": 201,
                     "evidence_items": {
                         "accepted_count": 2,
                         "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "M552_W557DEL",
+                    "id": 951,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "P551_E554delPMYE",
-                    "id": 1497,
+                    "name": "Mutation",
+                    "id": 388,
                     "evidence_items": {
                         "accepted_count": 2,
                         "rejected_count": 0,
@@ -428,17 +459,17 @@
                     }
                 },
                 {
-                    "name": "K558NP",
-                    "id": 1549,
+                    "name": "N505I",
+                    "id": 3237,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "T417_D419DELTYDINSI",
-                    "id": 1546,
+                    "name": "N505R",
+                    "id": 3238,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -446,89 +477,80 @@
                     }
                 },
                 {
-                    "name": "Q556_I571DEL",
-                    "id": 1541,
+                    "name": "N822H",
+                    "id": 987,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Y553_W557DELYEVQW",
-                    "id": 1542,
+                    "name": "N822K",
+                    "id": 1263,
                     "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
+                        "accepted_count": 8,
+                        "rejected_count": 1,
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "S692L",
-                    "id": 980,
+                    "name": "Overexpression",
+                    "id": 3731,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "T661I",
-                    "id": 979,
+                    "name": "P551L",
+                    "id": 950,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D820A",
-                    "id": 1265,
+                    "name": "P551_E554delPMYE",
+                    "id": 1497,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "T670I",
-                    "id": 1267,
+                    "name": "P577L",
+                    "id": 976,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D820G",
-                    "id": 1266,
+                    "name": "P577_D579DEL",
+                    "id": 2738,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "M541L",
-                    "id": 201,
+                    "name": "Q556_I571DEL",
+                    "id": 1541,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "N822K",
-                    "id": 1263,
-                    "evidence_items": {
-                        "accepted_count": 7,
-                        "rejected_count": 1,
-                        "submitted_count": 4
-                    }
-                },
-                {
-                    "name": "W557R",
-                    "id": 958,
+                    "name": "Q575L",
+                    "id": 975,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -536,53 +558,53 @@
                     }
                 },
                 {
-                    "name": "DEL 554-558",
-                    "id": 954,
+                    "name": "Q694K",
+                    "id": 981,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "V555_Q556DEL",
-                    "id": 956,
+                    "name": "RS3733542",
+                    "id": 482,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Q694K",
-                    "id": 981,
+                    "name": "S501_A502INSAY",
+                    "id": 1206,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 10
                     }
                 },
                 {
-                    "name": "K558R",
-                    "id": 965,
+                    "name": "S628N",
+                    "id": 1659,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V559DEL",
-                    "id": 966,
+                    "name": "S692L",
+                    "id": 980,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "Q575L",
-                    "id": 975,
+                    "name": "T417_D419DELTYDINSI",
+                    "id": 1546,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -590,17 +612,17 @@
                     }
                 },
                 {
-                    "name": "P551L",
-                    "id": 950,
+                    "name": "T417_D419delinsY",
+                    "id": 2620,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Y553D",
-                    "id": 952,
+                    "name": "T574A",
+                    "id": 974,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -608,26 +630,26 @@
                     }
                 },
                 {
-                    "name": "E554D",
-                    "id": 955,
+                    "name": "T661I",
+                    "id": 979,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "W557G",
-                    "id": 959,
+                    "name": "T670I",
+                    "id": 1267,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 4,
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
                 },
                 {
-                    "name": "V559A",
-                    "id": 969,
+                    "name": "V555_I571DEL",
+                    "id": 1543,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -635,8 +657,8 @@
                     }
                 },
                 {
-                    "name": "T574A",
-                    "id": 974,
+                    "name": "V555_P573DEL",
+                    "id": 957,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -644,17 +666,17 @@
                     }
                 },
                 {
-                    "name": "D816H",
-                    "id": 983,
+                    "name": "V555_Q556DEL",
+                    "id": 956,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 6
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "C809G",
-                    "id": 1264,
+                    "name": "V555_V559DEL",
+                    "id": 2695,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -662,8 +684,8 @@
                     }
                 },
                 {
-                    "name": "W557T",
-                    "id": 960,
+                    "name": "V559",
+                    "id": 1316,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -671,89 +693,80 @@
                     }
                 },
                 {
-                    "name": "D820Y",
-                    "id": 986,
+                    "name": "V559A",
+                    "id": 969,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V559G",
-                    "id": 970,
+                    "name": "V559D",
+                    "id": 968,
                     "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 3
+                        "accepted_count": 3,
+                        "rejected_count": 1,
+                        "submitted_count": 7
                     }
                 },
                 {
-                    "name": "K558_V559del",
-                    "id": 964,
+                    "name": "V559DEL",
+                    "id": 966,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
                 },
                 {
-                    "name": "K642E",
-                    "id": 978,
-                    "evidence_items": {
-                        "accepted_count": 4,
-                        "rejected_count": 1,
-                        "submitted_count": 2
-                    }
-                },
-                {
-                    "name": "P577L",
-                    "id": 976,
+                    "name": "V559G",
+                    "id": 970,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "S501_A502INSAY",
-                    "id": 1206,
+                    "name": "V559_V560DEL",
+                    "id": 967,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 10
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "V654A",
-                    "id": 73,
+                    "name": "V560D",
+                    "id": 971,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 4,
                         "rejected_count": 0,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "Y823D",
-                    "id": 989,
+                    "name": "V560DEL",
+                    "id": 202,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "M552_W557DEL",
-                    "id": 951,
+                    "name": "V560G",
+                    "id": 972,
                     "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
+                        "accepted_count": 2,
+                        "rejected_count": 2,
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "S628N",
-                    "id": 1659,
+                    "name": "V560_L576DEL",
+                    "id": 1550,
                     "evidence_items": {
                         "accepted_count": 2,
                         "rejected_count": 0,
@@ -761,17 +774,8 @@
                     }
                 },
                 {
-                    "name": "V559D",
-                    "id": 968,
-                    "evidence_items": {
-                        "accepted_count": 3,
-                        "rejected_count": 1,
-                        "submitted_count": 6
-                    }
-                },
-                {
-                    "name": "Y503_F504insAY",
-                    "id": 946,
+                    "name": "V569_L576DEL",
+                    "id": 1551,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -779,35 +783,17 @@
                     }
                 },
                 {
-                    "name": "V559_V560DEL",
-                    "id": 967,
+                    "name": "V654A",
+                    "id": 73,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "V560DEL",
-                    "id": 202,
-                    "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 4
-                    }
-                },
-                {
-                    "name": "N822H",
-                    "id": 987,
-                    "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 0
-                    }
-                },
-                {
-                    "name": "W557_V559insC",
-                    "id": 1498,
+                    "name": "W557G",
+                    "id": 959,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -815,71 +801,71 @@
                     }
                 },
                 {
-                    "name": "N822K",
-                    "id": 1403,
+                    "name": "W557R",
+                    "id": 958,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "K550_K558del",
-                    "id": 949,
+                    "name": "W557T",
+                    "id": 960,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V560G",
-                    "id": 972,
+                    "name": "W557_E561del",
+                    "id": 962,
                     "evidence_items": {
-                        "accepted_count": 2,
-                        "rejected_count": 2,
-                        "submitted_count": 6
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "L576P",
-                    "id": 72,
+                    "name": "W557_K558del",
+                    "id": 961,
                     "evidence_items": {
-                        "accepted_count": 5,
+                        "accepted_count": 4,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "D816V",
-                    "id": 65,
+                    "name": "W557_V559insC",
+                    "id": 1498,
                     "evidence_items": {
-                        "accepted_count": 5,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 9
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "D816E",
-                    "id": 1559,
+                    "name": "WILDTYPE",
+                    "id": 2651,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "D816G",
-                    "id": 1402,
+                    "name": "Y503A",
+                    "id": 3239,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "K550_W557del",
-                    "id": 948,
+                    "name": "Y503_F504insAY",
+                    "id": 946,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -887,17 +873,17 @@
                     }
                 },
                 {
-                    "name": "V555_V559DEL",
-                    "id": 2695,
+                    "name": "Y553D",
+                    "id": 952,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V555_P573DEL",
-                    "id": 957,
+                    "name": "Y553N",
+                    "id": 2737,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -905,17 +891,17 @@
                     }
                 },
                 {
-                    "name": "K550_K559DEL",
-                    "id": 2696,
+                    "name": "Y553_K558DEL",
+                    "id": 953,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "D820E",
-                    "id": 2736,
+                    "name": "Y553_W557DELYEVQW",
+                    "id": 1542,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -923,40 +909,40 @@
                     }
                 },
                 {
-                    "name": "Y553N",
-                    "id": 2737,
+                    "name": "Y570_L576DEL",
+                    "id": 1548,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "P577_D579DEL",
-                    "id": 2738,
+                    "name": "Y823D",
+                    "id": 989,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Mutations",
-                    "id": 3131,
+                    "name": "rs17084733",
+                    "id": 256,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 }
             ],
             "aliases": [
-                "MASTC",
+                "C-Kit",
+                "CD117",
                 "KIT",
-                "SCFR",
+                "MASTC",
                 "PBT",
-                "CD117",
-                "C-Kit"
+                "SCFR"
             ],
             "type": "gene"
         },
@@ -994,8 +980,7 @@
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1025,16 +1010,16 @@
                         "id": 3,
                         "name": "Acute Myeloid Leukemia",
                         "display_name": "Acute Myeloid Leukemia",
-                        "doid": "9119",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9119"
+                        "doid": 9119,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9119"
                     },
                     "drugs": [],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Prognostic",
-                    "clinical_significance": "Poor Outcome",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PROGNOSTIC",
+                    "clinical_significance": "POOR_OUTCOME",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -1042,26 +1027,74 @@
                         "id": 69,
                         "name": "Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.",
                         "citation": "Cairoli et al., 2006, Blood",
-                        "citation_id": "16384925",
-                        "source_type": "PubMed",
+                        "citation_id": 16384925,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16384925",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 5,
-                            "day": 1
-                        },
+                        "publication_date": "2006-5-1",
                         "journal": "Blood",
                         "full_journal_title": "Blood",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
+                {
+                    "id": 1725,
+                    "name": "EID1725",
+                    "description": "In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.",
+                    "disease": {
+                        "id": 2150,
+                        "name": "Systemic Mastocytosis",
+                        "display_name": "Systemic Mastocytosis",
+                        "doid": 349,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:349"
+                    },
+                    "drugs": [
+                        {
+                            "id": 323,
+                            "name": "Midostaurin",
+                            "ncit_id": "C1872",
+                            "aliases": [
+                                "CGP 41251",
+                                "CGP41251",
+                                "N-Benzoyl-Staurosporine",
+                                "N-Benzoylstaurosporine",
+                                "PKC-412",
+                                "PKC412",
+                                "Rydapt"
+                            ]
+                        }
+                    ],
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "accepted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 1170,
+                        "name": "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.",
+                        "citation": "Gotlib et al., 2016, N. Engl. J. Med.",
+                        "citation_id": 27355533,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27355533",
+                        "pmc_id": null,
+                        "publication_date": "2016-6-30",
+                        "journal": "N. Engl. J. Med.",
+                        "full_journal_title": "The New England journal of medicine",
+                        "clinical_trials": [
+                            {}
+                        ]
+                    },
+                    "variant_id": 65,
+                    "phenotypes": []
+                },
                 {
                     "id": 1726,
                     "name": "EID1726",
@@ -1070,16 +1103,16 @@
                         "id": 2150,
                         "name": "Systemic Mastocytosis",
                         "display_name": "Systemic Mastocytosis",
-                        "doid": "349",
-                        "url": "http://www.disease-ontology.org/?id=DOID:349"
+                        "doid": 349,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:349"
                     },
                     "drugs": [],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Prognostic",
-                    "clinical_significance": "Poor Outcome",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PROGNOSTIC",
+                    "clinical_significance": "POOR_OUTCOME",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -1087,35 +1120,29 @@
                         "id": 1171,
                         "name": "Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.",
                         "citation": "Jawhar et al., 2016, Leukemia",
-                        "citation_id": "26464169",
-                        "source_type": "PubMed",
+                        "citation_id": 26464169,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26464169",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 1
-                        },
+                        "publication_date": "2016-1",
                         "journal": "Leukemia",
                         "full_journal_title": "Leukemia",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 7465,
-                    "name": "EID7465",
-                    "description": "In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment.",
+                    "id": 4159,
+                    "name": "EID4159",
+                    "description": "In a systemic mastocytosis (SM) and acute myelogeneous leukemia (AML) patient harboring KIT D816V mutation, KIT D816V was associated with improved response to dasatinib therapy. The patient initially achieved a hematologic complete remission (HCR) with persistent mastocytes in the bone marrow with cytarbine treatment. Subsequently, the patient received dasatinib in combination with chemotherapy, followed by dasatinib monotherapy, experiencing HCR and eventual extinguishment of the KIT D816V mutation.",
                     "disease": {
-                        "id": 216,
-                        "name": "Cancer",
-                        "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "id": 3,
+                        "name": "Acute Myeloid Leukemia",
+                        "display_name": "Acute Myeloid Leukemia",
+                        "doid": 9119,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9119"
                     },
                     "drugs": [
                         {
@@ -1123,13 +1150,52 @@
                             "name": "Dasatinib",
                             "ncit_id": "C38713",
                             "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
                                 "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
                             ]
-                        },
+                        }
+                    ],
+                    "rating": null,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 2059,
+                        "name": "Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.",
+                        "citation": "Ustun et al., 2009, Leuk. Res.",
+                        "citation_id": 18986703,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18986703",
+                        "pmc_id": null,
+                        "publication_date": "2009-5",
+                        "journal": "Leuk. Res.",
+                        "full_journal_title": "Leukemia research",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 65,
+                    "phenotypes": []
+                },
+                {
+                    "id": 7465,
+                    "name": "EID7465",
+                    "description": "In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment.",
+                    "disease": {
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
+                    },
+                    "drugs": [
                         {
                             "id": 5,
                             "name": "Imatinib",
@@ -1137,117 +1203,155 @@
                             "aliases": [
                                 "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
+                        },
+                        {
+                            "id": 20,
+                            "name": "Dasatinib",
+                            "ncit_id": "C38713",
+                            "aliases": [
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
+                                "BMS-354825",
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
+                            ]
                         }
                     ],
                     "rating": 2,
                     "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": "Substitutes",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": "SUBSTITUTES",
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
                         "id": 2054,
                         "name": "Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.",
                         "citation": "Vita et al., 2014, JAMA Dermatol",
-                        "citation_id": "25317746",
-                        "source_type": "PubMed",
+                        "citation_id": 25317746,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/25317746",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 12
-                        },
+                        "publication_date": "2014-12",
                         "journal": "JAMA Dermatol",
                         "full_journal_title": "JAMA dermatology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 1725,
-                    "name": "EID1725",
-                    "description": "In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.",
+                    "id": 4160,
+                    "name": "EID4160",
+                    "description": "In an in vitro study, a 32D cell line expressing KIT D816V mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 294.7nM) compared to 32D cells expressing wild-type KIT (overexpression, IC50: 16.3nM). Sensitivity was determined by assessing cell proliferation.",
                     "disease": {
-                        "id": 2150,
-                        "name": "Systemic Mastocytosis",
-                        "display_name": "Systemic Mastocytosis",
-                        "doid": "349",
-                        "url": "http://www.disease-ontology.org/?id=DOID:349"
+                        "id": 2,
+                        "name": "Gastrointestinal Stromal Tumor",
+                        "display_name": "Gastrointestinal Stromal Tumor",
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
-                            "id": 323,
-                            "name": "Midostaurin",
-                            "ncit_id": "C1872",
+                            "id": 157,
+                            "name": "Sunitinib",
+                            "ncit_id": "C71622",
                             "aliases": [
-                                "Rydapt",
-                                "PKC412",
-                                "PKC-412",
-                                "N-Benzoylstaurosporine",
-                                "N-Benzoyl-Staurosporine",
-                                "CGP41251",
-                                "CGP 41251"
+                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": null,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 1170,
-                        "name": "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.",
-                        "citation": "Gotlib et al., 2016, N. Engl. J. Med.",
-                        "citation_id": "27355533",
-                        "source_type": "PubMed",
+                        "id": 2049,
+                        "name": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
+                        "citation": "Zhao et al., 2014, Cancer Sci.",
+                        "citation_id": 24205792,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27355533",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 6,
-                            "day": 30
-                        },
-                        "journal": "N. Engl. J. Med.",
-                        "full_journal_title": "The New England journal of medicine",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00782067",
-                                "name": "Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia",
-                                "description": "The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00782067"
-                            }
-                        ]
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792",
+                        "pmc_id": "PMC4317885",
+                        "publication_date": "2014-1",
+                        "journal": "Cancer Sci.",
+                        "full_journal_title": "Cancer science",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 65,
+                    "phenotypes": []
+                },
+                {
+                    "id": 4161,
+                    "name": "EID4161",
+                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with insensitivity to bosutinib treatment (IC50: 2772nM), comparable to wild-type KIT kinase (IC50: 6313nM). Resistance was assessed by analyzing kinase inhibition.",
+                    "disease": {
+                        "id": 4,
+                        "name": "Chronic Myeloid Leukemia",
+                        "display_name": "Chronic Myeloid Leukemia",
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
+                    },
+                    "drugs": [
+                        {
+                            "id": 520,
+                            "name": "Bosutinib",
+                            "ncit_id": "C60809",
+                            "aliases": [
+                                "4-Anilino-3-quinolinecarbonitrile",
+                                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
+                                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile",
+                                "Bosulif",
+                                "SKI 606",
+                                "SKI-606"
+                            ]
+                        }
+                    ],
+                    "rating": null,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 1994,
+                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
+                        "citation": "Remsing Rix et al., 2009, Leukemia",
+                        "citation_id": 19039322,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
+                        "pmc_id": null,
+                        "publication_date": "2009-3",
+                        "journal": "Leukemia",
+                        "full_journal_title": "Leukemia",
+                        "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 8361,
-                    "name": "EID8361",
-                    "description": "In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with dasatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding at increased concentrations of treatment.",
+                    "id": 4162,
+                    "name": "EID4162",
+                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with increased sensitivity to dasatinib treatment (IC50: 37nM vs. 79nM), as compared to wild-type KIT kinase. Sensitivity was assessed by analyzing kinase activity.",
                     "disease": {
                         "id": 4,
                         "name": "Chronic Myeloid Leukemia",
                         "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
@@ -1255,20 +1359,20 @@
                             "name": "Dasatinib",
                             "ncit_id": "C38713",
                             "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
                                 "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
                             ]
                         }
                     ],
-                    "rating": 4,
+                    "rating": null,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -1276,90 +1380,80 @@
                         "id": 2060,
                         "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
                         "citation": "Shah et al., 2006, Blood",
-                        "citation_id": "16434489",
-                        "source_type": "PubMed",
+                        "citation_id": 16434489,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 7,
-                            "day": 1
-                        },
+                        "publication_date": "2006-7-1",
                         "journal": "Blood",
                         "full_journal_title": "Blood",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 8360,
-                    "name": "EID8360",
-                    "description": "In an in vitro kinase experiment, kinases wtih the KIT D816V mutation demonstrated resistance to imatinib (IC50: >10,000nM vs. 1550nM) treatment compared to the KIT wild-type kinase. In the HMC-1 human cell line, KIT V560G+, D816V+ mutants treated with imatinib did not show reduced levels of phospho-KIT, growth inhibition, or Annexin V binding at any concentration of treatment. In an ex vivo experiment using primary bone marrow cells from four mastocytosis patients harboring the KIT D816V mutation, imatinib was not effective in reducing mast-cell percentage when compared to no treatment.",
+                    "id": 4163,
+                    "name": "EID4163",
+                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with  sensitivity to dasatinib treatment.",
                     "disease": {
                         "id": 4,
                         "name": "Chronic Myeloid Leukemia",
                         "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
-                            "id": 5,
-                            "name": "Imatinib",
-                            "ncit_id": "C62035",
+                            "id": 20,
+                            "name": "Dasatinib",
+                            "ncit_id": "C38713",
                             "aliases": [
-                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
+                                "BMS-354825",
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
                             ]
                         }
                     ],
-                    "rating": 4,
+                    "rating": null,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 2060,
-                        "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
-                        "citation": "Shah et al., 2006, Blood",
-                        "citation_id": "16434489",
-                        "source_type": "PubMed",
+                        "id": 1994,
+                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
+                        "citation": "Remsing Rix et al., 2009, Leukemia",
+                        "citation_id": 19039322,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 7,
-                            "day": 1
-                        },
-                        "journal": "Blood",
-                        "full_journal_title": "Blood",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2009-3",
+                        "journal": "Leukemia",
+                        "full_journal_title": "Leukemia",
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 8362,
-                    "name": "EID8362",
-                    "description": "In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with imatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding at increased concentrations of treatment.",
+                    "id": 8360,
+                    "name": "EID8360",
+                    "description": "In an in vitro kinase experiment, kinases wtih the KIT D816V mutation demonstrated resistance to imatinib (IC50: >10,000nM vs. 1550nM) treatment compared to the KIT wild-type kinase. In the HMC-1 human cell line, KIT V560G+, D816V+ mutants treated with imatinib did not show reduced levels of phospho-KIT, growth inhibition, or Annexin V binding at any concentration of treatment. In an ex vivo experiment using primary bone marrow cells from four mastocytosis patients harboring the KIT D816V mutation, imatinib was not effective in reducing mast-cell percentage when compared to no treatment.",
                     "disease": {
                         "id": 4,
                         "name": "Chronic Myeloid Leukemia",
                         "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
@@ -1373,10 +1467,10 @@
                     ],
                     "rating": 4,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -1384,36 +1478,29 @@
                         "id": 2060,
                         "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
                         "citation": "Shah et al., 2006, Blood",
-                        "citation_id": "16434489",
-                        "source_type": "PubMed",
+                        "citation_id": 16434489,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 7,
-                            "day": 1
-                        },
+                        "publication_date": "2006-7-1",
                         "journal": "Blood",
                         "full_journal_title": "Blood",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 4163,
-                    "name": "EID4163",
-                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with  sensitivity to dasatinib treatment.",
+                    "id": 8361,
+                    "name": "EID8361",
+                    "description": "In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with dasatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding at increased concentrations of treatment.",
                     "disease": {
                         "id": 4,
                         "name": "Chronic Myeloid Leukemia",
                         "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
@@ -1421,94 +1508,82 @@
                             "name": "Dasatinib",
                             "ncit_id": "C38713",
                             "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
+                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate",
                                 "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
+                                "Dasatinib Hydrate",
+                                "Dasatinib Monohydrate",
+                                "Sprycel"
                             ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 4,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 1994,
-                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
-                        "citation": "Remsing Rix et al., 2009, Leukemia",
-                        "citation_id": "19039322",
-                        "source_type": "PubMed",
+                        "id": 2060,
+                        "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
+                        "citation": "Shah et al., 2006, Blood",
+                        "citation_id": 16434489,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 3
-                        },
-                        "journal": "Leukemia",
-                        "full_journal_title": "Leukemia",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2006-7-1",
+                        "journal": "Blood",
+                        "full_journal_title": "Blood",
                         "clinical_trials": []
                     },
                     "variant_id": 65,
                     "phenotypes": []
                 },
                 {
-                    "id": 4160,
-                    "name": "EID4160",
-                    "description": "In an in vitro study, a 32D cell line expressing KIT D816V mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 294.7nM) compared to 32D cells expressing wild-type KIT (overexpression, IC50: 16.3nM). Sensitivity was determined by assessing cell proliferation.",
+                    "id": 8362,
+                    "name": "EID8362",
+                    "description": "In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with imatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding at increased concentrations of treatment.",
                     "disease": {
-                        "id": 2,
-                        "name": "Gastrointestinal Stromal Tumor",
-                        "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "id": 4,
+                        "name": "Chronic Myeloid Leukemia",
+                        "display_name": "Chronic Myeloid Leukemia",
+                        "doid": 8552,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:8552"
                     },
                     "drugs": [
                         {
-                            "id": 157,
-                            "name": "Sunitinib",
-                            "ncit_id": "C71622",
+                            "id": 5,
+                            "name": "Imatinib",
+                            "ncit_id": "C62035",
                             "aliases": [
-                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
+                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                             ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 4,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 2049,
-                        "name": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
-                        "citation": "Zhao et al., 2014, Cancer Sci.",
-                        "citation_id": "24205792",
-                        "source_type": "PubMed",
+                        "id": 2060,
+                        "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
+                        "citation": "Shah et al., 2006, Blood",
+                        "citation_id": 16434489,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792",
-                        "open_access": true,
-                        "pmc_id": "PMC4317885",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 1
-                        },
-                        "journal": "Cancer Sci.",
-                        "full_journal_title": "Cancer science",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
+                        "pmc_id": null,
+                        "publication_date": "2006-7-1",
+                        "journal": "Blood",
+                        "full_journal_title": "Blood",
                         "clinical_trials": []
                     },
                     "variant_id": 65,
@@ -1522,8 +1597,8 @@
                         "id": 216,
                         "name": "Cancer",
                         "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
@@ -1537,10 +1612,10 @@
                     ],
                     "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -1548,78 +1623,14 @@
                         "id": 412,
                         "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
                         "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
-                        "citation_id": "14645423",
-                        "source_type": "PubMed",
+                        "citation_id": 14645423,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2003,
-                            "month": 12,
-                            "day": 1
-                        },
+                        "publication_date": "2003-12-1",
                         "journal": "J. Clin. Oncol.",
                         "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 65,
-                    "phenotypes": []
-                },
-                {
-                    "id": 4159,
-                    "name": "EID4159",
-                    "description": "In a systemic mastocytosis (SM) and acute myelogeneous leukemia (AML) patient harboring KIT D816V mutation, KIT D816V was associated with improved response to dasatinib therapy. The patient initially achieved a hematologic complete remission (HCR) with persistent mastocytes in the bone marrow with cytarbine treatment. Subsequently, the patient received dasatinib in combination with chemotherapy, followed by dasatinib monotherapy, experiencing HCR and eventual extinguishment of the KIT D816V mutation.",
-                    "disease": {
-                        "id": 3,
-                        "name": "Acute Myeloid Leukemia",
-                        "display_name": "Acute Myeloid Leukemia",
-                        "doid": "9119",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9119"
-                    },
-                    "drugs": [
-                        {
-                            "id": 20,
-                            "name": "Dasatinib",
-                            "ncit_id": "C38713",
-                            "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
-                                "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
-                            ]
-                        }
-                    ],
-                    "rating": null,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "submitted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 2059,
-                        "name": "Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.",
-                        "citation": "Ustun et al., 2009, Leuk. Res.",
-                        "citation_id": "18986703",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18986703",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 5
-                        },
-                        "journal": "Leuk. Res.",
-                        "full_journal_title": "Leukemia research",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
@@ -1633,8 +1644,8 @@
                         "id": 2,
                         "name": "Gastrointestinal Stromal Tumor",
                         "display_name": "Gastrointestinal Stromal Tumor",
-                        "doid": "9253",
-                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
+                        "doid": 9253,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:9253"
                     },
                     "drugs": [
                         {
@@ -1648,10 +1659,10 @@
                     ],
                     "rating": 2,
                     "evidence_level": "E",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -1659,137 +1670,14 @@
                         "id": 2681,
                         "name": "KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.",
                         "citation": "Gajiwala et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",
-                        "citation_id": "19164557",
-                        "source_type": "PubMed",
+                        "citation_id": 19164557,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19164557",
-                        "open_access": true,
                         "pmc_id": "PMC2635778",
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 2,
-                            "day": 3
-                        },
+                        "publication_date": "2009-2-3",
                         "journal": "Proc. Natl. Acad. Sci. U.S.A.",
                         "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 65,
-                    "phenotypes": []
-                },
-                {
-                    "id": 4162,
-                    "name": "EID4162",
-                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with increased sensitivity to dasatinib treatment (IC50: 37nM vs. 79nM), as compared to wild-type KIT kinase. Sensitivity was assessed by analyzing kinase activity.",
-                    "disease": {
-                        "id": 4,
-                        "name": "Chronic Myeloid Leukemia",
-                        "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
-                    },
-                    "drugs": [
-                        {
-                            "id": 20,
-                            "name": "Dasatinib",
-                            "ncit_id": "C38713",
-                            "aliases": [
-                                "Sprycel",
-                                "Dasatinib Monohydrate",
-                                "Dasatinib Hydrate",
-                                "BMS-354825",
-                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
-                            ]
-                        }
-                    ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "submitted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 2060,
-                        "name": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
-                        "citation": "Shah et al., 2006, Blood",
-                        "citation_id": "16434489",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16434489",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 7,
-                            "day": 1
-                        },
-                        "journal": "Blood",
-                        "full_journal_title": "Blood",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 65,
-                    "phenotypes": []
-                },
-                {
-                    "id": 4161,
-                    "name": "EID4161",
-                    "description": "In an in vitro study, the recombinant KIT D816V mutation kinase was associated with insensitivity to bosutinib treatment (IC50: 2772nM), comparable to wild-type KIT kinase (IC50: 6313nM). Resistance was assessed by analyzing kinase inhibition.",
-                    "disease": {
-                        "id": 4,
-                        "name": "Chronic Myeloid Leukemia",
-                        "display_name": "Chronic Myeloid Leukemia",
-                        "doid": "8552",
-                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
-                    },
-                    "drugs": [
-                        {
-                            "id": 520,
-                            "name": "Bosutinib",
-                            "ncit_id": "C60809",
-                            "aliases": [
-                                "SKI-606",
-                                "SKI 606",
-                                "Bosulif",
-                                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
-                                "4-Anilino-3-quinolinecarbonitrile",
-                                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile"
-                            ]
-                        }
-                    ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "submitted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 1994,
-                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
-                        "citation": "Remsing Rix et al., 2009, Leukemia",
-                        "citation_id": "19039322",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 3
-                        },
-                        "journal": "Leukemia",
-                        "full_journal_title": "Leukemia",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 65,
@@ -1803,30 +1691,29 @@
                     "description": "",
                     "variants": [
                         {
-                            "id": 65,
+                            "id": 1264,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "D816V",
-                            "description": "KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.",
+                            "name": "C809G",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 67,
+                            "civic_actionability_score": 7.5,
                             "coordinates": {
-                                "chromosome": "4",
-                                "start": 55599321,
-                                "stop": 55599321,
-                                "reference_bases": "A",
-                                "variant_bases": "T",
+                                "chromosome": "4",
+                                "start": 55599299,
+                                "stop": 55599299,
+                                "reference_bases": "T",
+                                "variant_bases": "G",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
                                 "start2": null,
@@ -1841,14 +1728,13 @@
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
                             "name": "D816H",
-                            "description": "",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1871,29 +1757,28 @@
                             }
                         },
                         {
-                            "id": 986,
+                            "id": 65,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "D820Y",
-                            "description": "",
+                            "name": "D816V",
+                            "description": "KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.",
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 14.5,
+                            "civic_actionability_score": 67,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599332,
-                                "stop": 55599332,
-                                "reference_bases": "G",
+                                "start": 55599321,
+                                "stop": 55599321,
+                                "reference_bases": "A",
                                 "variant_bases": "T",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
@@ -1905,52 +1790,50 @@
                             }
                         },
                         {
-                            "id": 987,
+                            "id": 1265,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "N822H",
-                            "description": "",
+                            "name": "D820A",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 0,
+                            "civic_actionability_score": 7.5,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599338,
-                                "stop": 55599338,
+                                "start": 55599333,
+                                "stop": 55599333,
                                 "reference_bases": "A",
                                 "variant_bases": "C",
-                                "representative_transcript": null,
+                                "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
                                 "start2": null,
                                 "stop2": null,
                                 "representative_transcript2": null,
-                                "ensembl_version": null,
+                                "ensembl_version": 75,
                                 "reference_build": "GRCh37"
                             }
                         },
                         {
-                            "id": 989,
+                            "id": 1266,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "Y823D",
-                            "description": "",
+                            "name": "D820G",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -1959,9 +1842,9 @@
                             "civic_actionability_score": 7.5,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599341,
-                                "stop": 55599341,
-                                "reference_bases": "T",
+                                "start": 55599333,
+                                "stop": 55599333,
+                                "reference_bases": "A",
                                 "variant_bases": "G",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
@@ -1973,30 +1856,29 @@
                             }
                         },
                         {
-                            "id": 1263,
+                            "id": 986,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "N822K",
-                            "description": "",
+                            "name": "D820Y",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 24.5,
+                            "civic_actionability_score": 14.5,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599340,
-                                "stop": 55599340,
-                                "reference_bases": "T",
-                                "variant_bases": "A",
+                                "start": 55599332,
+                                "stop": 55599332,
+                                "reference_bases": "G",
+                                "variant_bases": "T",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
                                 "start2": null,
@@ -2007,64 +1889,62 @@
                             }
                         },
                         {
-                            "id": 1264,
+                            "id": 987,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "C809G",
-                            "description": "",
+                            "name": "N822H",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 7.5,
+                            "civic_actionability_score": 0,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599299,
-                                "stop": 55599299,
-                                "reference_bases": "T",
-                                "variant_bases": "G",
-                                "representative_transcript": "ENST00000288135.5",
+                                "start": 55599338,
+                                "stop": 55599338,
+                                "reference_bases": "A",
+                                "variant_bases": "C",
+                                "representative_transcript": null,
                                 "chromosome2": null,
                                 "start2": null,
                                 "stop2": null,
                                 "representative_transcript2": null,
-                                "ensembl_version": 75,
+                                "ensembl_version": null,
                                 "reference_build": "GRCh37"
                             }
                         },
                         {
-                            "id": 1265,
+                            "id": 1263,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "D820A",
-                            "description": "",
+                            "name": "N822K",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                 }
                             ],
-                            "civic_actionability_score": 7.5,
+                            "civic_actionability_score": 24.5,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599333,
-                                "stop": 55599333,
-                                "reference_bases": "A",
-                                "variant_bases": "C",
+                                "start": 55599340,
+                                "stop": 55599340,
+                                "reference_bases": "T",
+                                "variant_bases": "A",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
                                 "start2": null,
@@ -2075,18 +1955,17 @@
                             }
                         },
                         {
-                            "id": 1266,
+                            "id": 989,
                             "entrez_name": "KIT",
                             "entrez_id": 3815,
-                            "name": "D820G",
-                            "description": "",
+                            "name": "Y823D",
+                            "description": null,
                             "gene_id": 29,
                             "type": "variant",
                             "variant_types": [
                                 {
                                     "id": 47,
-                                    "name": "missense_variant",
-                                    "display_name": "Missense Variant",
+                                    "name": "Missense Variant",
                                     "so_id": "SO:0001583",
                                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2095,9 +1974,9 @@
                             "civic_actionability_score": 7.5,
                             "coordinates": {
                                 "chromosome": "4",
-                                "start": 55599333,
-                                "stop": 55599333,
-                                "reference_bases": "A",
+                                "start": 55599341,
+                                "stop": 55599341,
+                                "reference_bases": "T",
                                 "variant_bases": "G",
                                 "representative_transcript": "ENST00000288135.5",
                                 "chromosome2": null,
@@ -2114,8 +1993,8 @@
             ],
             "assertions": [],
             "variant_aliases": [
-                "RS121913507",
-                "ASP816VAL"
+                "ASP816VAL",
+                "RS121913507"
             ],
             "hgvs_expressions": [
                 "NM_000222.2:c.2447A>T",
@@ -2133,14 +2012,13 @@
             "entrez_name": "MTHFR",
             "entrez_id": 4524,
             "name": "A222V",
-            "description": "",
+            "description": null,
             "gene_id": 3672,
             "type": "variant",
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
@@ -2163,75 +2041,38 @@
             },
             "evidence_items": [
                 {
-                    "id": 669,
-                    "name": "EID669",
-                    "description": "The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.",
+                    "id": 1756,
+                    "name": "EID1756",
+                    "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai. Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",
                     "disease": {
-                        "id": 21,
-                        "name": "Stomach Cancer",
-                        "display_name": "Stomach Cancer",
-                        "doid": "10534",
-                        "url": "http://www.disease-ontology.org/?id=DOID:10534"
+                        "id": 556,
+                        "name": "Pancreatic Cancer",
+                        "display_name": "Pancreatic Cancer",
+                        "doid": 1793,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:1793"
                     },
-                    "drugs": [
-                        {
-                            "id": 420,
-                            "name": "Fluorouracil",
-                            "ncit_id": "C505",
-                            "aliases": [
-                                "Ro-2-9757",
-                                "Ro 2-9757",
-                                "Ribofluor",
-                                "Fluroblastin",
-                                "Fluril",
-                                "Fluracil",
-                                "Fluracedyl",
-                                "Flurablastin",
-                                "Fluouracil",
-                                "Fluoro Uracil",
-                                "Carac",
-                                "Adrucil",
-                                "AccuSite",
-                                "5FU",
-                                "5-FU",
-                                "5-Fluracil",
-                                "5-Fluorouracil",
-                                "5-Fluoro-2,4(1H,3H)-pyrimidinedione",
-                                "5-Fluoro-2,4(1H, 3H)-pyrimidinedione",
-                                "5 FU",
-                                "5 Fluorouracilum",
-                                "5 Fluorouracil",
-                                "2,4-Dioxo-5-fluoropyrimidine"
-                            ]
-                        }
-                    ],
-                    "rating": 3,
+                    "drugs": [],
+                    "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Rare Germline",
+                    "evidence_type": "PROGNOSTIC",
+                    "clinical_significance": "BETTER_OUTCOME",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "COMMON_GERMLINE",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 424,
-                        "name": "The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.",
-                        "citation": "Huang et al., 2009, Cancer Chemother. Pharmacol.",
-                        "citation_id": "18704422",
-                        "source_type": "PubMed",
+                        "id": 1218,
+                        "name": "MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.",
+                        "citation": "Wu et al., 2016, Sci Rep",
+                        "citation_id": 27819322,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18704422",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 4
-                        },
-                        "journal": "Cancer Chemother. Pharmacol.",
-                        "full_journal_title": "Cancer chemotherapy and pharmacology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27819322",
+                        "pmc_id": "PMC5098242",
+                        "publication_date": "2016-11-7",
+                        "journal": "Sci Rep",
+                        "full_journal_title": "Scientific reports",
                         "clinical_trials": []
                     },
                     "variant_id": 258,
@@ -2245,8 +2086,8 @@
                         "id": 579,
                         "name": "Rectum Cancer",
                         "display_name": "Rectum Cancer",
-                        "doid": "1993",
-                        "url": "http://www.disease-ontology.org/?id=DOID:1993"
+                        "doid": 1993,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:1993"
                     },
                     "drugs": [
                         {
@@ -2254,38 +2095,38 @@
                             "name": "Fluorouracil",
                             "ncit_id": "C505",
                             "aliases": [
-                                "Ro-2-9757",
-                                "Ro 2-9757",
-                                "Ribofluor",
-                                "Fluroblastin",
-                                "Fluril",
-                                "Fluracil",
-                                "Fluracedyl",
-                                "Flurablastin",
-                                "Fluouracil",
-                                "Fluoro Uracil",
-                                "Carac",
-                                "Adrucil",
-                                "AccuSite",
-                                "5FU",
-                                "5-FU",
-                                "5-Fluracil",
-                                "5-Fluorouracil",
-                                "5-Fluoro-2,4(1H,3H)-pyrimidinedione",
-                                "5-Fluoro-2,4(1H, 3H)-pyrimidinedione",
+                                "2,4-Dioxo-5-fluoropyrimidine",
                                 "5 FU",
-                                "5 Fluorouracilum",
                                 "5 Fluorouracil",
-                                "2,4-Dioxo-5-fluoropyrimidine"
+                                "5 Fluorouracilum",
+                                "5-FU",
+                                "5-Fluoro-2,4(1H, 3H)-pyrimidinedione",
+                                "5-Fluoro-2,4(1H,3H)-pyrimidinedione",
+                                "5-Fluorouracil",
+                                "5-Fluracil",
+                                "5FU",
+                                "AccuSite",
+                                "Adrucil",
+                                "Carac",
+                                "Fluoro Uracil",
+                                "Fluouracil",
+                                "Flurablastin",
+                                "Fluracedyl",
+                                "Fluracil",
+                                "Fluril",
+                                "Fluroblastin",
+                                "Ribofluor",
+                                "Ro 2-9757",
+                                "Ro-2-9757"
                             ]
                         }
                     ],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Common Germline",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "COMMON_GERMLINE",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2293,64 +2134,83 @@
                         "id": 1221,
                         "name": "A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.",
                         "citation": "Nikas et al., 2015, Am J Cancer Res",
-                        "citation_id": "26693073",
-                        "source_type": "PubMed",
+                        "citation_id": 26693073,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26693073",
-                        "open_access": true,
                         "pmc_id": "PMC4656744",
-                        "publication_date": {
-                            "year": 2015
-                        },
+                        "publication_date": "2015",
                         "journal": "Am J Cancer Res",
                         "full_journal_title": "American journal of cancer research",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 258,
                     "phenotypes": []
                 },
                 {
-                    "id": 1756,
-                    "name": "EID1756",
-                    "description": "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",
+                    "id": 669,
+                    "name": "EID669",
+                    "description": "The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.",
                     "disease": {
-                        "id": 556,
-                        "name": "Pancreatic Cancer",
-                        "display_name": "Pancreatic Cancer",
-                        "doid": "1793",
-                        "url": "http://www.disease-ontology.org/?id=DOID:1793"
+                        "id": 21,
+                        "name": "Stomach Cancer",
+                        "display_name": "Stomach Cancer",
+                        "doid": 10534,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:10534"
                     },
-                    "drugs": [],
-                    "rating": 4,
+                    "drugs": [
+                        {
+                            "id": 420,
+                            "name": "Fluorouracil",
+                            "ncit_id": "C505",
+                            "aliases": [
+                                "2,4-Dioxo-5-fluoropyrimidine",
+                                "5 FU",
+                                "5 Fluorouracil",
+                                "5 Fluorouracilum",
+                                "5-FU",
+                                "5-Fluoro-2,4(1H, 3H)-pyrimidinedione",
+                                "5-Fluoro-2,4(1H,3H)-pyrimidinedione",
+                                "5-Fluorouracil",
+                                "5-Fluracil",
+                                "5FU",
+                                "AccuSite",
+                                "Adrucil",
+                                "Carac",
+                                "Fluoro Uracil",
+                                "Fluouracil",
+                                "Flurablastin",
+                                "Fluracedyl",
+                                "Fluracil",
+                                "Fluril",
+                                "Fluroblastin",
+                                "Ribofluor",
+                                "Ro 2-9757",
+                                "Ro-2-9757"
+                            ]
+                        }
+                    ],
+                    "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Prognostic",
-                    "clinical_significance": "Better Outcome",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Rare Germline",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "COMMON_GERMLINE",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1218,
-                        "name": "MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.",
-                        "citation": "Wu et al., 2016, Sci Rep",
-                        "citation_id": "27819322",
-                        "source_type": "PubMed",
+                        "id": 424,
+                        "name": "The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.",
+                        "citation": "Huang et al., 2009, Cancer Chemother. Pharmacol.",
+                        "citation_id": 18704422,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27819322",
-                        "open_access": true,
-                        "pmc_id": "PMC5098242",
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 11,
-                            "day": 7
-                        },
-                        "journal": "Sci Rep",
-                        "full_journal_title": "Scientific reports",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18704422",
+                        "pmc_id": null,
+                        "publication_date": "2009-4",
+                        "journal": "Cancer Chemother. Pharmacol.",
+                        "full_journal_title": "Cancer chemotherapy and pharmacology",
                         "clinical_trials": []
                     },
                     "variant_id": 258,
@@ -2360,9 +2220,9 @@
             "variant_groups": [],
             "assertions": [],
             "variant_aliases": [
+                "RS1801133",
                 "C677T",
-                "ALA222VAL",
-                "RS1801133"
+                "ALA222VAL"
             ],
             "hgvs_expressions": [
                 "NM_005957.4:c.665C>T",
diff --git a/tests/data/transform/therapeutic/civic_harvester.json b/tests/data/transform/therapeutic/civic_harvester.json
index c049e902..47828a43 100644
--- a/tests/data/transform/therapeutic/civic_harvester.json
+++ b/tests/data/transform/therapeutic/civic_harvester.json
@@ -8,8 +8,8 @@
                 "id": 8,
                 "name": "Lung Non-small Cell Carcinoma",
                 "display_name": "Lung Non-small Cell Carcinoma",
-                "doid": "3908",
-                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                "doid": 3908,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
             },
             "drugs": [
                 {
@@ -17,18 +17,18 @@
                     "name": "Afatinib",
                     "ncit_id": "C66940",
                     "aliases": [
-                        "BIBW2992",
+                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                         "BIBW 2992",
-                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                        "BIBW2992"
                     ]
                 }
             ],
             "rating": 5,
             "evidence_level": "A",
-            "evidence_type": "Predictive",
-            "clinical_significance": "Sensitivity/Response",
-            "evidence_direction": "Supports",
-            "variant_origin": "Somatic",
+            "evidence_type": "PREDICTIVE",
+            "clinical_significance": "SENSITIVITYRESPONSE",
+            "evidence_direction": "SUPPORTS",
+            "variant_origin": "SOMATIC",
             "drug_interaction_type": null,
             "status": "accepted",
             "type": "evidence",
@@ -36,20 +36,14 @@
                 "id": 1725,
                 "name": "Afatinib: first global approval.",
                 "citation": "Dungo et al., 2013, Drugs",
-                "citation_id": "23982599",
-                "source_type": "PubMed",
+                "citation_id": 23982599,
+                "source_type": "PUBMED",
                 "asco_abstract_id": null,
                 "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
-                "open_access": null,
                 "pmc_id": null,
-                "publication_date": {
-                    "year": 2013,
-                    "month": 9
-                },
+                "publication_date": "2013-9",
                 "journal": "Drugs",
                 "full_journal_title": "Drugs",
-                "status": "fully curated",
-                "is_review": false,
                 "clinical_trials": []
             },
             "variant_id": 33,
@@ -61,20 +55,14 @@
                     "name": "AID6",
                     "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                     "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                    "gene": {
-                        "name": "EGFR",
-                        "id": 19
-                    },
-                    "variant": {
-                        "name": "L858R",
-                        "id": 33
-                    },
+                    "gene_id": 19,
+                    "variant_id": 33,
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -82,15 +70,15 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "evidence_type": "Predictive",
-                    "evidence_direction": "Supports",
-                    "clinical_significance": "Sensitivity/Response",
+                    "evidence_type": "PREDICTIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
                     "fda_regulatory_approval": true,
                     "status": "accepted"
                 }
@@ -105,20 +93,14 @@
             "name": "AID6",
             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-            "gene": {
-                "name": "EGFR",
-                "id": 19
-            },
-            "variant": {
-                "name": "L858R",
-                "id": 33
-            },
+            "gene_id": 19,
+            "variant_id": 33,
             "disease": {
                 "id": 8,
                 "name": "Lung Non-small Cell Carcinoma",
                 "display_name": "Lung Non-small Cell Carcinoma",
-                "doid": "3908",
-                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                "doid": 3908,
+                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
             },
             "drugs": [
                 {
@@ -126,20 +108,22 @@
                     "name": "Afatinib",
                     "ncit_id": "C66940",
                     "aliases": [
-                        "BIBW2992",
+                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                         "BIBW 2992",
-                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                        "BIBW2992"
                     ]
                 }
             ],
-            "evidence_type": "Predictive",
-            "evidence_direction": "Supports",
-            "clinical_significance": "Sensitivity/Response",
+            "evidence_type": "PREDICTIVE",
+            "evidence_direction": "SUPPORTS",
+            "clinical_significance": "SENSITIVITYRESPONSE",
             "fda_regulatory_approval": true,
             "status": "accepted",
-            "nccn_guideline": "Non-Small Cell Lung Cancer",
+            "nccn_guideline": {
+                "name": "Non-Small Cell Lung Cancer"
+            },
             "nccn_guideline_version": "3.2018",
-            "amp_level": "Tier I - Level A",
+            "amp_level": "TIER_I_LEVEL_A",
             "evidence_items": [
                 {
                     "id": 2997,
@@ -149,8 +133,8 @@
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -158,18 +142,18 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
                     "rating": 5,
                     "evidence_level": "A",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -177,20 +161,14 @@
                         "id": 1725,
                         "name": "Afatinib: first global approval.",
                         "citation": "Dungo et al., 2013, Drugs",
-                        "citation_id": "23982599",
-                        "source_type": "PubMed",
+                        "citation_id": 23982599,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2013,
-                            "month": 9
-                        },
+                        "publication_date": "2013-9",
                         "journal": "Drugs",
                         "full_journal_title": "Drugs",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 33,
@@ -202,20 +180,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -223,15 +195,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -239,15 +211,15 @@
                     "gene_id": 19
                 },
                 {
-                    "id": 2629,
-                    "name": "EID2629",
-                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
+                    "id": 879,
+                    "name": "EID879",
+                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -255,41 +227,36 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1525,
-                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
-                        "citation": "Li et al., 2008, Oncogene",
-                        "citation_id": "18408761",
-                        "source_type": "PubMed",
+                        "id": 592,
+                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
+                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
+                        "citation_id": 23816960,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
-                        "open_access": true,
-                        "pmc_id": "PMC2748240",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 8,
-                            "day": 7
-                        },
-                        "journal": "Oncogene",
-                        "full_journal_title": "Oncogene",
-                        "status": "partially curated",
-                        "is_review": false,
-                        "clinical_trials": []
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
+                        "pmc_id": null,
+                        "publication_date": "2013-9-20",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
+                        "clinical_trials": [
+                            {}
+                        ]
                     },
                     "variant_id": 33,
                     "phenotypes": [],
@@ -300,20 +267,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -321,15 +282,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -344,8 +305,8 @@
                         "id": 30,
                         "name": "Lung Adenocarcinoma",
                         "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -353,18 +314,18 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -372,27 +333,16 @@
                         "id": 679,
                         "name": "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.",
                         "citation": "Wu et al., 2014, Lancet Oncol.",
-                        "citation_id": "24439929",
-                        "source_type": "PubMed",
+                        "citation_id": 24439929,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24439929",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 2
-                        },
+                        "publication_date": "2014-2",
                         "journal": "Lancet Oncol.",
                         "full_journal_title": "The Lancet. Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": [
-                            {
-                                "nct_id": "NCT01121393",
-                                "name": "BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)",
-                                "description": "To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT01121393"
-                            }
+                            {}
                         ]
                     },
                     "variant_id": 33,
@@ -404,20 +354,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -425,15 +369,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -441,15 +385,15 @@
                     "gene_id": 19
                 },
                 {
-                    "id": 968,
-                    "name": "EID968",
-                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
+                    "id": 883,
+                    "name": "EID883",
+                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -457,41 +401,36 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 669,
-                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
-                        "citation": "Hirano et al., 2015, Oncotarget",
-                        "citation_id": "26515464",
-                        "source_type": "PubMed",
+                        "id": 594,
+                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
+                        "citation": "Yang et al., 2012, Lancet Oncol.",
+                        "citation_id": 22452895,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
-                        "open_access": true,
-                        "pmc_id": "PMC4770737",
-                        "publication_date": {
-                            "year": 2015,
-                            "month": 11,
-                            "day": 17
-                        },
-                        "journal": "Oncotarget",
-                        "full_journal_title": "Oncotarget",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
+                        "pmc_id": null,
+                        "publication_date": "2012-5",
+                        "journal": "Lancet Oncol.",
+                        "full_journal_title": "The Lancet. Oncology",
+                        "clinical_trials": [
+                            {}
+                        ]
                     },
                     "variant_id": 33,
                     "phenotypes": [],
@@ -502,20 +441,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -523,15 +456,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -539,15 +472,15 @@
                     "gene_id": 19
                 },
                 {
-                    "id": 883,
-                    "name": "EID883",
-                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
+                    "id": 968,
+                    "name": "EID968",
+                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -555,47 +488,34 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 3,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 594,
-                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
-                        "citation": "Yang et al., 2012, Lancet Oncol.",
-                        "citation_id": "22452895",
-                        "source_type": "PubMed",
+                        "id": 669,
+                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
+                        "citation": "Hirano et al., 2015, Oncotarget",
+                        "citation_id": 26515464,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 5
-                        },
-                        "journal": "Lancet Oncol.",
-                        "full_journal_title": "The Lancet. Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00525148",
-                                "name": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",
-                                "description": "The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST criteria in patients with advanced NSCLC Stage IIIB or IV whose tumors harbor activating mutations within exon 18 to exon 21 of the EGFR receptor. Patients progressing or relapsing after one prior cytotoxic chemotherapy regimen as well as chemotherapy na\u00efve patients (only in stage 2) will be allowed to enter into the trial.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00525148"
-                            }
-                        ]
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
+                        "pmc_id": "PMC4770737",
+                        "publication_date": "2015-11-17",
+                        "journal": "Oncotarget",
+                        "full_journal_title": "Oncotarget",
+                        "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": [],
@@ -606,20 +526,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -627,15 +541,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -643,15 +557,15 @@
                     "gene_id": 19
                 },
                 {
-                    "id": 879,
-                    "name": "EID879",
-                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
+                    "id": 2629,
+                    "name": "EID2629",
+                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -659,48 +573,34 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 592,
-                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
-                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
-                        "citation_id": "23816960",
-                        "source_type": "PubMed",
+                        "id": 1525,
+                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
+                        "citation": "Li et al., 2008, Oncogene",
+                        "citation_id": 18408761,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2013,
-                            "month": 9,
-                            "day": 20
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00949650",
-                                "name": "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation",
-                                "description": "This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00949650"
-                            }
-                        ]
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
+                        "pmc_id": "PMC2748240",
+                        "publication_date": "2008-8-7",
+                        "journal": "Oncogene",
+                        "full_journal_title": "Oncogene",
+                        "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": [],
@@ -711,20 +611,14 @@
                             "name": "AID6",
                             "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                             "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                            "gene": {
-                                "name": "EGFR",
-                                "id": 19
-                            },
-                            "variant": {
-                                "name": "L858R",
-                                "id": 33
-                            },
+                            "gene_id": 19,
+                            "variant_id": 33,
                             "disease": {
                                 "id": 8,
                                 "name": "Lung Non-small Cell Carcinoma",
                                 "display_name": "Lung Non-small Cell Carcinoma",
-                                "doid": "3908",
-                                "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                                "doid": 3908,
+                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                             },
                             "drugs": [
                                 {
@@ -732,15 +626,15 @@
                                     "name": "Afatinib",
                                     "ncit_id": "C66940",
                                     "aliases": [
-                                        "BIBW2992",
+                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                         "BIBW 2992",
-                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                        "BIBW2992"
                                     ]
                                 }
                             ],
-                            "evidence_type": "Predictive",
-                            "evidence_direction": "Supports",
-                            "clinical_significance": "Sensitivity/Response",
+                            "evidence_type": "PREDICTIVE",
+                            "evidence_direction": "SUPPORTS",
+                            "clinical_significance": "SENSITIVITYRESPONSE",
                             "fda_regulatory_approval": true,
                             "status": "accepted"
                         }
@@ -751,9 +645,8 @@
             "acmg_codes": [],
             "drug_interaction_type": null,
             "fda_companion_test": true,
-            "allele_registry_id": "CA126713",
             "phenotypes": [],
-            "variant_origin": "Somatic"
+            "variant_origin": "SOMATIC"
         }
     ],
     "genes": [
@@ -761,20 +654,20 @@
             "id": 19,
             "name": "EGFR",
             "entrez_id": 1956,
-            "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. \nOverproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).",
+            "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).",
             "variants": [
                 {
-                    "name": "N771DELinsVH",
-                    "id": 1662,
+                    "name": "3' UTR MUTATION",
+                    "id": 253,
                     "evidence_items": {
                         "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
+                        "rejected_count": 1,
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "Y764_V765insHH",
-                    "id": 1665,
+                    "name": "A289V",
+                    "id": 996,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -782,17 +675,17 @@
                     }
                 },
                 {
-                    "name": "E746_S752>D",
-                    "id": 1009,
+                    "name": "A702S",
+                    "id": 2255,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "P546S",
-                    "id": 1582,
+                    "name": "A750T",
+                    "id": 2332,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -800,62 +693,62 @@
                     }
                 },
                 {
-                    "name": "V834I",
-                    "id": 1897,
+                    "name": "A763_Y764insFQEA",
+                    "id": 1515,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "EXON 4 DELETION",
-                    "id": 252,
+                    "name": "A767_V769dupASV",
+                    "id": 1579,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "T725M",
-                    "id": 861,
+                    "name": "A859T",
+                    "id": 1474,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "R832L",
-                    "id": 2741,
+                    "name": "A864T",
+                    "id": 1187,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "T263P",
-                    "id": 995,
+                    "name": "AUTOCRINE ACTIVATION",
+                    "id": 309,
                     "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
+                        "accepted_count": 0,
+                        "rejected_count": 2,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "D770_N771insNPG",
-                    "id": 1569,
+                    "name": "Amplification",
+                    "id": 190,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 11,
                         "rejected_count": 0,
                         "submitted_count": 4
                     }
                 },
                 {
-                    "name": "S752_I759delSPKANKEI",
-                    "id": 891,
+                    "name": "C797G",
+                    "id": 3003,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -863,26 +756,26 @@
                     }
                 },
                 {
-                    "name": "D761Y",
-                    "id": 712,
+                    "name": "C797S",
+                    "id": 415,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "K467N",
-                    "id": 2605,
+                    "name": "C797Y",
+                    "id": 1574,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "K757R",
-                    "id": 723,
+                    "name": "Copy Number Variation",
+                    "id": 191,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -890,17 +783,17 @@
                     }
                 },
                 {
-                    "name": "G719",
-                    "id": 718,
+                    "name": "D761N",
+                    "id": 1013,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "Y801H",
-                    "id": 1575,
+                    "name": "D761Y",
+                    "id": 712,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -908,35 +801,17 @@
                     }
                 },
                 {
-                    "name": "R831H",
-                    "id": 1017,
+                    "name": "D770_N771insG",
+                    "id": 1512,
                     "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 3
-                    }
-                },
-                {
-                    "name": "R776C",
-                    "id": 1181,
-                    "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 1
-                    }
-                },
-                {
-                    "name": "V441G",
-                    "id": 2611,
-                    "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "L838V",
-                    "id": 1018,
+                    "name": "D770_N771insGL",
+                    "id": 1514,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -944,53 +819,53 @@
                     }
                 },
                 {
-                    "name": "WILDTYPE",
-                    "id": 2174,
+                    "name": "D770_N771insGT",
+                    "id": 1566,
                     "evidence_items": {
                         "accepted_count": 1,
-                        "rejected_count": 1,
+                        "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "VIII",
-                    "id": 312,
+                    "name": "D770_N771insNPG",
+                    "id": 1569,
                     "evidence_items": {
-                        "accepted_count": 7,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "E746V",
-                    "id": 1005,
+                    "name": "D770_N771insSVD",
+                    "id": 1445,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 6
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "Y1092 PHOSPHORYLATION",
-                    "id": 390,
+                    "name": "D770delinsGY",
+                    "id": 2214,
                     "evidence_items": {
                         "accepted_count": 1,
-                        "rejected_count": 0,
+                        "rejected_count": 1,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "S768_D770dup",
-                    "id": 1511,
+                    "name": "E114K",
+                    "id": 3464,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "E746_S752>A",
-                    "id": 1433,
+                    "name": "E709A and G719C",
+                    "id": 2258,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -998,26 +873,26 @@
                     }
                 },
                 {
-                    "name": "L792H",
-                    "id": 3004,
+                    "name": "E709K",
+                    "id": 1412,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "E746_T751delinsA",
-                    "id": 1004,
+                    "name": "E709K and G719A",
+                    "id": 2256,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "E746_A750>IP",
-                    "id": 1635,
+                    "name": "E709Q",
+                    "id": 1413,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1025,26 +900,26 @@
                     }
                 },
                 {
-                    "name": "G465E",
-                    "id": 2603,
+                    "name": "E709_T710>D",
+                    "id": 1577,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "G719S",
-                    "id": 134,
+                    "name": "E734Q",
+                    "id": 1572,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "L747P",
-                    "id": 1891,
+                    "name": "E746G",
+                    "id": 724,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1052,26 +927,26 @@
                     }
                 },
                 {
-                    "name": "S720",
-                    "id": 720,
+                    "name": "E746K",
+                    "id": 1431,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "D770_N771insGT",
-                    "id": 1566,
+                    "name": "E746V",
+                    "id": 1005,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "G465V",
-                    "id": 2604,
+                    "name": "E746_A750>IP",
+                    "id": 1635,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1079,17 +954,17 @@
                     }
                 },
                 {
-                    "name": "A859T",
-                    "id": 1474,
+                    "name": "E746_A750del",
+                    "id": 1002,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 3,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 19
                     }
                 },
                 {
-                    "name": "K489Q",
-                    "id": 2606,
+                    "name": "E746_S752>A",
+                    "id": 1433,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1097,35 +972,35 @@
                     }
                 },
                 {
-                    "name": "L747_S752del",
-                    "id": 890,
+                    "name": "E746_S752delinsD",
+                    "id": 1009,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 7
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "L747_P753delinsS",
-                    "id": 1012,
+                    "name": "E746_T751>I",
+                    "id": 1003,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 8
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "S768I",
-                    "id": 562,
+                    "name": "E746_T751delinsA",
+                    "id": 1004,
                     "evidence_items": {
-                        "accepted_count": 5,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 5
                     }
                 },
                 {
-                    "name": "F404V",
-                    "id": 2617,
+                    "name": "E746_T751delinsVA",
+                    "id": 1214,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1133,44 +1008,44 @@
                     }
                 },
                 {
-                    "name": "C797S",
-                    "id": 415,
+                    "name": "E868G",
+                    "id": 1482,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 6
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "L747_T751>P",
-                    "id": 1010,
+                    "name": "E884K",
+                    "id": 1390,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 6
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "G810S",
-                    "id": 1016,
+                    "name": "EGFR::RAD51",
+                    "id": 2203,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "L718V",
-                    "id": 3000,
+                    "name": "Ex19 del L858R",
+                    "id": 1854,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 3,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "RARE EGRF MUT",
-                    "id": 2334,
+                    "name": "Exon 18 Overexpression",
+                    "id": 375,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1178,35 +1053,35 @@
                     }
                 },
                 {
-                    "name": "L718V and L718Q",
-                    "id": 2997,
+                    "name": "Exon 18 deletion",
+                    "id": 2257,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Ex19 del L858R",
-                    "id": 1854,
+                    "name": "Exon 19 Deletion",
+                    "id": 133,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 16,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "T785A",
-                    "id": 1573,
+                    "name": "Exon 20 Insertion",
+                    "id": 726,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "N826Y",
-                    "id": 1896,
+                    "name": "Exon 4 Deletion",
+                    "id": 252,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1214,35 +1089,26 @@
                     }
                 },
                 {
-                    "name": "M766_A767insASV",
-                    "id": 2213,
+                    "name": "Expression",
+                    "id": 354,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 5,
                         "rejected_count": 0,
-                        "submitted_count": 1
-                    }
-                },
-                {
-                    "name": "MUTATION",
-                    "id": 442,
-                    "evidence_items": {
-                        "accepted_count": 15,
-                        "rejected_count": 1,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "V774_C775insHV",
-                    "id": 1567,
+                    "name": "F404I",
+                    "id": 2616,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "I744_K745insKIPVAI",
-                    "id": 2259,
+                    "name": "F404V",
+                    "id": 2617,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1250,71 +1116,71 @@
                     }
                 },
                 {
-                    "name": "L718Q",
-                    "id": 2999,
+                    "name": "G465E",
+                    "id": 2603,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "G724S",
-                    "id": 317,
+                    "name": "G465R",
+                    "id": 443,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "L838P",
-                    "id": 1457,
+                    "name": "G465V",
+                    "id": 2604,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "L861R",
-                    "id": 1477,
+                    "name": "G598V",
+                    "id": 997,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "EXON 19 DELETION",
-                    "id": 133,
+                    "name": "G63R",
+                    "id": 3488,
                     "evidence_items": {
-                        "accepted_count": 16,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 2
                     }
                 },
                 {
-                    "name": "E734Q",
-                    "id": 1572,
+                    "name": "G719",
+                    "id": 718,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "R451C",
-                    "id": 454,
-                    "evidence_items": {
-                        "accepted_count": 1,
+                    "name": "G719A",
+                    "id": 999,
+                    "evidence_items": {
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "Gain-of-function",
-                    "id": 1765,
+                    "name": "G719D",
+                    "id": 1420,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1322,44 +1188,35 @@
                     }
                 },
                 {
-                    "name": "M766Q",
-                    "id": 2745,
-                    "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 3
-                    }
-                },
-                {
-                    "name": "S492C",
-                    "id": 2610,
+                    "name": "G719S",
+                    "id": 134,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 4,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 7
                     }
                 },
                 {
-                    "name": "P753S",
-                    "id": 460,
+                    "name": "G724S",
+                    "id": 317,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "C797Y",
-                    "id": 1574,
+                    "name": "G810S",
+                    "id": 1016,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "M766_A767insAI",
-                    "id": 1664,
+                    "name": "Gain-of-function",
+                    "id": 1765,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1367,35 +1224,17 @@
                     }
                 },
                 {
-                    "name": "EXPRESSION",
-                    "id": 354,
-                    "evidence_items": {
-                        "accepted_count": 6,
-                        "rejected_count": 0,
-                        "submitted_count": 3
-                    }
-                },
-                {
-                    "name": "E746_T751delinsVA",
-                    "id": 1214,
+                    "name": "H773_V774insH",
+                    "id": 1446,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "EXON 20 INSERTION",
-                    "id": 726,
-                    "evidence_items": {
-                        "accepted_count": 2,
-                        "rejected_count": 0,
-                        "submitted_count": 4
-                    }
-                },
-                {
-                    "name": "L747_S752delinsQ",
-                    "id": 1580,
+                    "name": "H773_V774insNPH",
+                    "id": 1513,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1403,8 +1242,8 @@
                     }
                 },
                 {
-                    "name": "E709A and G719C",
-                    "id": 2258,
+                    "name": "I462K",
+                    "id": 2599,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1412,26 +1251,26 @@
                     }
                 },
                 {
-                    "name": "V774M",
-                    "id": 1894,
+                    "name": "I462R",
+                    "id": 2600,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V851I",
-                    "id": 1466,
+                    "name": "I491K",
+                    "id": 2608,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V441F",
-                    "id": 2613,
+                    "name": "I491R",
+                    "id": 2609,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1439,21 +1278,21 @@
                     }
                 },
                 {
-                    "name": "S492R",
-                    "id": 453,
+                    "name": "I744_K745insKIPVAI",
+                    "id": 2259,
                     "evidence_items": {
-                        "accepted_count": 4,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "H773_V774insNPH",
-                    "id": 1513,
+                    "name": "K467N",
+                    "id": 2605,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
@@ -1466,26 +1305,17 @@
                     }
                 },
                 {
-                    "name": "G719D",
-                    "id": 1420,
-                    "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 0
-                    }
-                },
-                {
-                    "name": "3' UTR MUTATION",
-                    "id": 253,
+                    "name": "K489E",
+                    "id": 2607,
                     "evidence_items": {
                         "accepted_count": 0,
-                        "rejected_count": 1,
-                        "submitted_count": 0
+                        "rejected_count": 0,
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "P848L",
-                    "id": 1465,
+                    "name": "K489Q",
+                    "id": 2606,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1493,17 +1323,17 @@
                     }
                 },
                 {
-                    "name": "V769A",
-                    "id": 1578,
+                    "name": "K708R",
+                    "id": 3490,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "A702S",
-                    "id": 2255,
+                    "name": "K745_E749delKELRE",
+                    "id": 1638,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1511,53 +1341,53 @@
                     }
                 },
                 {
-                    "name": "L858R",
-                    "id": 33,
+                    "name": "K757R",
+                    "id": 723,
                     "evidence_items": {
-                        "accepted_count": 37,
-                        "rejected_count": 1,
-                        "submitted_count": 4
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "E746_T751>I",
-                    "id": 1003,
+                    "name": "K806E",
+                    "id": 1895,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 6
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "N826S",
-                    "id": 1188,
+                    "name": "L718Q",
+                    "id": 2999,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "OVEREXPRESSION",
-                    "id": 193,
+                    "name": "L718V",
+                    "id": 3000,
                     "evidence_items": {
-                        "accepted_count": 8,
-                        "rejected_count": 2,
+                        "accepted_count": 0,
+                        "rejected_count": 0,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "P772_H773insH",
-                    "id": 2217,
+                    "name": "L718V and L718Q",
+                    "id": 2997,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "R705K",
-                    "id": 2333,
+                    "name": "L747P",
+                    "id": 1891,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1565,17 +1395,17 @@
                     }
                 },
                 {
-                    "name": "T847I",
-                    "id": 1463,
+                    "name": "L747_A750>P",
+                    "id": 1006,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "G598V",
-                    "id": 997,
+                    "name": "L747_P753>Q",
+                    "id": 1011,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1583,35 +1413,35 @@
                     }
                 },
                 {
-                    "name": "V774A",
-                    "id": 1892,
+                    "name": "L747_P753delinsS",
+                    "id": 1012,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 8
                     }
                 },
                 {
-                    "name": "Y69FS*11",
-                    "id": 1672,
+                    "name": "L747_S752del",
+                    "id": 890,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 7
                     }
                 },
                 {
-                    "name": "V769_770insASV",
-                    "id": 736,
+                    "name": "L747_S752delinsQ",
+                    "id": 1580,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "L747_A750>P",
-                    "id": 1006,
+                    "name": "L747_T751delLREAT",
+                    "id": 1007,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1619,26 +1449,26 @@
                     }
                 },
                 {
-                    "name": "G465R",
-                    "id": 443,
+                    "name": "L747_T751delinsP",
+                    "id": 1010,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 6
                     }
                 },
                 {
-                    "name": "E746_A750del",
-                    "id": 1002,
+                    "name": "L747_T751delinsQ",
+                    "id": 1008,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 19
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "N771>GY",
-                    "id": 1581,
+                    "name": "L792H",
+                    "id": 3004,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1646,17 +1476,17 @@
                     }
                 },
                 {
-                    "name": "D770delinsGY",
-                    "id": 2214,
+                    "name": "L838P",
+                    "id": 1457,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "E746G",
-                    "id": 724,
+                    "name": "L838V",
+                    "id": 1018,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1664,89 +1494,89 @@
                     }
                 },
                 {
-                    "name": "L747_T751>Q",
-                    "id": 1008,
+                    "name": "L858Q",
+                    "id": 1473,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "E709Q",
-                    "id": 1413,
+                    "name": "L858R",
+                    "id": 33,
                     "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
+                        "accepted_count": 36,
+                        "rejected_count": 1,
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "S784F",
-                    "id": 1182,
+                    "name": "L861",
+                    "id": 1866,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "G719A",
-                    "id": 999,
+                    "name": "L861Q",
+                    "id": 1020,
                     "evidence_items": {
                         "accepted_count": 2,
                         "rejected_count": 0,
-                        "submitted_count": 4
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "S442R",
-                    "id": 2614,
+                    "name": "L861R",
+                    "id": 1477,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "A767_V769dupASV",
-                    "id": 1579,
+                    "name": "M766Q",
+                    "id": 2745,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 3
                     }
                 },
                 {
-                    "name": "D770_N771insSVD",
-                    "id": 1445,
+                    "name": "M766_A767insAI",
+                    "id": 1664,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "I491R",
-                    "id": 2609,
+                    "name": "M766_A767insASV",
+                    "id": 2213,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "P772_V774insPHV",
-                    "id": 1668,
+                    "name": "Mutation",
+                    "id": 442,
                     "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 0
+                        "accepted_count": 16,
+                        "rejected_count": 1,
+                        "submitted_count": 4
                     }
                 },
                 {
-                    "name": "I462R",
-                    "id": 2600,
+                    "name": "N771>GY",
+                    "id": 1581,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1754,8 +1584,8 @@
                     }
                 },
                 {
-                    "name": "G719X",
-                    "id": 2912,
+                    "name": "N771_P772insL",
+                    "id": 3304,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1763,8 +1593,8 @@
                     }
                 },
                 {
-                    "name": "A750T",
-                    "id": 2332,
+                    "name": "N771delinsVH",
+                    "id": 1662,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1772,8 +1602,8 @@
                     }
                 },
                 {
-                    "name": "K806E",
-                    "id": 1895,
+                    "name": "N826S",
+                    "id": 1188,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1781,17 +1611,17 @@
                     }
                 },
                 {
-                    "name": "E884K",
-                    "id": 1390,
+                    "name": "N826Y",
+                    "id": 1896,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "L861",
-                    "id": 1866,
+                    "name": "N842S",
+                    "id": 1899,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1799,44 +1629,44 @@
                     }
                 },
                 {
-                    "name": "A763_Y764insFQEA",
-                    "id": 1515,
+                    "name": "Overexpression",
+                    "id": 193,
                     "evidence_items": {
-                        "accepted_count": 1,
-                        "rejected_count": 0,
-                        "submitted_count": 4
+                        "accepted_count": 9,
+                        "rejected_count": 2,
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "EXON 18 OVEREXPRESSION",
-                    "id": 375,
+                    "name": "P546S",
+                    "id": 1582,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "E868G",
-                    "id": 1482,
+                    "name": "P596L",
+                    "id": 3489,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "EGFR-RAD51",
-                    "id": 2203,
+                    "name": "P753S",
+                    "id": 460,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "S464T",
-                    "id": 2602,
+                    "name": "P772_H773insH",
+                    "id": 2217,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1844,8 +1674,8 @@
                     }
                 },
                 {
-                    "name": "A289V",
-                    "id": 996,
+                    "name": "P772_H773insYNP",
+                    "id": 1667,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1853,17 +1683,17 @@
                     }
                 },
                 {
-                    "name": "F404I",
-                    "id": 2616,
+                    "name": "P772_V774insPHV",
+                    "id": 1668,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "K489E",
-                    "id": 2607,
+                    "name": "P848L",
+                    "id": 1465,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1871,44 +1701,35 @@
                     }
                 },
                 {
-                    "name": "COPY NUMBER VARIATION",
-                    "id": 191,
+                    "name": "R108K",
+                    "id": 994,
                     "evidence_items": {
-                        "accepted_count": 3,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "S464L",
-                    "id": 2601,
+                    "name": "R165Q",
+                    "id": 3470,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "N842S",
-                    "id": 1899,
+                    "name": "R222C",
+                    "id": 3344,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
-                    }
-                },
-                {
-                    "name": "T790M",
-                    "id": 34,
-                    "evidence_items": {
-                        "accepted_count": 30,
-                        "rejected_count": 2,
-                        "submitted_count": 8
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "S442I",
-                    "id": 2615,
+                    "name": "R252C",
+                    "id": 3961,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -1916,8 +1737,8 @@
                     }
                 },
                 {
-                    "name": "W731L",
-                    "id": 1571,
+                    "name": "R451C",
+                    "id": 454,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -1925,89 +1746,80 @@
                     }
                 },
                 {
-                    "name": "T415M",
-                    "id": 2618,
-                    "evidence_items": {
-                        "accepted_count": 0,
-                        "rejected_count": 0,
-                        "submitted_count": 1
-                    }
-                },
-                {
-                    "name": "RARE Exon 18-21 Mutation",
-                    "id": 1863,
+                    "name": "R705K",
+                    "id": 2333,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "E709K and G719A",
-                    "id": 2256,
+                    "name": "R776C",
+                    "id": 1181,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "L747_T751delLREAT",
-                    "id": 1007,
+                    "name": "R831H",
+                    "id": 1017,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 3
                     }
                 },
                 {
-                    "name": "L747_P753>Q",
-                    "id": 1011,
+                    "name": "R832L",
+                    "id": 2741,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 5
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "R108K",
-                    "id": 994,
+                    "name": "Rare Exon 18-21 Mutation",
+                    "id": 1863,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 2,
                         "rejected_count": 0,
                         "submitted_count": 0
                     }
                 },
                 {
-                    "name": "V742A",
-                    "id": 1001,
+                    "name": "Rare Mutation",
+                    "id": 2334,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "S768N",
-                    "id": 1443,
+                    "name": "S442I",
+                    "id": 2615,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "AUTOCRINE ACTIVATION",
-                    "id": 309,
+                    "name": "S442R",
+                    "id": 2614,
                     "evidence_items": {
                         "accepted_count": 0,
-                        "rejected_count": 2,
-                        "submitted_count": 0
+                        "rejected_count": 0,
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "Exon 18 deletion",
-                    "id": 2257,
+                    "name": "S464L",
+                    "id": 2601,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2015,44 +1827,44 @@
                     }
                 },
                 {
-                    "name": "L861Q",
-                    "id": 1020,
+                    "name": "S464T",
+                    "id": 2602,
                     "evidence_items": {
-                        "accepted_count": 2,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "H773_V774insH",
-                    "id": 1446,
+                    "name": "S492C",
+                    "id": 2610,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 0,
                         "rejected_count": 0,
                         "submitted_count": 1
                     }
                 },
                 {
-                    "name": "V441D",
-                    "id": 2612,
+                    "name": "S492R",
+                    "id": 453,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 4,
                         "rejected_count": 0,
-                        "submitted_count": 1
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "D761N",
-                    "id": 1013,
+                    "name": "S720",
+                    "id": 720,
                     "evidence_items": {
-                        "accepted_count": 0,
+                        "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 2
+                        "submitted_count": 0
                     }
                 },
                 {
-                    "name": "T854A",
-                    "id": 1467,
+                    "name": "S752_I759delSPKANKEI",
+                    "id": 891,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2060,35 +1872,62 @@
                     }
                 },
                 {
-                    "name": "D770_N771insGL",
-                    "id": 1514,
+                    "name": "S768I",
+                    "id": 562,
                     "evidence_items": {
-                        "accepted_count": 1,
+                        "accepted_count": 5,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 5
                     }
                 },
                 {
-                    "name": "AMPLIFICATION",
-                    "id": 190,
+                    "name": "S768N",
+                    "id": 1443,
                     "evidence_items": {
-                        "accepted_count": 9,
+                        "accepted_count": 0,
                         "rejected_count": 0,
-                        "submitted_count": 3
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "S768_D770dup",
+                    "id": 1511,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 2
                     }
                 },
                 {
-                    "name": "D770_N771insGY",
-                    "id": 1666,
+                    "name": "S784F",
+                    "id": 1182,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 4
+                    }
+                },
+                {
+                    "name": "T263P",
+                    "id": 995,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
-                        "submitted_count": 0
+                        "submitted_count": 1
                     }
                 },
                 {
-                    "name": "E709_T710>D",
-                    "id": 1577,
+                    "name": "T415M",
+                    "id": 2618,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 1
+                    }
+                },
+                {
+                    "name": "T725M",
+                    "id": 861,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2096,8 +1935,35 @@
                     }
                 },
                 {
-                    "name": "delL747_P753insS",
-                    "id": 2215,
+                    "name": "T785A",
+                    "id": 1573,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "T790M",
+                    "id": 34,
+                    "evidence_items": {
+                        "accepted_count": 31,
+                        "rejected_count": 2,
+                        "submitted_count": 9
+                    }
+                },
+                {
+                    "name": "T847I",
+                    "id": 1463,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "T854A",
+                    "id": 1467,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2105,8 +1971,8 @@
                     }
                 },
                 {
-                    "name": "K745_E749delKELRE",
-                    "id": 1638,
+                    "name": "V441D",
+                    "id": 2612,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2114,8 +1980,17 @@
                     }
                 },
                 {
-                    "name": "I462K",
-                    "id": 2599,
+                    "name": "V441F",
+                    "id": 2613,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "V441G",
+                    "id": 2611,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2123,8 +1998,17 @@
                     }
                 },
                 {
-                    "name": "C797G",
-                    "id": 3003,
+                    "name": "V742A",
+                    "id": 1001,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "V769A",
+                    "id": 1578,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2132,8 +2016,17 @@
                     }
                 },
                 {
-                    "name": "A864T",
-                    "id": 1187,
+                    "name": "V769_D770insASV",
+                    "id": 736,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "V774A",
+                    "id": 1892,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -2141,8 +2034,80 @@
                     }
                 },
                 {
-                    "name": "I491K",
-                    "id": 2608,
+                    "name": "V774M",
+                    "id": 1894,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "V774_C775insHV",
+                    "id": 1567,
+                    "evidence_items": {
+                        "accepted_count": 0,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "V834I",
+                    "id": 1897,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "V851I",
+                    "id": 1466,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "VIII",
+                    "id": 312,
+                    "evidence_items": {
+                        "accepted_count": 7,
+                        "rejected_count": 0,
+                        "submitted_count": 2
+                    }
+                },
+                {
+                    "name": "W731L",
+                    "id": 1571,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "Wildtype",
+                    "id": 2174,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 1,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "Y1092 PHOSPHORYLATION",
+                    "id": 390,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 0
+                    }
+                },
+                {
+                    "name": "Y69FS*11",
+                    "id": 1672,
                     "evidence_items": {
                         "accepted_count": 0,
                         "rejected_count": 0,
@@ -2150,8 +2115,17 @@
                     }
                 },
                 {
-                    "name": "P772_H773insYNP",
-                    "id": 1667,
+                    "name": "Y764_V765insHH",
+                    "id": 1665,
+                    "evidence_items": {
+                        "accepted_count": 1,
+                        "rejected_count": 0,
+                        "submitted_count": 1
+                    }
+                },
+                {
+                    "name": "Y801H",
+                    "id": 1575,
                     "evidence_items": {
                         "accepted_count": 1,
                         "rejected_count": 0,
@@ -2160,14 +2134,14 @@
                 }
             ],
             "aliases": [
-                "ERRP",
                 "EGFR",
-                "mENA",
-                "PIG61",
-                "NISBD2",
-                "HER1",
+                "ERBB",
                 "ERBB1",
-                "ERBB"
+                "ERRP",
+                "HER1",
+                "NISBD2",
+                "PIG61",
+                "mENA"
             ],
             "type": "gene"
         }
@@ -2184,14 +2158,13 @@
             "variant_types": [
                 {
                     "id": 47,
-                    "name": "missense_variant",
-                    "display_name": "Missense Variant",
+                    "name": "Missense Variant",
                     "so_id": "SO:0001583",
                     "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                     "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                 }
             ],
-            "civic_actionability_score": 352.5,
+            "civic_actionability_score": 375,
             "coordinates": {
                 "chromosome": "7",
                 "start": 55259515,
@@ -2208,29 +2181,17 @@
             },
             "evidence_items": [
                 {
-                    "id": 229,
-                    "name": "EID229",
-                    "description": "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).",
+                    "id": 2994,
+                    "name": "EID2994",
+                    "description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
-                        {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
-                            "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
-                            ]
-                        },
                         {
                             "id": 15,
                             "name": "Erlotinib",
@@ -2238,106 +2199,42 @@
                             "aliases": []
                         }
                     ],
-                    "rating": 3,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": "Substitutes",
+                    "rating": 5,
+                    "evidence_level": "A",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 162,
-                        "name": "Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.",
-                        "citation": "Lim et al., 2014, J Thorac Oncol",
-                        "citation_id": "24736073",
-                        "source_type": "PubMed",
+                        "id": 1724,
+                        "name": "U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.",
+                        "citation": "Khozin et al., 2014, Oncologist",
+                        "citation_id": 24868098,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24736073",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 4
-                        },
-                        "journal": "J Thorac Oncol",
-                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24868098",
+                        "pmc_id": "PMC4077454",
+                        "publication_date": "2014-7",
+                        "journal": "Oncologist",
+                        "full_journal_title": "The oncologist",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 276,
-                    "name": "EID276",
-                    "description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.",
+                    "id": 2997,
+                    "name": "EID2997",
+                    "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
-                    },
-                    "drugs": [
-                        {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
-                            "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
-                            ]
-                        }
-                    ],
-                    "rating": 4,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "accepted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 181,
-                        "name": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.",
-                        "citation": "Paez et al., 2004, Science",
-                        "citation_id": "15118125",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15118125",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2004,
-                            "month": 6,
-                            "day": 4
-                        },
-                        "journal": "Science",
-                        "full_journal_title": "Science (New York, N.Y.)",
-                        "status": "partially curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 33,
-                    "phenotypes": []
-                },
-                {
-                    "id": 879,
-                    "name": "EID879",
-                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
-                    "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -2345,126 +2242,118 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 5,
+                    "evidence_level": "A",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 592,
-                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
-                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
-                        "citation_id": "23816960",
-                        "source_type": "PubMed",
+                        "id": 1725,
+                        "name": "Afatinib: first global approval.",
+                        "citation": "Dungo et al., 2013, Drugs",
+                        "citation_id": 23982599,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2013,
-                            "month": 9,
-                            "day": 20
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00949650",
-                                "name": "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation",
-                                "description": "This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00949650"
-                            }
-                        ]
+                        "publication_date": "2013-9",
+                        "journal": "Drugs",
+                        "full_journal_title": "Drugs",
+                        "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 883,
-                    "name": "EID883",
-                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
+                    "id": 4860,
+                    "name": "EID4860",
+                    "description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 146,
-                            "name": "Afatinib",
-                            "ncit_id": "C66940",
+                            "id": 44,
+                            "name": "Dacomitinib",
+                            "ncit_id": "C53398",
                             "aliases": [
-                                "BIBW2992",
-                                "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
+                                "EGFR Inhibitor PF-00299804",
+                                "PF-00299804",
+                                "PF-00299804-03",
+                                "PF-299804",
+                                "Vizimpro"
                             ]
                         }
                     ],
-                    "rating": 3,
+                    "rating": 5,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 594,
-                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
-                        "citation": "Yang et al., 2012, Lancet Oncol.",
-                        "citation_id": "22452895",
-                        "source_type": "PubMed",
+                        "id": 2158,
+                        "name": "Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.",
+                        "citation": "Ramalingam et al., 2016, Ann. Oncol.",
+                        "citation_id": 26768165,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26768165",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 5
-                        },
-                        "journal": "Lancet Oncol.",
-                        "full_journal_title": "The Lancet. Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2016-3",
+                        "journal": "Ann. Oncol.",
+                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
                         "clinical_trials": [
-                            {
-                                "nct_id": "NCT00525148",
-                                "name": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",
-                                "description": "The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST criteria in patients with advanced NSCLC Stage IIIB or IV whose tumors harbor activating mutations within exon 18 to exon 21 of the EGFR receptor. Patients progressing or relapsing after one prior cytotoxic chemotherapy regimen as well as chemotherapy na\u00efve patients (only in stage 2) will be allowed to enter into the trial.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00525148"
-                            }
+                            {},
+                            {},
+                            {}
                         ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 885,
-                    "name": "EID885",
-                    "description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",
+                    "id": 275,
+                    "name": "EID275",
+                    "description": "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
+                        {
+                            "id": 14,
+                            "name": "Gefitinib",
+                            "ncit_id": "C1855",
+                            "aliases": [
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
+                                "Iressa",
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
+                            ]
+                        },
                         {
                             "id": 15,
                             "name": "Erlotinib",
@@ -2472,55 +2361,42 @@
                             "aliases": []
                         }
                     ],
-                    "rating": 3,
+                    "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": "SUBSTITUTES",
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 595,
-                        "name": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
-                        "citation": "Rosell et al., 2012, Lancet Oncol.",
-                        "citation_id": "22285168",
-                        "source_type": "PubMed",
+                        "id": 182,
+                        "name": "Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.",
+                        "citation": "Fukihara et al., 2014, Oncology",
+                        "citation_id": 24457318,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22285168",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24457318",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 3
-                        },
-                        "journal": "Lancet Oncol.",
-                        "full_journal_title": "The Lancet. Oncology",
-                        "status": "partially curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00446225",
-                                "name": "Phase III Study (Tarceva\u00ae) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR",
-                                "description": "A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva\u00ae) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00446225"
-                            }
-                        ]
+                        "publication_date": "2014",
+                        "journal": "Oncology",
+                        "full_journal_title": "Oncology",
+                        "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 968,
-                    "name": "EID968",
-                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
+                    "id": 879,
+                    "name": "EID879",
+                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -2528,41 +2404,36 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 4,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 669,
-                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
-                        "citation": "Hirano et al., 2015, Oncotarget",
-                        "citation_id": "26515464",
-                        "source_type": "PubMed",
+                        "id": 592,
+                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
+                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
+                        "citation_id": 23816960,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
-                        "open_access": true,
-                        "pmc_id": "PMC4770737",
-                        "publication_date": {
-                            "year": 2015,
-                            "month": 11,
-                            "day": 17
-                        },
-                        "journal": "Oncotarget",
-                        "full_journal_title": "Oncotarget",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
+                        "pmc_id": null,
+                        "publication_date": "2013-9-20",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
+                        "clinical_trials": [
+                            {}
+                        ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
@@ -2575,8 +2446,8 @@
                         "id": 30,
                         "name": "Lung Adenocarcinoma",
                         "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -2584,18 +2455,18 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -2603,42 +2474,31 @@
                         "id": 679,
                         "name": "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.",
                         "citation": "Wu et al., 2014, Lancet Oncol.",
-                        "citation_id": "24439929",
-                        "source_type": "PubMed",
+                        "citation_id": 24439929,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24439929",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 2
-                        },
+                        "publication_date": "2014-2",
                         "journal": "Lancet Oncol.",
                         "full_journal_title": "The Lancet. Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": [
-                            {
-                                "nct_id": "NCT01121393",
-                                "name": "BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)",
-                                "description": "To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT01121393"
-                            }
+                            {}
                         ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 275,
-                    "name": "EID275",
-                    "description": "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.",
+                    "id": 2621,
+                    "name": "EID2621",
+                    "description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -2646,61 +2506,52 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
-                        },
-                        {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
                         }
                     ],
                     "rating": 4,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": "Substitutes",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 182,
-                        "name": "Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.",
-                        "citation": "Fukihara et al., 2014, Oncology",
-                        "citation_id": "24457318",
-                        "source_type": "PubMed",
+                        "id": 1501,
+                        "name": "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.",
+                        "citation": "Douillard et al., 2010, J. Clin. Oncol.",
+                        "citation_id": 20038723,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24457318",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20038723",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014
-                        },
-                        "journal": "Oncology",
-                        "full_journal_title": "Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
+                        "publication_date": "2010-2-10",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
+                        "clinical_trials": [
+                            {}
+                        ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 1665,
-                    "name": "EID1665",
-                    "description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).",
+                    "id": 229,
+                    "name": "EID229",
+                    "description": "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -2708,180 +2559,190 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
+                        },
+                        {
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
                     "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": "SUBSTITUTES",
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1127,
-                        "name": "Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.",
-                        "citation": "Yang et al., 2008, J. Clin. Oncol.",
-                        "citation_id": "18509184",
-                        "source_type": "PubMed",
+                        "id": 162,
+                        "name": "Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.",
+                        "citation": "Lim et al., 2014, J Thorac Oncol",
+                        "citation_id": 24736073,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18509184",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24736073",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 6,
-                            "day": 1
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2014-4",
+                        "journal": "J Thorac Oncol",
+                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2621,
-                    "name": "EID2621",
-                    "description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.",
+                    "id": 347,
+                    "name": "EID347",
+                    "description": "Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
+                    },
+                    "drugs": [],
+                    "rating": 3,
+                    "evidence_level": "B",
+                    "evidence_type": "PROGNOSTIC",
+                    "clinical_significance": "BETTER_OUTCOME",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "accepted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 213,
+                        "name": "Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.",
+                        "citation": "Douillard et al., 2014, J Thorac Oncol",
+                        "citation_id": 24662454,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24662454",
+                        "pmc_id": null,
+                        "publication_date": "2014-5",
+                        "journal": "J Thorac Oncol",
+                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 33,
+                    "phenotypes": []
+                },
+                {
+                    "id": 883,
+                    "name": "EID883",
+                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
+                    "disease": {
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
+                            "id": 146,
+                            "name": "Afatinib",
+                            "ncit_id": "C66940",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
+                                "BIBW 2992",
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 4,
+                    "rating": 3,
                     "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1501,
-                        "name": "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.",
-                        "citation": "Douillard et al., 2010, J. Clin. Oncol.",
-                        "citation_id": "20038723",
-                        "source_type": "PubMed",
+                        "id": 594,
+                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
+                        "citation": "Yang et al., 2012, Lancet Oncol.",
+                        "citation_id": 22452895,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20038723",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2010,
-                            "month": 2,
-                            "day": 10
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2012-5",
+                        "journal": "Lancet Oncol.",
+                        "full_journal_title": "The Lancet. Oncology",
                         "clinical_trials": [
-                            {
-                                "nct_id": "NCT00076388",
-                                "name": "Iressa Versus Docetaxel (Taxotere)",
-                                "description": "The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00076388"
-                            }
+                            {}
                         ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2623,
-                    "name": "EID2623",
-                    "description": "In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, HR: 0.30, 95% CI: 0.22-0.41, P<0.001), compared to patients treated with carboplatin and paclitaxel combination therapy. The frequency of mutation of exon 19 deletion and L858R was 25.2% (58/230) and 21.3% (49/230), respectively.",
+                    "id": 885,
+                    "name": "EID885",
+                    "description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
-                            "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
-                            ]
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1508,
-                        "name": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.",
-                        "citation": "Maemondo et al., 2010, N. Engl. J. Med.",
-                        "citation_id": "20573926",
-                        "source_type": "PubMed",
+                        "id": 595,
+                        "name": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
+                        "citation": "Rosell et al., 2012, Lancet Oncol.",
+                        "citation_id": 22285168,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20573926",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22285168",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2010,
-                            "month": 6,
-                            "day": 24
-                        },
-                        "journal": "N. Engl. J. Med.",
-                        "full_journal_title": "The New England journal of medicine",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "publication_date": "2012-3",
+                        "journal": "Lancet Oncol.",
+                        "full_journal_title": "The Lancet. Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2624,
-                    "name": "EID2624",
-                    "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.",
+                    "id": 1665,
+                    "name": "EID1665",
+                    "description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004).",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -2889,57 +2750,50 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         }
                     ],
-                    "rating": 1,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1509,
-                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
-                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
-                        "citation_id": "15329413",
-                        "source_type": "PubMed",
+                        "id": 1127,
+                        "name": "Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.",
+                        "citation": "Yang et al., 2008, J. Clin. Oncol.",
+                        "citation_id": 18509184,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
-                        "open_access": true,
-                        "pmc_id": "PMC516528",
-                        "publication_date": {
-                            "year": 2004,
-                            "month": 9,
-                            "day": 7
-                        },
-                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
-                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18509184",
+                        "pmc_id": null,
+                        "publication_date": "2008-6-1",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2625,
-                    "name": "EID2625",
-                    "description": "In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
+                    "id": 2634,
+                    "name": "EID2634",
+                    "description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -2947,213 +2801,184 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         }
                     ],
-                    "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 665,
-                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
-                        "citation": "Cross et al., 2014, Cancer Discov",
-                        "citation_id": "24893891",
-                        "source_type": "PubMed",
+                        "id": 1513,
+                        "name": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.",
+                        "citation": "Han et al., 2012, J. Clin. Oncol.",
+                        "citation_id": 22370314,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
-                        "open_access": true,
-                        "pmc_id": "PMC4315625",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 9
-                        },
-                        "journal": "Cancer Discov",
-                        "full_journal_title": "Cancer discovery",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22370314",
+                        "pmc_id": null,
+                        "publication_date": "2012-4-1",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2626,
-                    "name": "EID2626",
-                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.",
+                    "id": 4290,
+                    "name": "EID4290",
+                    "description": "In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
-                            "id": 45,
-                            "name": "Lapatinib",
-                            "ncit_id": "C26653",
-                            "aliases": [
-                                "GW572016",
-                                "GW2016",
-                                "GW 2016",
-                                "GSK572016"
-                            ]
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
-                    "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1525,
-                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
-                        "citation": "Li et al., 2008, Oncogene",
-                        "citation_id": "18408761",
-                        "source_type": "PubMed",
+                        "id": 2067,
+                        "name": "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).",
+                        "citation": "De Gr\u00e8ve et al., 2016, PLoS ONE",
+                        "citation_id": 27032107,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
-                        "open_access": true,
-                        "pmc_id": "PMC2748240",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 8,
-                            "day": 7
-                        },
-                        "journal": "Oncogene",
-                        "full_journal_title": "Oncogene",
-                        "status": "partially curated",
-                        "is_review": false,
-                        "clinical_trials": []
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27032107",
+                        "pmc_id": "PMC4816447",
+                        "publication_date": "2016",
+                        "journal": "PLoS ONE",
+                        "full_journal_title": "PloS one",
+                        "clinical_trials": [
+                            {}
+                        ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2628,
-                    "name": "EID2628",
-                    "description": "In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L).",
+                    "id": 6183,
+                    "name": "EID6183",
+                    "description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
-                            "id": 52,
-                            "name": "Neratinib",
-                            "ncit_id": "C49094",
+                            "id": 14,
+                            "name": "Gefitinib",
+                            "ncit_id": "C1855",
                             "aliases": [
-                                "PB-272",
-                                "PB 272",
-                                "HKI-272",
-                                "HKI 272",
-                                "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-",
-                                "(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide"
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
+                                "Iressa",
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "B",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1526,
-                        "name": "Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.",
-                        "citation": "Shimamura et al., 2006, Cancer Res.",
-                        "citation_id": "16818618",
-                        "source_type": "PubMed",
+                        "id": 2478,
+                        "name": "Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.",
+                        "citation": "Urata et al., 2016, J. Clin. Oncol.",
+                        "citation_id": 27022112,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16818618",
-                        "open_access": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27022112",
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 7,
-                            "day": 1
-                        },
-                        "journal": "Cancer Res.",
-                        "full_journal_title": "Cancer research",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "publication_date": "2016",
+                        "journal": "J. Clin. Oncol.",
+                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2629,
-                    "name": "EID2629",
-                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
+                    "id": 2623,
+                    "name": "EID2623",
+                    "description": "In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, HR: 0.30, 95% CI: 0.22-0.41, P<0.001), compared to patients treated with carboplatin and paclitaxel combination therapy. The frequency of mutation of exon 19 deletion and L858R was 25.2% (58/230) and 21.3% (49/230), respectively.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 146,
-                            "name": "Afatinib",
-                            "ncit_id": "C66940",
+                            "id": 14,
+                            "name": "Gefitinib",
+                            "ncit_id": "C1855",
                             "aliases": [
-                                "BIBW2992",
-                                "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
+                                "Iressa",
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         }
                     ],
-                    "rating": 2,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": null,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 1525,
-                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
-                        "citation": "Li et al., 2008, Oncogene",
-                        "citation_id": "18408761",
-                        "source_type": "PubMed",
+                        "id": 1508,
+                        "name": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.",
+                        "citation": "Maemondo et al., 2010, N. Engl. J. Med.",
+                        "citation_id": 20573926,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
-                        "open_access": true,
-                        "pmc_id": "PMC2748240",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 8,
-                            "day": 7
-                        },
-                        "journal": "Oncogene",
-                        "full_journal_title": "Oncogene",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20573926",
+                        "pmc_id": null,
+                        "publication_date": "2010-6-24",
+                        "journal": "N. Engl. J. Med.",
+                        "full_journal_title": "The New England journal of medicine",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
@@ -3167,8 +2992,8 @@
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -3176,18 +3001,18 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
                     "rating": null,
                     "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "submitted",
                     "type": "evidence",
@@ -3195,153 +3020,179 @@
                         "id": 1510,
                         "name": "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.",
                         "citation": "Miller et al., 2012, Lancet Oncol.",
-                        "citation_id": "22452896",
-                        "source_type": "PubMed",
+                        "citation_id": 22452896,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452896",
-                        "open_access": null,
                         "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 5
-                        },
+                        "publication_date": "2012-5",
                         "journal": "Lancet Oncol.",
                         "full_journal_title": "The Lancet. Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": [
-                            {
-                                "nct_id": "NCT00656136",
-                                "name": "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)",
-                                "description": "This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed. The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00656136"
-                            }
+                            {}
                         ]
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2631,
-                    "name": "EID2631",
-                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.",
+                    "id": 8053,
+                    "name": "EID8053",
+                    "description": "A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutation and the patient started 80mg osimertinib treatment with excellent response of all disease sites, including brain metastases. The patient had continued response until 8.5 months after treatment initiation when a new liver lesion was found. NGS sequencing of a repeat biopsy detected the original EGFR L858R mutation as well as L718V and L718Q mutations. Afatinib treatment led to a partial response for 4.5 months, at which time disease progression occurred. Biopsy of a progressing liver lesion showed acquired EGFR T790M mutation as well as increase and decrease of L718V and L718Q mutation frequencies, respectively.",
+                    "disease": {
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
+                    },
+                    "drugs": [
+                        {
+                            "id": 187,
+                            "name": "Osimertinib",
+                            "ncit_id": "C116377",
+                            "aliases": [
+                                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
+                                "AZD-9291",
+                                "AZD9291",
+                                "Mereletinib",
+                                "Tagrisso"
+                            ]
+                        }
+                    ],
+                    "rating": 4,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
+                    "status": "submitted",
+                    "type": "evidence",
+                    "source": {
+                        "id": 3253,
+                        "name": "Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations.",
+                        "citation": "Starrett et al., 2020, Cancer Res.",
+                        "citation_id": 32193290,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32193290",
+                        "pmc_id": null,
+                        "publication_date": "2020-3-19",
+                        "journal": "Cancer Res.",
+                        "full_journal_title": "Cancer research",
+                        "clinical_trials": []
+                    },
+                    "variant_id": 33,
+                    "phenotypes": []
+                },
+                {
+                    "id": 4288,
+                    "name": "EID4288",
+                    "description": "This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R).",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 465,
-                            "name": "Canertinib",
-                            "ncit_id": "C77588",
+                            "id": 12,
+                            "name": "Crizotinib",
+                            "ncit_id": "C74061",
                             "aliases": [
-                                "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide",
-                                "2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-"
+                                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
+                                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
+                                "MET Tyrosine Kinase Inhibitor PF-02341066",
+                                "PF-02341066",
+                                "PF-2341066",
+                                "Xalkori"
                             ]
                         }
                     ],
                     "rating": 3,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "RESISTANCE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1525,
-                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
-                        "citation": "Li et al., 2008, Oncogene",
-                        "citation_id": "18408761",
-                        "source_type": "PubMed",
+                        "id": 507,
+                        "name": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
+                        "citation": "Doebele et al., 2012, Clin. Cancer Res.",
+                        "citation_id": 22235099,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
-                        "open_access": true,
-                        "pmc_id": "PMC2748240",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 8,
-                            "day": 7
-                        },
-                        "journal": "Oncogene",
-                        "full_journal_title": "Oncogene",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22235099",
+                        "pmc_id": "PMC3311875",
+                        "publication_date": "2012-3-1",
+                        "journal": "Clin. Cancer Res.",
+                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2633,
-                    "name": "EID2633",
-                    "description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
+                    "id": 2632,
+                    "name": "EID2632",
+                    "description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 427,
-                            "name": "Durvalumab",
-                            "ncit_id": "C103194",
-                            "aliases": [
-                                "MEDI4736",
-                                "MEDI-4736",
-                                "Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer",
-                                "Imfinzi"
-                            ]
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": null,
-                    "evidence_direction": null,
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "rejected",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 665,
-                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
-                        "citation": "Cross et al., 2014, Cancer Discov",
-                        "citation_id": "24893891",
-                        "source_type": "PubMed",
+                        "id": 1509,
+                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
+                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
+                        "citation_id": 15329413,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
-                        "open_access": true,
-                        "pmc_id": "PMC4315625",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 9
-                        },
-                        "journal": "Cancer Discov",
-                        "full_journal_title": "Cancer discovery",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
+                        "pmc_id": "PMC516528",
+                        "publication_date": "2004-9-7",
+                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
+                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2634,
-                    "name": "EID2634",
-                    "description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.",
+                    "id": 2624,
+                    "name": "EID2624",
+                    "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.",
                     "disease": {
                         "id": 30,
                         "name": "Lung Adenocarcinoma",
                         "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
@@ -3349,57 +3200,50 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         }
                     ],
-                    "rating": 3,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 1,
+                    "evidence_level": "C",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1513,
-                        "name": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.",
-                        "citation": "Han et al., 2012, J. Clin. Oncol.",
-                        "citation_id": "22370314",
-                        "source_type": "PubMed",
+                        "id": 1509,
+                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
+                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
+                        "citation_id": 15329413,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22370314",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 4,
-                            "day": 1
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
+                        "pmc_id": "PMC516528",
+                        "publication_date": "2004-9-7",
+                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
+                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4265,
-                    "name": "EID4265",
-                    "description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.",
+                    "id": 4287,
+                    "name": "EID4287",
+                    "description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.",
                     "disease": {
-                        "id": 216,
-                        "name": "Cancer",
-                        "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -3409,473 +3253,407 @@
                             "aliases": []
                         }
                     ],
-                    "rating": 3,
+                    "rating": null,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1991,
-                        "name": "Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.",
-                        "citation": "de Gunst et al., 2007, Mol. Cancer",
-                        "citation_id": "17877814",
-                        "source_type": "PubMed",
+                        "id": 2070,
+                        "name": "Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.",
+                        "citation": "Ray et al., 2016, Oncotarget",
+                        "citation_id": 27612423,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17877814",
-                        "open_access": true,
-                        "pmc_id": "PMC2064929",
-                        "publication_date": {
-                            "year": 2007,
-                            "month": 9,
-                            "day": 18
-                        },
-                        "journal": "Mol. Cancer",
-                        "full_journal_title": "Molecular cancer",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27612423",
+                        "pmc_id": "PMC5356576",
+                        "publication_date": "2016-10-18",
+                        "journal": "Oncotarget",
+                        "full_journal_title": "Oncotarget",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4284,
-                    "name": "EID4284",
-                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.",
+                    "id": 276,
+                    "name": "EID276",
+                    "description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
+                            "id": 14,
+                            "name": "Gefitinib",
+                            "ncit_id": "C1855",
+                            "aliases": [
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
+                                "Iressa",
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
+                            ]
                         }
                     ],
-                    "rating": 2,
+                    "rating": 4,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1525,
-                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
-                        "citation": "Li et al., 2008, Oncogene",
-                        "citation_id": "18408761",
-                        "source_type": "PubMed",
+                        "id": 181,
+                        "name": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.",
+                        "citation": "Paez et al., 2004, Science",
+                        "citation_id": 15118125,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
-                        "open_access": true,
-                        "pmc_id": "PMC2748240",
-                        "publication_date": {
-                            "year": 2008,
-                            "month": 8,
-                            "day": 7
-                        },
-                        "journal": "Oncogene",
-                        "full_journal_title": "Oncogene",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15118125",
+                        "pmc_id": null,
+                        "publication_date": "2004-6-4",
+                        "journal": "Science",
+                        "full_journal_title": "Science (New York, N.Y.)",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4285,
-                    "name": "EID4285",
-                    "description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.",
+                    "id": 2626,
+                    "name": "EID2626",
+                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
+                            "id": 45,
+                            "name": "Lapatinib",
+                            "ncit_id": "C26653",
+                            "aliases": [
+                                "GSK572016",
+                                "GW 2016",
+                                "GW2016",
+                                "GW572016"
+                            ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1993,
-                        "name": "Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.",
-                        "citation": "Harada et al., 2011, Oncogene",
-                        "citation_id": "21132006",
-                        "source_type": "PubMed",
+                        "id": 1525,
+                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
+                        "citation": "Li et al., 2008, Oncogene",
+                        "citation_id": 18408761,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21132006",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2011,
-                            "month": 4,
-                            "day": 14
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
+                        "pmc_id": "PMC2748240",
+                        "publication_date": "2008-8-7",
                         "journal": "Oncogene",
                         "full_journal_title": "Oncogene",
-                        "status": "fully curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4286,
-                    "name": "EID4286",
-                    "description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006\ufffdM). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.",
+                    "id": 2627,
+                    "name": "EID2627",
+                    "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
+                            "id": 44,
+                            "name": "Dacomitinib",
+                            "ncit_id": "C53398",
+                            "aliases": [
+                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
+                                "EGFR Inhibitor PF-00299804",
+                                "PF-00299804",
+                                "PF-00299804-03",
+                                "PF-299804",
+                                "Vizimpro"
+                            ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1230,
-                        "name": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
-                        "citation": "Yasuda et al., 2013, Sci Transl Med",
-                        "citation_id": "24353160",
-                        "source_type": "PubMed",
+                        "id": 1515,
+                        "name": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.",
+                        "citation": "Engelman et al., 2007, Cancer Res.",
+                        "citation_id": 18089823,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160",
-                        "open_access": true,
-                        "pmc_id": "PMC3954775",
-                        "publication_date": {
-                            "year": 2013,
-                            "month": 12,
-                            "day": 18
-                        },
-                        "journal": "Sci Transl Med",
-                        "full_journal_title": "Science translational medicine",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18089823",
+                        "pmc_id": null,
+                        "publication_date": "2007-12-15",
+                        "journal": "Cancer Res.",
+                        "full_journal_title": "Cancer research",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4287,
-                    "name": "EID4287",
-                    "description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.",
+                    "id": 2628,
+                    "name": "EID2628",
+                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 \u03bcmol/L) compared to EGFRwt A549 cells (IC50 > 1 \u03bcmol/L).",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
+                            "id": 52,
+                            "name": "Neratinib",
+                            "ncit_id": "C49094",
+                            "aliases": [
+                                "(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide",
+                                "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-",
+                                "HKI 272",
+                                "HKI-272",
+                                "PB 272",
+                                "PB-272"
+                            ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2070,
-                        "name": "Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.",
-                        "citation": "Ray et al., 2016, Oncotarget",
-                        "citation_id": "27612423",
-                        "source_type": "PubMed",
+                        "id": 1526,
+                        "name": "Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.",
+                        "citation": "Shimamura et al., 2006, Cancer Res.",
+                        "citation_id": 16818618,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27612423",
-                        "open_access": true,
-                        "pmc_id": "PMC5356576",
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 10,
-                            "day": 18
-                        },
-                        "journal": "Oncotarget",
-                        "full_journal_title": "Oncotarget",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16818618",
+                        "pmc_id": null,
+                        "publication_date": "2006-7-1",
+                        "journal": "Cancer Res.",
+                        "full_journal_title": "Cancer research",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4288,
-                    "name": "EID4288",
-                    "description": "In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.",
+                    "id": 2631,
+                    "name": "EID2631",
+                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 12,
-                            "name": "Crizotinib",
-                            "ncit_id": "C74061",
+                            "id": 465,
+                            "name": "Canertinib",
+                            "ncit_id": "C77588",
                             "aliases": [
-                                "Xalkori",
-                                "PF-2341066",
-                                "PF-02341066",
-                                "MET Tyrosine Kinase Inhibitor PF-02341066",
-                                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
-                                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
+                                "2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-",
+                                "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"
                             ]
                         }
                     ],
-                    "rating": null,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Resistance",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "accepted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 507,
-                        "name": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
-                        "citation": "Doebele et al., 2012, Clin. Cancer Res.",
-                        "citation_id": "22235099",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22235099",
-                        "open_access": true,
-                        "pmc_id": "PMC3311875",
-                        "publication_date": {
-                            "year": 2012,
-                            "month": 3,
-                            "day": 1
-                        },
-                        "journal": "Clin. Cancer Res.",
-                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": []
-                    },
-                    "variant_id": 33,
-                    "phenotypes": []
-                },
-                {
-                    "id": 4290,
-                    "name": "EID4290",
-                    "description": "In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.",
-                    "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
-                    },
-                    "drugs": [
-                        {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
-                        }
-                    ],
-                    "rating": 2,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 2067,
-                        "name": "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).",
-                        "citation": "De Gr\u00e8ve et al., 2016, PLoS ONE",
-                        "citation_id": "27032107",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27032107",
-                        "open_access": true,
-                        "pmc_id": "PMC4816447",
-                        "publication_date": {
-                            "year": 2016
-                        },
-                        "journal": "PLoS ONE",
-                        "full_journal_title": "PloS one",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT00339586",
-                                "name": "First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene",
-                                "description": "Current chemotherapy for advanced non-small cell lung cancer, not amenable for curative local treatment (surgery or chemoradiotherapy), has a modest life-prolonging effect and can improve quality of life. There is however no potential for long-term cure for these patients. Chemotherapy also produces variable and often significant toxicity. Current retrospective evidence suggests that significant clinical responses can be obtained when patients whose cancer cells have an EGFR TKD mutation are treated with an EGFR TKI. The ease of administration and toxicity profile of TKI compare favourably with that of chemotherapy, even single agents such as for example gemcitabine The present study will establish the clinical benefit rate of TKI as a first line treatment in patients with EGFR mutations and thus estimate the proportion of patients who might benefit for a prolonged period from a treatment with a modest toxicity profile.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00339586"
-                            }
-                        ]
+                    "type": "evidence",
+                    "source": {
+                        "id": 1525,
+                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
+                        "citation": "Li et al., 2008, Oncogene",
+                        "citation_id": 18408761,
+                        "source_type": "PUBMED",
+                        "asco_abstract_id": null,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
+                        "pmc_id": "PMC2748240",
+                        "publication_date": "2008-8-7",
+                        "journal": "Oncogene",
+                        "full_journal_title": "Oncogene",
+                        "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4291,
-                    "name": "EID4291",
-                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.",
+                    "id": 3811,
+                    "name": "EID3811",
+                    "description": "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
+                        {
+                            "id": 14,
+                            "name": "Gefitinib",
+                            "ncit_id": "C1855",
+                            "aliases": [
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
+                                "Iressa",
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
+                            ]
+                        },
                         {
                             "id": 15,
                             "name": "Erlotinib",
                             "ncit_id": "C65530",
                             "aliases": []
+                        },
+                        {
+                            "id": 90,
+                            "name": "Multikinase Inhibitor AEE788",
+                            "ncit_id": "C48369",
+                            "aliases": [
+                                "AEE 788",
+                                "AEE-788",
+                                "AEE788"
+                            ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": "SUBSTITUTES",
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2086,
-                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
-                        "citation": "Konduri et al., 2016, Cancer Discov",
-                        "citation_id": "27102076",
-                        "source_type": "PubMed",
+                        "id": 1528,
+                        "name": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.",
+                        "citation": "Kancha et al., 2009, Clin. Cancer Res.",
+                        "citation_id": 19147750,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
-                        "open_access": true,
-                        "pmc_id": "PMC4893907",
-                        "publication_date": {
-                            "year": 2016
-                        },
-                        "journal": "Cancer Discov",
-                        "full_journal_title": "Cancer discovery",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19147750",
+                        "pmc_id": null,
+                        "publication_date": "2009-1-15",
+                        "journal": "Clin. Cancer Res.",
+                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4292,
-                    "name": "EID4292",
-                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to cetuximab treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.",
+                    "id": 4265,
+                    "name": "EID4265",
+                    "description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
-                            "id": 16,
-                            "name": "Cetuximab",
-                            "ncit_id": "C1723",
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
                             "aliases": []
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2086,
-                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
-                        "citation": "Konduri et al., 2016, Cancer Discov",
-                        "citation_id": "27102076",
-                        "source_type": "PubMed",
+                        "id": 1991,
+                        "name": "Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.",
+                        "citation": "de Gunst et al., 2007, Mol. Cancer",
+                        "citation_id": 17877814,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
-                        "open_access": true,
-                        "pmc_id": "PMC4893907",
-                        "publication_date": {
-                            "year": 2016
-                        },
-                        "journal": "Cancer Discov",
-                        "full_journal_title": "Cancer discovery",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17877814",
+                        "pmc_id": "PMC2064929",
+                        "publication_date": "2007-9-18",
+                        "journal": "Mol. Cancer",
+                        "full_journal_title": "Molecular cancer",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4293,
-                    "name": "EID4293",
-                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated an sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
+                    "id": 4286,
+                    "name": "EID4286",
+                    "description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 \u00b5M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.",
                     "disease": {
-                        "id": 174,
-                        "name": "Lung Small Cell Carcinoma",
-                        "display_name": "Lung Small Cell Carcinoma",
-                        "doid": "5409",
-                        "url": "http://www.disease-ontology.org/?id=DOID:5409"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -3885,84 +3663,81 @@
                             "aliases": []
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 665,
-                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
-                        "citation": "Cross et al., 2014, Cancer Discov",
-                        "citation_id": "24893891",
-                        "source_type": "PubMed",
+                        "id": 1230,
+                        "name": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
+                        "citation": "Yasuda et al., 2013, Sci Transl Med",
+                        "citation_id": 24353160,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
-                        "open_access": true,
-                        "pmc_id": "PMC4315625",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 9
-                        },
-                        "journal": "Cancer Discov",
-                        "full_journal_title": "Cancer discovery",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160",
+                        "pmc_id": "PMC3954775",
+                        "publication_date": "2013-12-18",
+                        "journal": "Sci Transl Med",
+                        "full_journal_title": "Science translational medicine",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4294,
-                    "name": "EID4294",
-                    "description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
+                    "id": 4292,
+                    "name": "EID4292",
+                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.",
                     "disease": {
-                        "id": 217,
-                        "name": "Hematologic Cancer",
-                        "display_name": "Hematologic Cancer",
-                        "doid": "2531",
-                        "url": "http://www.disease-ontology.org/?id=DOID:2531"
+                        "id": 30,
+                        "name": "Lung Adenocarcinoma",
+                        "display_name": "Lung Adenocarcinoma",
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
                             "id": 16,
                             "name": "Cetuximab",
                             "ncit_id": "C1723",
-                            "aliases": []
+                            "aliases": [
+                                "Cetuximab Biosimilar CDP-1",
+                                "Cetuximab Biosimilar CMAB009",
+                                "Cetuximab Biosimilar KL 140",
+                                "Chimeric Anti-EGFR Monoclonal Antibody",
+                                "Chimeric MoAb C225",
+                                "Chimeric Monoclonal Antibody C225",
+                                "Erbitux",
+                                "IMC-C225"
+                            ]
                         }
                     ],
-                    "rating": null,
+                    "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "DOES_NOT_SUPPORT",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 665,
-                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
-                        "citation": "Cross et al., 2014, Cancer Discov",
-                        "citation_id": "24893891",
-                        "source_type": "PubMed",
+                        "id": 2086,
+                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
+                        "citation": "Konduri et al., 2016, Cancer Discov",
+                        "citation_id": 27102076,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
-                        "open_access": true,
-                        "pmc_id": "PMC4315625",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 9
-                        },
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
+                        "pmc_id": "PMC4893907",
+                        "publication_date": "2016",
                         "journal": "Cancer Discov",
                         "full_journal_title": "Cancer discovery",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 33,
@@ -3974,10 +3749,10 @@
                     "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).",
                     "disease": {
                         "id": 695,
-                        "name": "Malignant Glioma",
-                        "display_name": "Malignant Glioma",
-                        "doid": "3070",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3070"
+                        "name": "High Grade Glioma",
+                        "display_name": "High Grade Glioma",
+                        "doid": 3070,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3070"
                     },
                     "drugs": [
                         {
@@ -3989,10 +3764,10 @@
                     ],
                     "rating": 3,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
@@ -4000,35 +3775,29 @@
                         "id": 1608,
                         "name": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.",
                         "citation": "Lee et al., 2006, PLoS Med.",
-                        "citation_id": "17177598",
-                        "source_type": "PubMed",
+                        "citation_id": 17177598,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
                         "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17177598",
-                        "open_access": true,
                         "pmc_id": "PMC1702556",
-                        "publication_date": {
-                            "year": 2006,
-                            "month": 12
-                        },
+                        "publication_date": "2006-12",
                         "journal": "PLoS Med.",
                         "full_journal_title": "PLoS medicine",
-                        "status": "partially curated",
-                        "is_review": false,
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2994,
-                    "name": "EID2994",
-                    "description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
+                    "id": 5922,
+                    "name": "EID5922",
+                    "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 216,
+                        "name": "Cancer",
+                        "display_name": "Cancer",
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
@@ -4038,48 +3807,42 @@
                             "aliases": []
                         }
                     ],
-                    "rating": 5,
-                    "evidence_level": "A",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 3,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "submitted",
                     "type": "evidence",
                     "source": {
-                        "id": 1724,
-                        "name": "U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.",
-                        "citation": "Khozin et al., 2014, Oncologist",
-                        "citation_id": "24868098",
-                        "source_type": "PubMed",
+                        "id": 2081,
+                        "name": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.",
+                        "citation": "Foster et al., 2010, World J Surg Oncol",
+                        "citation_id": 20942962,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24868098",
-                        "open_access": true,
-                        "pmc_id": "PMC4077454",
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 7
-                        },
-                        "journal": "Oncologist",
-                        "full_journal_title": "The oncologist",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20942962",
+                        "pmc_id": "PMC2970593",
+                        "publication_date": "2010-10-13",
+                        "journal": "World J Surg Oncol",
+                        "full_journal_title": "World journal of surgical oncology",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2997,
-                    "name": "EID2997",
-                    "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
+                    "id": 968,
+                    "name": "EID968",
+                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -4087,251 +3850,142 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "rating": 5,
-                    "evidence_level": "A",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1725,
-                        "name": "Afatinib: first global approval.",
-                        "citation": "Dungo et al., 2013, Drugs",
-                        "citation_id": "23982599",
-                        "source_type": "PubMed",
+                        "id": 669,
+                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
+                        "citation": "Hirano et al., 2015, Oncotarget",
+                        "citation_id": 26515464,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2013,
-                            "month": 9
-                        },
-                        "journal": "Drugs",
-                        "full_journal_title": "Drugs",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
+                        "pmc_id": "PMC4770737",
+                        "publication_date": "2015-11-17",
+                        "journal": "Oncotarget",
+                        "full_journal_title": "Oncotarget",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 4860,
-                    "name": "EID4860",
-                    "description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.",
-                    "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
-                    },
-                    "drugs": [
-                        {
-                            "id": 44,
-                            "name": "Dacomitinib",
-                            "ncit_id": "C53398",
-                            "aliases": [
-                                "Vizimpro",
-                                "PF-299804",
-                                "PF-00299804-03",
-                                "PF-00299804",
-                                "EGFR Inhibitor PF-00299804",
-                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide"
-                            ]
-                        }
-                    ],
-                    "rating": 5,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": null,
-                    "status": "accepted",
-                    "type": "evidence",
-                    "source": {
-                        "id": 2158,
-                        "name": "Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.",
-                        "citation": "Ramalingam et al., 2016, Ann. Oncol.",
-                        "citation_id": "26768165",
-                        "source_type": "PubMed",
-                        "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26768165",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2016,
-                            "month": 3
-                        },
-                        "journal": "Ann. Oncol.",
-                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
-                        "clinical_trials": [
-                            {
-                                "nct_id": "NCT01360554",
-                                "name": "ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer",
-                                "description": "This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT01360554"
-                            },
-                            {
-                                "nct_id": "NCT00769067",
-                                "name": "A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen",
-                                "description": "This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.",
-                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00769067"
-                            }
-                        ]
-                    },
-                    "variant_id": 33,
-                    "phenotypes": []
-                },
-                {
-                    "id": 2632,
-                    "name": "EID2632",
-                    "description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.",
+                    "id": 2629,
+                    "name": "EID2629",
+                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
-                            "id": 15,
-                            "name": "Erlotinib",
-                            "ncit_id": "C65530",
-                            "aliases": []
+                            "id": 146,
+                            "name": "Afatinib",
+                            "ncit_id": "C66940",
+                            "aliases": [
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
+                                "BIBW 2992",
+                                "BIBW2992"
+                            ]
                         }
                     ],
                     "rating": 2,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1509,
-                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
-                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
-                        "citation_id": "15329413",
-                        "source_type": "PubMed",
+                        "id": 1525,
+                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
+                        "citation": "Li et al., 2008, Oncogene",
+                        "citation_id": 18408761,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
-                        "open_access": true,
-                        "pmc_id": "PMC516528",
-                        "publication_date": {
-                            "year": 2004,
-                            "month": 9,
-                            "day": 7
-                        },
-                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
-                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
+                        "pmc_id": "PMC2748240",
+                        "publication_date": "2008-8-7",
+                        "journal": "Oncogene",
+                        "full_journal_title": "Oncogene",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 3811,
-                    "name": "EID3811",
-                    "description": "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.",
+                    "id": 4284,
+                    "name": "EID4284",
+                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.",
                     "disease": {
-                        "id": 216,
-                        "name": "Cancer",
-                        "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
-                        {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
-                            "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
-                            ]
-                        },
                         {
                             "id": 15,
                             "name": "Erlotinib",
                             "ncit_id": "C65530",
                             "aliases": []
-                        },
-                        {
-                            "id": 90,
-                            "name": "Multikinase Inhibitor AEE788",
-                            "ncit_id": "C48369",
-                            "aliases": [
-                                "AEE788",
-                                "AEE-788",
-                                "AEE 788"
-                            ]
                         }
                     ],
-                    "rating": 3,
+                    "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
-                    "drug_interaction_type": "Substitutes",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
+                    "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1528,
-                        "name": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.",
-                        "citation": "Kancha et al., 2009, Clin. Cancer Res.",
-                        "citation_id": "19147750",
-                        "source_type": "PubMed",
+                        "id": 1525,
+                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
+                        "citation": "Li et al., 2008, Oncogene",
+                        "citation_id": 18408761,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19147750",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2009,
-                            "month": 1,
-                            "day": 15
-                        },
-                        "journal": "Clin. Cancer Res.",
-                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
+                        "pmc_id": "PMC2748240",
+                        "publication_date": "2008-8-7",
+                        "journal": "Oncogene",
+                        "full_journal_title": "Oncogene",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 5922,
-                    "name": "EID5922",
-                    "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.",
+                    "id": 4285,
+                    "name": "EID4285",
+                    "description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.",
                     "disease": {
                         "id": 216,
                         "name": "Cancer",
                         "display_name": "Cancer",
-                        "doid": "162",
-                        "url": "http://www.disease-ontology.org/?id=DOID:162"
+                        "doid": 162,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                     },
                     "drugs": [
                         {
@@ -4341,165 +3995,132 @@
                             "aliases": []
                         }
                     ],
-                    "rating": 3,
+                    "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2081,
-                        "name": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.",
-                        "citation": "Foster et al., 2010, World J Surg Oncol",
-                        "citation_id": "20942962",
-                        "source_type": "PubMed",
+                        "id": 1993,
+                        "name": "Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.",
+                        "citation": "Harada et al., 2011, Oncogene",
+                        "citation_id": 21132006,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20942962",
-                        "open_access": true,
-                        "pmc_id": "PMC2970593",
-                        "publication_date": {
-                            "year": 2010,
-                            "month": 10,
-                            "day": 13
-                        },
-                        "journal": "World J Surg Oncol",
-                        "full_journal_title": "World journal of surgical oncology",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21132006",
+                        "pmc_id": null,
+                        "publication_date": "2011-4-14",
+                        "journal": "Oncogene",
+                        "full_journal_title": "Oncogene",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 6183,
-                    "name": "EID6183",
-                    "description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).",
+                    "id": 4291,
+                    "name": "EID4291",
+                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 \u00b1 12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.",
                     "disease": {
                         "id": 30,
                         "name": "Lung Adenocarcinoma",
                         "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "doid": 3910,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                     },
                     "drugs": [
                         {
-                            "id": 14,
-                            "name": "Gefitinib",
-                            "ncit_id": "C1855",
-                            "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
-                                "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
-                            ]
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
                     "rating": 2,
-                    "evidence_level": "B",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Reduced Sensitivity",
-                    "evidence_direction": "Does Not Support",
-                    "variant_origin": "Somatic",
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 2478,
-                        "name": "Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.",
-                        "citation": "Urata et al., 2016, J. Clin. Oncol.",
-                        "citation_id": "27022112",
-                        "source_type": "PubMed",
+                        "id": 2086,
+                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
+                        "citation": "Konduri et al., 2016, Cancer Discov",
+                        "citation_id": 27102076,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27022112",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2016,
-                            "day": 20
-                        },
-                        "journal": "J. Clin. Oncol.",
-                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
+                        "pmc_id": "PMC4893907",
+                        "publication_date": "2016",
+                        "journal": "Cancer Discov",
+                        "full_journal_title": "Cancer discovery",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 2627,
-                    "name": "EID2627",
-                    "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).",
+                    "id": 4293,
+                    "name": "EID4293",
+                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM).",
                     "disease": {
-                        "id": 8,
-                        "name": "Lung Non-small Cell Carcinoma",
-                        "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "id": 174,
+                        "name": "Lung Small Cell Carcinoma",
+                        "display_name": "Lung Small Cell Carcinoma",
+                        "doid": 5409,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:5409"
                     },
                     "drugs": [
                         {
-                            "id": 44,
-                            "name": "Dacomitinib",
-                            "ncit_id": "C53398",
-                            "aliases": [
-                                "Vizimpro",
-                                "PF-299804",
-                                "PF-00299804-03",
-                                "PF-00299804",
-                                "EGFR Inhibitor PF-00299804",
-                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide"
-                            ]
+                            "id": 15,
+                            "name": "Erlotinib",
+                            "ncit_id": "C65530",
+                            "aliases": []
                         }
                     ],
-                    "rating": 3,
+                    "rating": 2,
                     "evidence_level": "D",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
                     "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 1515,
-                        "name": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.",
-                        "citation": "Engelman et al., 2007, Cancer Res.",
-                        "citation_id": "18089823",
-                        "source_type": "PubMed",
+                        "id": 665,
+                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
+                        "citation": "Cross et al., 2014, Cancer Discov",
+                        "citation_id": 24893891,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18089823",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2007,
-                            "month": 12,
-                            "day": 15
-                        },
-                        "journal": "Cancer Res.",
-                        "full_journal_title": "Cancer research",
-                        "status": "partially curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
+                        "pmc_id": "PMC4315625",
+                        "publication_date": "2014-9",
+                        "journal": "Cancer Discov",
+                        "full_journal_title": "Cancer discovery",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 8053,
-                    "name": "EID8053",
-                    "description": "A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutation and the patient started 80mg osimertinib treatment with excellent response of all disease sites, including brain metastases. The patient had continued response until 8.5 months after treatment initiation when a new liver lesion was found. NGS sequencing of a repeat biopsy detected the original EGFR L858R mutation as well as L718V and L718Q mutations. Afatinib treatment led to a partial response for 4.5 months, at which time disease progression occurred. Biopsy of a progressing liver lesion showed acquired EGFR T790M mutation as well as increase and decrease of L718V and L718Q mutation frequencies, respectively.",
+                    "id": 4294,
+                    "name": "EID4294",
+                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291.",
                     "disease": {
-                        "id": 30,
-                        "name": "Lung Adenocarcinoma",
-                        "display_name": "Lung Adenocarcinoma",
-                        "doid": "3910",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3910"
+                        "id": 8,
+                        "name": "Lung Non-small Cell Carcinoma",
+                        "display_name": "Lung Non-small Cell Carcinoma",
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -4507,86 +4128,85 @@
                             "name": "Osimertinib",
                             "ncit_id": "C116377",
                             "aliases": [
-                                "Tagrisso",
-                                "Mereletinib",
-                                "AZD9291",
+                                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
                                 "AZD-9291",
-                                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-"
+                                "AZD9291",
+                                "Mereletinib",
+                                "Tagrisso"
                             ]
                         }
                     ],
-                    "rating": 4,
-                    "evidence_level": "C",
-                    "evidence_type": "Predictive",
-                    "clinical_significance": "Sensitivity/Response",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "rating": 2,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "submitted",
+                    "status": "accepted",
                     "type": "evidence",
                     "source": {
-                        "id": 3253,
-                        "name": "Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations.",
-                        "citation": "Starrett et al., 2020, Cancer Res.",
-                        "citation_id": "32193290",
-                        "source_type": "PubMed",
+                        "id": 665,
+                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
+                        "citation": "Cross et al., 2014, Cancer Discov",
+                        "citation_id": 24893891,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32193290",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2020,
-                            "month": 3,
-                            "day": 19
-                        },
-                        "journal": "Cancer Res.",
-                        "full_journal_title": "Cancer research",
-                        "status": "submitted",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
+                        "pmc_id": "PMC4315625",
+                        "publication_date": "2014-9",
+                        "journal": "Cancer Discov",
+                        "full_journal_title": "Cancer discovery",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
                     "phenotypes": []
                 },
                 {
-                    "id": 347,
-                    "name": "EID347",
-                    "description": "Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.",
+                    "id": 2633,
+                    "name": "EID2633",
+                    "description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
-                    "drugs": [],
-                    "rating": 3,
-                    "evidence_level": "B",
-                    "evidence_type": "Prognostic",
-                    "clinical_significance": "Better Outcome",
-                    "evidence_direction": "Supports",
-                    "variant_origin": "Somatic",
+                    "drugs": [
+                        {
+                            "id": 427,
+                            "name": "Durvalumab",
+                            "ncit_id": "C103194",
+                            "aliases": [
+                                "Imfinzi",
+                                "Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer",
+                                "MEDI-4736",
+                                "MEDI4736"
+                            ]
+                        }
+                    ],
+                    "rating": 1,
+                    "evidence_level": "D",
+                    "evidence_type": "PREDICTIVE",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
+                    "evidence_direction": "SUPPORTS",
+                    "variant_origin": "SOMATIC",
                     "drug_interaction_type": null,
-                    "status": "accepted",
+                    "status": "rejected",
                     "type": "evidence",
                     "source": {
-                        "id": 213,
-                        "name": "Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.",
-                        "citation": "Douillard et al., 2014, J Thorac Oncol",
-                        "citation_id": "24662454",
-                        "source_type": "PubMed",
+                        "id": 665,
+                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
+                        "citation": "Cross et al., 2014, Cancer Discov",
+                        "citation_id": 24893891,
+                        "source_type": "PUBMED",
                         "asco_abstract_id": null,
-                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24662454",
-                        "open_access": null,
-                        "pmc_id": null,
-                        "publication_date": {
-                            "year": 2014,
-                            "month": 5
-                        },
-                        "journal": "J Thorac Oncol",
-                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
-                        "status": "fully curated",
-                        "is_review": false,
+                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
+                        "pmc_id": "PMC4315625",
+                        "publication_date": "2014-9",
+                        "journal": "Cancer Discov",
+                        "full_journal_title": "Cancer discovery",
                         "clinical_trials": []
                     },
                     "variant_id": 33,
@@ -4601,20 +4221,14 @@
                     "name": "AID5",
                     "summary": "Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotininb or gefitinib.",
                     "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitors erlotinib and gefitinib are associated with improved progression free survival over chemotherapy in EGFR L858R patients. NCCN guidelines recommend (category 1) erlotinib and gefitinib for NSCLC with sensitizing EGFR mutations, along with afatinib and osimertinib.",
-                    "gene": {
-                        "name": "EGFR",
-                        "id": 19
-                    },
-                    "variant": {
-                        "name": "L858R",
-                        "id": 33
-                    },
+                    "gene_id": 19,
+                    "variant_id": 33,
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -4622,11 +4236,11 @@
                             "name": "Gefitinib",
                             "ncit_id": "C1855",
                             "aliases": [
-                                "ZD1839",
-                                "ZD 1839",
-                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                 "Iressa",
-                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline"
+                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
+                                "ZD 1839",
+                                "ZD1839"
                             ]
                         },
                         {
@@ -4636,9 +4250,9 @@
                             "aliases": []
                         }
                     ],
-                    "evidence_type": "Predictive",
-                    "evidence_direction": "Supports",
-                    "clinical_significance": "Sensitivity/Response",
+                    "evidence_type": "PREDICTIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
                     "fda_regulatory_approval": true,
                     "status": "accepted"
                 },
@@ -4648,20 +4262,14 @@
                     "name": "AID6",
                     "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                     "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
-                    "gene": {
-                        "name": "EGFR",
-                        "id": 19
-                    },
-                    "variant": {
-                        "name": "L858R",
-                        "id": 33
-                    },
+                    "gene_id": 19,
+                    "variant_id": 33,
                     "disease": {
                         "id": 8,
                         "name": "Lung Non-small Cell Carcinoma",
                         "display_name": "Lung Non-small Cell Carcinoma",
-                        "doid": "3908",
-                        "url": "http://www.disease-ontology.org/?id=DOID:3908"
+                        "doid": 3908,
+                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                     },
                     "drugs": [
                         {
@@ -4669,33 +4277,33 @@
                             "name": "Afatinib",
                             "ncit_id": "C66940",
                             "aliases": [
-                                "BIBW2992",
+                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                 "BIBW 2992",
-                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
+                                "BIBW2992"
                             ]
                         }
                     ],
-                    "evidence_type": "Predictive",
-                    "evidence_direction": "Supports",
-                    "clinical_significance": "Sensitivity/Response",
+                    "evidence_type": "PREDICTIVE",
+                    "evidence_direction": "SUPPORTS",
+                    "clinical_significance": "SENSITIVITYRESPONSE",
                     "fda_regulatory_approval": true,
                     "status": "accepted"
                 }
             ],
             "variant_aliases": [
-                "RS121434568",
-                "LEU858ARG"
+                "LEU858ARG",
+                "RS121434568"
             ],
             "hgvs_expressions": [
-                "NP_005219.2:p.Leu858Arg",
-                "ENST00000275493.2:c.2573T>G",
+                "NC_000007.13:g.55259515T>G",
                 "NM_005228.4:c.2573T>G",
-                "NC_000007.13:g.55259515T>G"
+                "ENST00000275493.2:c.2573T>G",
+                "NP_005219.2:p.Leu858Arg"
             ],
             "clinvar_entries": [
-                "376280",
+                "16609",
                 "376282",
-                "16609"
+                "376280"
             ],
             "allele_registry_id": "CA126713"
         }
diff --git a/tests/unit/harvesters/civic/test_civic_assertions.py b/tests/unit/harvesters/civic/test_civic_assertions.py
index bd1d6cba..0c312427 100644
--- a/tests/unit/harvesters/civic/test_civic_assertions.py
+++ b/tests/unit/harvesters/civic/test_civic_assertions.py
@@ -41,20 +41,14 @@ def aid40():
                        "Gilteritinib as the first FLT3 inhibitor indicated "
                        "for use as monotherapy R/R AML with FLT3 ITD "
                        "mutations or TKD D835 or I836 mutations.",
-        'gene': {
-            'name': "FLT3",
-            'id': 24
-        },
-        'variant': {
-            'name': "I836",
-            'id': 3232
-        },
+        'gene_id': 24,
+        'variant_id': 3232,
         'disease': {
             'id': 3,
             'name': "Acute Myeloid Leukemia",
             'display_name': "Acute Myeloid Leukemia",
             'doid': "9119",
-            'url': "http://www.disease-ontology.org/?id=DOID:9119"
+            'disease_url': "http://www.disease-ontology.org/?id=DOID:9119"
         },
         'drugs': [
             {
@@ -86,7 +80,6 @@ def aid40():
         'acmg_codes': [],
         'drug_interaction_type': None,
         'fda_companion_test': True,
-        'allele_registry_id': None,
         'phenotypes': [],
         'variant_origin': "Somatic"
     }
@@ -99,10 +92,11 @@ def test_assertions(test_get_all_assertions, aid40):
               f"harvesters/civic/assertions.json") as f:
         data = json.load(f)
     test_get_all_assertions.return_value = data
-    assertions = CIViCHarvester()._harvest_assertions()
+    assertions = CIViCHarvester().harvest_assertions()
     c_assertion = None
     for assertion in assertions:
         if assertion['id'] == 40:
             c_assertion = assertion
+    assert c_assertion['evidence_items']
     c_assertion['evidence_items'] = []
     assert c_assertion == aid40
diff --git a/tests/unit/harvesters/civic/test_civic_evidence.py b/tests/unit/harvesters/civic/test_civic_evidence.py
index e7bc407f..eb07d725 100644
--- a/tests/unit/harvesters/civic/test_civic_evidence.py
+++ b/tests/unit/harvesters/civic/test_civic_evidence.py
@@ -27,7 +27,7 @@ def lnscc():
             "name": "Lung Non-small Cell Carcinoma",
             "display_name": "Lung Non-small Cell Carcinoma",
             "doid": "3908",
-            "url": "http://www.disease-ontology.org/?id=DOID:3908"
+            "disease_url": "http://www.disease-ontology.org/?id=DOID:3908"
         },
         "drugs": [
             {
@@ -71,7 +71,6 @@ def lnscc():
             "source_type": "PubMed",
             "asco_abstract_id": None,
             "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27283860",
-            "open_access": True,
             "pmc_id": "PMC4993103",
             "publication_date": {
                 "year": 2016,
@@ -79,8 +78,6 @@ def lnscc():
             },
             "journal": "Lancet Oncol.",
             "full_journal_title": "The Lancet. Oncology",
-            "status": "partially curated",
-            "is_review": False,
             "clinical_trials": [{
                 "nct_id": "NCT01336634",
                 "name": "Study of Selective BRAF Kinase Inhibitor Dabrafenib "
@@ -123,7 +120,7 @@ def test_evidence(test_get_all_evidence, lnscc):
               f"harvesters/civic/evidence.json") as f:
         data = json.load(f)
     test_get_all_evidence.return_value = data
-    evidence = CIViCHarvester()._harvest_evidence()
+    evidence = CIViCHarvester().harvest_evidence()
     evidence_item = None
     for ev in evidence:
         if ev['id'] == 3017:
diff --git a/tests/unit/harvesters/civic/test_civic_genes.py b/tests/unit/harvesters/civic/test_civic_genes.py
index e9b9aaf4..cd0f3049 100644
--- a/tests/unit/harvesters/civic/test_civic_genes.py
+++ b/tests/unit/harvesters/civic/test_civic_genes.py
@@ -120,7 +120,7 @@ def test_genes(test_get_all_genes, dux4, alk):
     with open(f"{PROJECT_ROOT}/tests/data/harvesters/civic/genes.json") as f:
         data = json.load(f)
     test_get_all_genes.return_value = data
-    genes = CIViCHarvester()._harvest_genes()
+    genes = CIViCHarvester().harvest_genes()
     actual_dux4 = None
     actual_alk = None
     for gene in genes:
diff --git a/tests/unit/harvesters/civic/test_civic_variants.py b/tests/unit/harvesters/civic/test_civic_variants.py
index 089b3e32..d631331a 100644
--- a/tests/unit/harvesters/civic/test_civic_variants.py
+++ b/tests/unit/harvesters/civic/test_civic_variants.py
@@ -28,7 +28,6 @@ def pdgfra():
             {
                 'id': 47,
                 'name': "missense_variant",
-                'display_name': "Missense Variant",
                 'so_id': "SO:0001583",
                 'description': "A sequence variant, that changes one or more"
                                " bases, resulting in a different amino acid "
@@ -66,7 +65,7 @@ def pdgfra():
                     'name': "Gastrointestinal Stromal Tumor",
                     'display_name': "Gastrointestinal Stromal Tumor",
                     'doid': "9253",
-                    'url': "http://www.disease-ontology.org/?id=DOID:9253"
+                    'disease_url': "http://www.disease-ontology.org/?id=DOID:9253"
                 },
                 'drugs': [
                     {
@@ -105,7 +104,6 @@ def pdgfra():
                     'asco_abstract_id': None,
                     'source_url':
                         "http://www.ncbi.nlm.nih.gov/pubmed/22745105",
-                    'open_access': None,
                     'pmc_id': None,
                     'publication_date': {
                         'year': 2012,
@@ -117,8 +115,6 @@ def pdgfra():
                         "Clinical cancer research : an official"
                         " journal of the American Association"
                         " for Cancer Research",
-                    'status': "fully curated",
-                    'is_review': False,
                     'clinical_trials': []
                 },
                 'variant_id': 100,
@@ -168,7 +164,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases, "
@@ -182,7 +177,6 @@ def pdgfra():
                             {
                                 'id': 120,
                                 'name': "transcript_fusion",
-                                'display_name': "Transcript Fusion",
                                 'so_id': "SO:0001886",
                                 'description': "A feature fusion where the"
                                                " deletion brings together "
@@ -233,7 +227,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases, "
@@ -246,7 +239,6 @@ def pdgfra():
                             {
                                 'id': 120,
                                 'name': "transcript_fusion",
-                                'display_name': "Transcript Fusion",
                                 'so_id': "SO:0001886",
                                 'description': "A feature fusion where the "
                                                "deletion brings together "
@@ -294,7 +286,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases, "
@@ -352,7 +343,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases,"
@@ -403,7 +393,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases, "
@@ -454,7 +443,6 @@ def pdgfra():
                             {
                                 'id': 107,
                                 'name': "inframe_deletion",
-                                'display_name': "Inframe Deletion",
                                 'so_id': "SO:0001822",
                                 'description': "An inframe non synonymous "
                                                "variant that deletes bases "
@@ -505,7 +493,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases, "
@@ -552,7 +539,6 @@ def pdgfra():
                             {
                                 'id': 47,
                                 'name': "missense_variant",
-                                'display_name': "Missense Variant",
                                 'so_id': "SO:0001583",
                                 'description': "A sequence variant, that "
                                                "changes one or more bases,"
@@ -565,7 +551,6 @@ def pdgfra():
                             {
                                 'id': 120,
                                 'name': "transcript_fusion",
-                                'display_name': "Transcript Fusion",
                                 'so_id': "SO:0001886",
                                 'description': "A feature fusion where the"
                                                " deletion brings together "
@@ -619,7 +604,7 @@ def test_variants(test_get_all_variants, pdgfra):
               f"harvesters/civic/variants.json") as f:
         data = json.load(f)
     test_get_all_variants.return_value = data
-    variants = CIViCHarvester()._harvest_variants()
+    variants = CIViCHarvester().harvest_variants()
     actul_pdgfra = None
     for v in variants:
         if v['id'] == 100:
diff --git a/tests/unit/harvesters/moa/test_moa_assertions.py b/tests/unit/harvesters/moa/test_moa_assertions.py
index e93ae9c3..0f3135b1 100644
--- a/tests/unit/harvesters/moa/test_moa_assertions.py
+++ b/tests/unit/harvesters/moa/test_moa_assertions.py
@@ -1,21 +1,22 @@
 """Test MOAlmanac assertions"""
+import json
+
 import pytest
-from metakb import PROJECT_ROOT
-from metakb.harvesters import MOAHarvester
 from mock import patch
-import json
+
+from metakb import PROJECT_ROOT  # noqa: I202
+from metakb.harvesters import MOAHarvester
 
 
-@pytest.fixture(scope='module')
-def assertion168():
-    """Create a fixture for assertion #168."""
+@pytest.fixture(scope="module")
+def assertion170():
+    """Create a fixture for assertion #170."""
     return {
-        "id": 168,
-        "context": None,
-        "description": "Administration of bevacizumab in a "
-                       "dabrafenib-resistant cell line counteracted the tumor"
-                       " growth stimulating effect of administering "
-                       "dabrafenib post-resistance.",
+        "id": 170,
+        "context": "",
+        "description": "Administration of bevacizumab in a dabrafenib-resistant cell "
+                       "line counteracted the tumor growth stimulating effect of "
+                       "administering dabrafenib post-resistance.",
         "disease": {
             "name": "Melanoma",
             "oncotree_code": "MEL",
@@ -25,35 +26,35 @@ def assertion168():
         "therapy_type": "Targeted therapy",
         "clinical_significance": "sensitivity",
         "predictive_implication": "Preclinical",
-        "favorable_prognosis": None,
-        "created_on": "03/31/21",
+        "favorable_prognosis": False,
+        "created_on": "09/08/22",
         "last_updated": "2019-06-13",
         "submitted_by": "breardon@broadinstitute.org",
         "validated": True,
-        "source_ids": 67,
+        "source_ids": 69,
         "variant": {
-            "id": 147,
+            "id": 149,
             "alternate_allele": "T",
             "cdna_change": "c.1799T>A",
             "chromosome": "7",
-            "end_position": "140453136.0",
-            "exon": "15.0",
+            "end_position": "140453136",
+            "exon": "15",
             "feature_type": "somatic_variant",
             "gene": "BRAF",
             "protein_change": "p.V600E",
             "reference_allele": "A",
             "rsid": "rs113488022",
-            "start_position": "140453136.0",
+            "start_position": "140453136",
             "variant_annotation": "Missense",
             "feature": "BRAF p.V600E (Missense)"
         }
     }
 
 
-@patch.object(MOAHarvester, '_get_all_variants')
-@patch.object(MOAHarvester, '_get_all_assertions')
-def test_assertion_168(test_get_all_assertions, test_get_all_variants,
-                       assertion168):
+@patch.object(MOAHarvester, "_get_all_variants")
+@patch.object(MOAHarvester, "_get_all_assertions")
+def test_assertion_170(test_get_all_assertions, test_get_all_variants,
+                       assertion170):
     """Test moa harvester works correctly for assertions."""
     with open(f"{PROJECT_ROOT}/tests/data/"
               f"harvesters/moa/assertions.json") as f:
@@ -66,13 +67,13 @@ def test_assertion_168(test_get_all_assertions, test_get_all_variants,
     test_get_all_variants.return_value = data
 
     assertion_resp = MOAHarvester()._get_all_assertions()
-    variants, variants_list = MOAHarvester()._harvest_variants()
-    assertions = MOAHarvester()._harvest_assertions(
+    _, variants_list = MOAHarvester().harvest_variants()
+    assertions = MOAHarvester().harvest_assertions(
         assertion_resp, variants_list)
 
     actual = None
     for a in assertions:
-        if a['id'] == 168:
+        if a["id"] == 170:
             actual = a
             break
-    assert actual == assertion168
+    assert actual == assertion170
diff --git a/tests/unit/harvesters/moa/test_moa_source.py b/tests/unit/harvesters/moa/test_moa_source.py
index c65e1607..20b665da 100644
--- a/tests/unit/harvesters/moa/test_moa_source.py
+++ b/tests/unit/harvesters/moa/test_moa_source.py
@@ -1,12 +1,14 @@
 """Test MOAlmanac source"""
+import json
+
+from mock import patch
 import pytest
-from metakb import PROJECT_ROOT
+
+from metakb import PROJECT_ROOT  # noqa: I202
 from metakb.harvesters import MOAHarvester
-from mock import patch
-import json
 
 
-@pytest.fixture(scope='module')
+@pytest.fixture(scope="module")
 def sources():
     """Create a list of sources."""
     moa = MOAHarvester()
@@ -14,11 +16,11 @@ def sources():
     return moa._harvest_sources()
 
 
-@pytest.fixture(scope='module')
-def source66():
-    """Create a fixture for source of evidence #66."""
+@pytest.fixture(scope="module")
+def source68():
+    """Create a fixture for source of evidence #68."""
     return {
-        "id": 66,
+        "id": 68,
         "type": "Journal",
         "doi": "10.1186/s40425-016-0148-7",
         "nct": "NCT01673854",
@@ -31,8 +33,8 @@ def source66():
     }
 
 
-@patch.object(MOAHarvester, '_get_all_assertions')
-def test_source66(test_get_all_assertions, source66):
+@patch.object(MOAHarvester, "_get_all_assertions")
+def test_source68(test_get_all_assertions, source68):
     """Test moa harvester works correctly for evidence."""
     with open(f"{PROJECT_ROOT}/tests/data/"
               f"harvesters/moa/assertions.json") as f:
@@ -44,7 +46,7 @@ def test_source66(test_get_all_assertions, source66):
 
     actual = None
     for s in sources:
-        if s['id'] == 66:
+        if s["id"] == 68:
             actual = s
             break
-    assert actual == source66
+    assert actual == source68